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Abstract 
 
Histaminergic regulation of appetite 
 
 
 
Food intake is essential to all animals. However, when energy consumption 
through food overtakes energy expenditure, obesity can result. Obesity has been 
identified as a worldwide health problem associated with diseases such as type 2 
diabetes and hypertension. Thus, it is essential to find effective anti-obesity 
therapies. The aim of this thesis was to determine whether the histaminergic 
system could be pharmacologically manipulated to alter food intake and whether 
in particular the H3R is a suitable therapeutic target. Histamine is a central 
neurotransmitter that plays a major role in controlling energy balance by acting 
through specific hypothalamic sites. Injections of histamine receptor-1 (H1R) 
antagonists into the ventromedial hypothalamic nucleus (VMN) cause 
hyperphagia, whereas antagonism of presynaptic histamine receptor-3 (H3R) 
causes hypophagia, leading to the hypothesis that selective antagonists or 
inverse agonists might be potential treatments for obesity through their actions on 
central H3R. My aim was to assess the precise mode of action of histamine and 
H3R drugs to affect acute, appetitive behaviour. Using feeding and behavioural 
studies I demonstrated the acute anorexigenic actions of histamine (ICV) and the 
H3R inverse agonist, thioperamide (ICV or IP), in rats without disrupting the 
behavioural satiety sequence. In accordance with predictions, the H3R agonist, 
imetit (ICV or IP), increased feeding. The actions of both thioperamide and imetit 
were blocked by the drug proxyfan, which in our model is acting as a neutral H3R 
antagonist. Interestingly, both thioperamide and imetit caused anorexia in mice. 
C-Fos functional immunostaining revealed that systemic administration of 
thioperamide and imetit increased the activity of neurones in the key feeding 
nuclei of the hypothalamus, including the VMN. To further investigate the mode of 
action of histaminergic drugs, I carried out extracellular electrophysiological 
recordings from neurones of the rat VMN in vitro. Of the 197 VMN cells recorded, 
62% were histamine-responsive, with 97% of these showing an increase in 
neuronal firing rates in response to histamine. The excitatory response to 
histamine was blocked in 90% of instances by pyrilamine, a selective H1R 
antagonist. Neurones that responded to histamine previously were treated also 
with thioperamide. 88% of these neurones also responded with an increase in 
firing. The effect of thioperamide was blocked in all cases by co-administrating 
pyrilamine, proving that H3R in the VMN are presynaptic autoreceptors, rather 
than heteroreceptors modulating the release of other transmitters. Imetit had an 
inhibitory effect on VMN neuronal firing in 86% of recorded cells. Proxyfan was 
able to block the changes in neuronal firing that both thioperamide and imetit 
caused. This suggests it is acting as a neutral H3R antagonist in both our in vivo 
and in vitro models. Thus, using a neutral H3R antagonist we have proven the 
effects imetit and thioperamide had on feeding and neuronal VMN firing were a 
direct result of activating a H3R and, therefore, these compounds are receptor-
specific for the H3R. In conclusion, our results support a role for histaminergic 
receptors, including postsynaptic H1R and presynaptic H3R autoreceptors in the 
VMN, to modulate feeding. 
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General Introduction 
 
Food is essential to all animals and physiological states associated with 
energy balance (e.g., hunger and satiety) are major determinants of eating 
behaviour (Beaver et al., 2006). By ingesting food, an animal gains energy to 
survive and maintain its internal environment. However, food intake must be 
balanced with energy expenditure otherwise over eating coupled with a lack of 
exercise can result in obesity. Obesity has been identified as a worldwide public 
health and economic problem affecting all age groups. It is associated with 
diseases such as type 2 diabetes, hypertension and hyperlipidemia (Masaki et al., 
2006). Genetic and environmental factors influence the development of obesity, 
yet the molecular mechanisms that are involved in obesity have not yet been 
determined (Blissmer et al., 2006). As a consequence of increasing cases of 
obesity worldwide, numerous investigations have been carried out to determine 
the multiple factors at the origin of this imbalance between energy intake and 
energy expenditure (Beck, 2000). Attention was first focused on the nutritional 
aspects such as the use and storage of ingested food but, more recently, 
research has focused on the central nervous system (CNS) and its involvement in 
energy homeostasis. 
 Over the last few decades we have witnessed a huge advance in the study 
and the understanding of the central mechanisms and pathways involved in 
regulating food intake and the control of energy balance. One of the key 
discoveries over the years has been and the acceptance of the prominent 
involvement of the hypothalamus in the control of feeding behaviours. The 
hypothalamus plays an important physiological role in regulating energy balance 
and has a central role in the development of obesity (Morimoto et al., 2001).  
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The overall aims of this project were to determine the effects of histamine, 
a neurotransmitter within the CNS associated with the regulation of appetite, on 
feeding and to describe the central mechanisms which might be targeted by 
potential therapeutic agents.  
In this chapter I will first give an overview of the central and peripheral 
mechanisms controlling appetite and energy expenditure and then go on to 
discuss the histaminergic system and the role it plays in the regulation of feeding 
and the possibility of manipulating this system for the pharmaceutical control of 
appetite and body weight. 
 
 
1.1 Central regulation of appetite 
The control of food intake and energy metabolism is an extremely complicated 
process which depends on the brain’s ability to receive, interpret and integrate a 
wide range of signals which indicate to the organism its nutritional state and 
energy level, and to make appropriate adjustments in the intake of food, energy 
expended and metabolism (Williams et al., 2000). Body weight is regulated by 
complex interrelationships between central and peripheral factors. The CNS 
controls satiety, hunger and hedonistic drive. The peripheral nervous system 
(PNS) controls the metabolism and energy utilization associated with peripheral 
tissue, but is regulated by the CNS. These central and peripheral components of 
weight control are mediated by a multitude of neurotransmitters and hormones 
and their respective receptors (Williams et al., 2000). Peripheral signals are sent 
to central neurones in specific areas of the brain known to control food intake and 
body weight (Jobst et al., 2006). 
By whatever means central neurones receive information regarding energy 
status, it is clear that the effects of peripheral signals are mediated by specific 
transduction systems in identifiable areas of the brain known to control food 
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intake and body weight (Jobst et al., 2006). The hypothalamus is one of these 
brain areas and has been identified as having an important role in controlling food 
intake and energy expenditure. From brain lesion studies, the ventromedial 
hypothalamic nucleus (VMN) and paraventricular nucleus (PVN) are regarded 
predominantly as satiety centres, and the lateral hypothalamus (LH) as a feeding 
centre (for review see King, 2006) (Figure 1.1). After the discovery of these 
centres, several new areas located mainly in the hypothalamus have also been 
associated with food intake. The most important include the hypothalamic arcuate 
(ARC), dorsomedial (DMN) and suprachiasmatic (SCN) nuclei. They form, along 
with the VMN, PVN and LH, complex networks for the regulation of energy intake 
and expenditure (Beck et al., 2000).  
Appetite or the sensation of hunger is the leading force in the drive to eat. 
However, it is also controlled in a circadian fashion by a biological clock located 
within the suprachiasmatic nucleus (SCN). The SCN consists of two small, round 
nuclei resting dorsally on the optic chiasm either side of the third ventricle, that 
act as the internal clock within the body (Nagai et al., 1978). The SCN responds 
to daily and seasonal light cycles to anticipate changes in the local environment 
and ensure changes in behavior, such as the organisms’ ability to coordinate 
daily patterns in activity, feeding, energy utilization and energy storage, to 
maintain the optimum chance of survival (Bechtold DA, 2008). The pattern of 
eating behaviour is a highly-regulated phenomenon in all living organisms (Kalra 
et al., 1999) and lesion studies have shown damage to the SCN results in loss of 
regulated feeding (Nagai et al., 1978).  
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Figure 1.1.; A schematic diagram showing a coronal section through the hypothalamus at 
the level of the ventromedial nucleus (VMN). Other hypothalamic nuclei present at the 
level of this area are; dorsomedial nucleus (DMN), lateral hypothalamus (LH) and arcuate 
nucleus (ARC). 3V denotes the third ventricle. 
 
 
1.2 The homeostatic pathways involved in regulating appetite 
The regulation of food intake is very complex and organized by a complicated 
loop system involving humoral signals and afferent neuronal pathways to the 
brain, which are processed within the hypothalamic neuronal circuitry, and with 
commands then being sent back through vagal and spinal neurones to the body 
(Dozio et al., 2007). Body weight is regulated by these complex interrelationships 
between central and peripheral factors (Ahima et al., 2008).  
Over the last few decades more and more experiments have investigated the 
role of the neuropeptides present in the areas associated with controlling appetite 
and feeding behaviours. These neuromodulators include peptides that inhibit or 
stimulate feeding behaviour. Corticotropin-releasing factor (CRF), cholecystokinin 
(CCK), neurotensin, cocaine- and amphetamine-regulated transcript (CART), α-
melanocyte-stimulating hormone  (α-MSH), pro-opiomelanocortin (POMC) and 
vasopressin are all anorexigenic and decrease feeding, whereas neuropeptide Y 
3V 
LH 
DMN 
VMN 
ARC 
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(NPY), galanin, agouti-related protein (AgRP), melanin-concentrating hormone 
(MCH), and the orexins all stimulate food intake and are, thus, referred to as 
orexigenic (Beck et al., 2000).  
The ARC, situated at the base of the hypothalamus either side of the third 
ventricle, is important in the control of appetite. The ARC has been shown to 
contain the largest co-expression of the orexigenic peptides NPY and AgRP 
(Dhillo WS., 2007). Although research has also revealed a large population of 
cells within the ARC express anorectic signals, including CART and POMC (Elias 
et al., 1998). The ARC neurones receive information regarding energy status from 
peripheral circulating factors, such as ghrelin from the stomach, passing the 
blood-brain barrier (Schwartz et al., 2000). The orexigenic and anorexigenic 
neurones in the ARC project into a number of other hypothalamic sites involved in 
appetite, including the VMN, DMN, LH, and the PVN, allowing the signals from 
the peripheral system to be processed in the necessary brain areas and body 
homeostasis to be maintained (Harrold et al., 2006) (figure 1.2).  
The LH receives extensive connections from the ARC including both orexigenic 
and anorexic inputs from the NPY/AgRP and POMC/CART neurones (Dhillo WS., 
2007). This hypothalamus is the site of production of the orexigenic 
neuropeptides, MCH and the orexins (Sakurai et al., 1998).  
Although electrolytic lesions in the DMN have been shown to disrupt feeding to 
a much lesser degree than those of the VMN (Kalra et al., 1999), suggesting a 
less pivotal role in the control of food intake, microinjection of orexigenic 
compounds into the DMN elicits feeding (Li et al., 1998). Yokosuka et al. 
illustrated that the inhibition of NPY-induced feeding by leptin administration, 
increased neuronal c-Fos in the DMN, which acts as a marker of neuronal 
activation (Yokosuka et al., 1998). Prominent ARC efferents project to the DMN 
and a large number of DMN efferents project to both the VMN and PVN (Kalra et 
al., 1999) illustrating the complex and multiple connections these areas have with 
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each other and showing the complex network systems involved in the control n 
feeding. 
The PVN is situated in the dorsal region of the hypothalamus. It contains a 
dense and heterogeneous cluster of neurones that extend out either side of the 
third ventricle within a well-defined area (Sawchenko et al., 1993). Research 
suggests these vast neuronal elements contained within the PVN are involved in 
the control of ingestive behaviour. Microinjection of virtually all the known 
orexigenic signals, including, NPY, GAL, orexins, GABA, opioids, noradrenaline, 
and adrenaline, into the PVN stimulates feeding (Xu et al., 1995). Whereas 
microinjection of a number of anorexigenic neuropeptides, such as CRH and 
leptin, cause a significant reduction in food intake. Additionally, high densities of 
c-Fos-positive neurones have been shown within the PVN in response to 
administration of both orexigenic and anorexigenic peptides (Dhillo WS., 2007). 
These findings coincide with other evidence that suggests the PVN is one of the 
crucial sites for the release of both orexigenic and anorexgenic signals (Kalra et 
al., 1999). 
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Figure 1.2.; Adapted from DhillO, 2007. Schematic diagram the circulating factors and 
central appetite circuits involved in the regulation of appetite. Peripheral circulating factors 
activate circuits within the hypothalamus and brainstem mediating their effects on food 
intake. There are extensive reciprocal connections between the hypothalamus and the 
brainstem with energy intake being coordinated based on the information received by both 
regions. PVN: paraventricular nucleus; 3V: third ventricle; ARC: arcuate nucleus; VMN: 
ventromedial nucleus; BBB: blood–brain barrier; SNS: sympathetic nervous system; HPT 
axis: hypothalamo-pituitary-thyroid axis; Y1-Y5: Y1-Y5 NPY receptors; MC4R: 
melanocortin 4 receptor; NPY: neuropeptide Y; AgRP: agouti-related protein; α-MSH: 
alpha melanocyte-stimulating hormone; CCK: cholecystokinin; GLP-1: glucagon-like 
peptide-1; PYY: peptide YY; T3: triiodothyronine. Appetite-regulating factors in blue 
stimulate and those in black inhibit food intake. Green arrows represent activation, and 
red arrows represent inhibition of the pathway. 
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1.3 VMN regulation of appetite 
As described above, the hypothalamus has an important role in controlling food 
intake and energy expenditure. To further support this, evidence obtained from 
clinical presentations in hypothalamic tumour patients and from preclinical lesion 
studies suggest that damage to the mediobasal hypothalamic areas, in particular 
the VMN, are associated with increased food intake, morbid obesity and insulin 
resistance, while damage to more lateral hypothalamic structures are associated 
with anorexia and adipsia (Anand et al., 1951). Neuroimaging studies have 
illustrated neurones within the immediate area of the VMN become activated 
during feeding (Liu et al., 2001). Electrical stimulation of the VMN decreases 
feeding, whereas stimulation of the LH region increases appetite (Mittleman et al., 
1984). It has even been noted that rats with VMN lesions often begin eating 
insatiably, even before fully recovering from the effects of anesthesia (Brobeck et 
al., 1943, Brooks et al., 1946). Brooks et al. suggested the overeating and obesity 
resulting from VMN lesions can be crudely divided into two stages; firstly, a 
dynamic phase of marked hyperphagia and rapid weight gain, which is then 
followed by a reduction in food intake as body weight levels off and is then 
maintained during the static second phase of obesity (Brooks et al., 1946). Thus, 
the VMN is a “satiety centre” of the brain and therefore, if damaged, it can no 
longer enforce feeding restraints, resulting in overeating and weight gain (Sclafani 
A., 1971, Bray et al., 1981). The VMN has direct links with the PVN and DMN and 
via these it connects indirectly with the LH (Harrold et al., 2004), illustrating the 
complex circuitry surrounding the VMN involved in regulating food intake within 
the hypothalamus. 
VMN lesion-induced obesity has been found in a wide variety of species, which 
include mice (Mayer et al., 1955), rabbits (Romanouk A., 1962), ground squirrels 
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(Mrosovsky et al., 1974), cats (Anand et al., 1955), chickens (Lepkovsky et al., 
1966), sparrows (Chen et al., 2006), dogs (Rozkowska et al., 1971), monkeys 
(Brooks et al., 1946) and humans (Bray et al., 1979).  
Research has illustrated that the VMN has a large number of glucose-sensing 
neurones that dynamically respond to hypo- or hyperglycaemia (Anand et al., 
1964, Oomura et al., 1973, Song et al., 2001). Studies have also revealed that 
the VMN has many receptors that respond to neurotransmitters and hormones, 
such as dopamine (Davidowa et al., 2002, Fetissov et al., 2002, Meguid et al., 
1997), serotonin (Leibowitz SF., 1986, Meguid et al., 2000), GABA (Dellouade et 
al., 2001), insulin (Baskin et al., 1999, Bruning et al., 2000), leptin (Dhillo WS., 
2007), histamine (Magrani et al., 2004, Mollet et al., 2003, Sakata et al., 2003), 
ghrelin (Kamegai et al., 2001), orexin (Heidel et al., 1999), and estrogen (Pfaff et 
al., 1973, Wade et al., 1970) to affect feeding behaviour. The response of many 
of these receptors has been found to be abnormal in obese animals that were 
overfed since birth (King et al., 2006). The VMN receives projections from ARC 
NPY-, AgRP- and POMC-immunoreactive neurones and in turn VMN neurones 
project to other hypothalamic nuclei, such as the DMN, and to brainstem regions, 
such as the nucleus of the solitary tract (NTS) (Wynne et al., 2005). Mice with 
reduced brain-derived neurotrophic factor (BDNF) receptor expression or 
decreased BDNF signalling have been shown to significantly increase food intake 
resulting in increased body weight (Rios et al. 2001, Xu et al. 2003). Xu et al. 
demonstrated that BDNF is highly expressed within the VMN, and its expression 
is dramatically reduced by fasting (Xu et al. 2003) or by melanocortin agonists 
(figure 1.2). This suggests BDNF neurones within the VMN may form downstream 
pathways through which the melanocortin system regulates appetite and body 
weight (Wynne et al., 2005). The VMN has also been identified as a key target for 
leptin, which acts on the hypothalamus to inhibit feeding and stimulate energy 
expenditure (Dhillon et al. 2006). Here leptin could be acting via cells containing 
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the VMN-expressed neuropeptide, pituitary adenylate cyclase-activating 
polypeptide (PACAP), which also reduce food intake and energy expenditure 
(Hawke et al., 2009). 
 
 
1.4 The brainstem and gut involvement in the regulation of appetite 
The brainstem has numerous interactions with hypothalamic circuits and plays 
a major role in the regulation of energy homeostasis. In particular there are 
extensive reciprocal connections between the NTS and other brainstem areas 
(Ter Horst et al. 1986). The ARC in the hypothalamus is pivotal for receiving 
peripheral signals mediating information on appetite and metabolic needs, whilst 
the NTS is the key entry port for signals from the gastrointestinal (GI) tract 
(MacDougald et al., 2002) (figure 1.3). The GI tract acts not only as a conduit for 
food, but is also crucial for the digestion and absorption of nutrients (Ahima et al., 
2008). The brain, and in particular the NTS receives signals from the GI tract 
about meal size and content through sensory nerves and via the circulation 
(Schwartz et al., 2000 b). Projections from the NTS and the parabrachial nucleus 
in the brainstem innervate the PVN, DMN and ARC nuclei of the hypothalamus 
and the LH area, central nucleus of the amygdala (AMY) and bed nucleus of the 
stria terminalis (Ahima et al., 2008). The NTS projects also to the visceral sensory 
thalamus, which goes on to communicate with the visceral sensory cortex, which 
mediates the conscious perception of fullness and satiety. Studies demonstrate a 
powerful negative feedback control of vagal afferent innervation on feeding 
(Schwartz et al., 2000, Smith et al., 1985, South et al., 1988). 
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Figure 1.3.; Figure taken from Naslund et al., 2007, Afferent gastrointestinal signals 
controlling food intake. CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; PYY(3-36), 
peptide YY(3-36); NPY, neuropeptide Y; AgRP, agouti-related peptide; α-MSH, α 
melanocyte-stimulating hormone; POMC, pro-opiomelanocortin; NTS nucleus of the 
tractus solitarius; ARC, arcuate nucleus. 
 
 
 
Many of the peptides involved in the regulation of energy homeostasis in the 
brain are also found in the enteric nervous system and enteroendocrine cells of 
the mucosa of the GI tract (Naslund et al., 2007). Peptide signalling from the gut 
influences food intake, that then goes on to influence neuropeptidergic neurones 
in the brain. These hormones include CCK, which was the first gut secreted 
peptide to be identified as a satiety factor; GLP-1, a product of the 
preproglucagon gene secreted primarily by endocrine cells of the small and large 
intestine after eating: PYY, a gut peptide belonging to the same family as NPY 
and is released in response to feeding to cause a decrease in food intake; amylin, 
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which exerts anorectic effects; ghrelin, a growth hormone-releasing peptide that is 
predominantly released from the stomach and acts as a hunger signal: insulin 
which is secreted in response to meals and increases glycogen storage; and the 
endocannabinoids which have significant effects on appetite and metabolism 
along with glucocorticoids (Ahima et al., 2008).  
 
 
1.5 The reward pathways involved in regulating appetite 
There are multiple interactions between the homeostatic and hedonic 
mechanisms controlling food intake (Zheng et al., 2009). The rewarding nature of 
food can act as a stimulus to feeding, even when hunger and energy homeostasis 
are missing. Although the sensation of reward is ultimately influenced by energy 
status, the subjective palatability of food is altered in the fed state compared with 
the fasting state (Berridge et al., 1991). Thus, signals of energy status influence 
reward pathways (Wynne et al., 2005). The reward circuitry is complex and 
involves many interactions between numerous signalling systems (figure 1.4). 
Cognitive and emotional factors have an important role in regulating feeding, 
especially in humans (Zheng et al., 2009). This high-level control involves 
integration of a number of external and internal signals, which include, peripheral 
signals related to energy status, food-related signals conveyed by taste, smell, 
and other senses, environmental cues, such as the sight of food, and memory of 
past feeding experiences (Benarroch et al., 2010). Several functional 
neuroimaging studies indicate that the insular, orbitofrontal, and anterior cingulate 
cortical areas are activated in relationship to these stimuli and participate in 
motivational aspects of feeding behaviour in humans (Rolls ET., 2008, Zheng et 
al., 2009). The nucleus accumbens is vital in the reward aspect of food intake as 
it integrates the homeostatic, hedonic, motivational, and cognitive aspects of food 
intake via its connections with the prefrontal cortex, amygdala, and lateral 
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PVN 
hypothalamus (Kelley et al., 2005). Although, it has also been recognised that the 
reinforcing effect is lost in the fasted state, suggesting homeostatic mechanisms 
can override hedonistic mechanisms (Hayward et al., 2002, Wynne et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.; Adapted from Wynne et al. 2005. This diagram illustrates the central control 
of appetite. AP, area postrema; ME, median eminence; NAc, nucleus accumbens; PFA, 
perifornical area.  
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Orexin neurones are important in linking energy balance, behavioural 
arousal, and reward. These neurones are active during wakefulness and 
participate in the short-term regulation of energy homeostasis (Sakurai T., 1999). 
Orexin neurones that activate ventral tegmental area dopaminergic neurones 
have been implicated in hedonic mechanisms of food intake (Harris et al., 2006). 
Opioids also play an important role in feeding and reward behaviours. For 
example, Hayward et al. (2002) found that regardless of the palatability of the 
food tested, a lack of enkephalin or β-endorphin abolishes the reinforcing property 
of food in mice. The dopaminergic system is also integral to reward-induced 
feeding behaviour, for example, mice which lack dopamine have fatal 
hypophagia. Injections of opioid and dopamine agonists into the nucleus 
accumbens preferentially stimulate the ingestion of highly-palatable foods (Zhang 
et al., 2003). Stratford et al. have suggested that GABA-ergic connections 
between the nucleus accumbens and the LH may mediate hedonistic feeding by 
disinhibition of LH neurones (Stratford et al., 1999). Additionally, the MCH 
neurones in the LH may reciprocally influence the reward circuitry, as the nucleus 
accumbens expresses MCH receptors (Saito et al., 2001). Other systems, 
including those mediated by endocannabinoids and serotonin, may also be able 
to modulate both reward circuitry and homeostatic mechanisms controlling 
feeding (Cota et al., 2003).  
Signaling systems expressed in the hypothalamus also contribute to both 
homeostatic and hedonic control of food intake are those containing CART 
peptide and the endocannabinoids (Harrold et al., 2006). CART is colocalized 
with POMC in neurones of the ARC and exerts a potent anorexigenic effect in 
rodents (Dietrich et al., 2009). Whereas the endocannabinoids promote feeding 
and provide anabolic signals via multiple actions at the hypothalamus, mesolimbic 
reward system and periphery (Bellocchio et al., 2008). Additionally, leptin inhibits 
firing of dopaminergic neurones and feeding-induced dopamine release in the 
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nucleus accumbens (Hommel et al., 2006), whereas ghrelin stimulates both 
dopamine release and feeding (Abizaid et al., 2006).  
 
 
1.6 The histaminergic system 
While the role of histamine in neural functioning and behaviour is only partially 
understood, it is widely accepted that histamine functions as a central 
neurotransmitter (Orthen-Gambil et al., 1992, Sakata et al., 1997, Takahashi et 
al., 2002, Zawilska et al., 1985). In the mammalian CNS, anatomical, 
neurochemical, pharmacological and electrophysiological data have converged to 
demonstrate that histamine is involved in a wide array of neuroendocrine, 
cardiovascular and thermoregulatory functions, including arousal, cognition, 
locomotor activity, autonomic and vestibular functions, feeding and drinking, 
sexual behaviour and analgesia (Hough LB., 1988; Schwartz et al., 1991; Wada 
et al., 1991, Chotard et al., 2002, Gomez-Ramirez et al., 2002, Hancock et al., 
2004).  
In the mammalian brain, histamine is synthesized by a population of neurones 
whose cell bodies are restricted to the tuberomammillary nuclei (TM) of the 
posterior hypothalamus (Schwartz et al., 1991). Diffuse histaminergic nerve fibres 
consisting of long, varicose, arborizing, slowly-conducting axons project from the 
TM to virtually all parts of the brain (figure 1.5). These axons form synaptic 
contacts with other neurones, while varicosities can be apposed to neurones, glial 
cells and capillaries (Bugajski, et al., 2003). The highest density of histamine 
fibres in the brain is in the ventral half of the posterior hypothalamus, including the 
VMN. Although the median eminence, SCN and PVN are also highly innervated 
with histaminergic fibres, all areas of the hypothalamus receive a moderate to 
strong histaminergic innervation (Gomez-Ramirez et al., 2002).  
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Figure 1.5.; Diagram taken from Schwartz et al., 1990. The disposition of the main 
histaminergic pathways in the rat brain as indicated by the black arrows. The diagram 
illustrates the sagital section of the rat brain. AH, anterior hypothalamic area; cc, corpus 
callosum; Cer, cerebellum; CG, central grey; CX, cerebral cortex; DR, dorsal raphe 
nucleus; Hip, hippocampus; LS, lateral septum; MD, mediodorsal thalamus; MMN, medial 
mammillary nucleus; OB, olfactory bulb; Pn, pontine nuclei; Sol, nucleus of the tractus 
solitarius; Sox, supraoptic decussation; VDB, nucleus of vertical limb of diagonal band; 
VMN, ventromedial hypothalamic nucleus. 
 
 
 
Cortically projecting histaminergic neurones share, along with other aminergic 
neurones, certain electrophysiological properties evidenced by extracellular 
recording. Histaminergic neurons fire spontaneously, slowly and regularly, and 
their action potentials are of long duration (Haas et al., 1989). The rate of firing 
varies depending on the behavioural state of the animal. For example, direct 
recordings of histamine neurones in cats indicated their activity is high during 
waking and attention, but low or absent during sleep (Haas et al., 2003). Thus, 
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histaminergic neurones exhibit a circadian rhythm in their firing rate (Schwartz et 
al., 1991). Furthermore, in the rat hypothalamus, histamine levels are low, 
whereas synthesis is high during the dark period, suggesting neuronal activity is 
enhanced during the active phase (Hill et al., 1997). In addition, in the mouse 
cerebral cortex, striatum and hypothalamus, tele-methylhistamine levels, a 
histamine analogue, are doubled at the end of the dark phase compared with the 
beginning of the light phase (Morisset et al., 2000). Mochizuki et al. have also 
demonstrated that histamine release from the anterior hypothalamus of freely 
moving rats, evaluated by in vivo microdialysis, gradually increases in the second 
half of the light period and is maintained at a maximal level during the active 
phase (Mochizuki et al., 1992).  
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Figure 1.6.; This diagram has been adapted from Haas et al., and illustrates histamine 
transport and metabolism in neurones. Histidine is brought into neurones via the L-amino-
acid-transporter. Here histamine is synthesized by the specific enzyme histidine 
decarboxylase. Histamine is then taken up into vesicles by the vesicular monoamine-
transporter VMAT-2. After release, histamine is methylated by histamine-
methyltransferase, which is located post-synaptically in glia, to tele-methylhistamine. Tele-
methylhistamine exhibits no histamine-like activity. The turnover rate for neuronal 
histamine is very high, and its half-life, which is normally about 30 minutes, can change 
quickly depending on neuronal activity. Increased neuronal activity, such as stressful 
situations increases histamine turnover (Haas et al., 2003). 
 
 
 
A vast body of evidence illustrates the importance of central histamine 
signaling in the control of food intake and energy regulation (Yoshimatsu et al., 
1993, Yoshimatsu et al., 2001, Yoshimatsu H., 2006, Yoshimoto et al., 2006, 
Gotoh et al., 2007). Behavioural studies have revealed histamine suppresses 
food intake when administered centrally or systemically (Doi et al., 1994, Endou 
et al., 2000, Lecklin et al., 1998, Lecklin et al., 1995). Orthen-Gambill et al. 
suggested that removal of histamine’s inhibitory effect might in turn stimulate 
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feeding (Orthen-Gambill et al., 1992). They found in rodents, if histamine levels 
were decreased using the histamine synthesis inhibitor α-fluoromethylhistidine (α-
FMH), which is a potent, highly specific, and irreversible inhibitor of histidine 
decarboxylase (HDC), an increase in both food intake and body weight was 
produced. Additionally, central histaminergic activity is increased by food intake 
after fasting (Itoh et al., 1991). Yoshizawa et al. showed there were alterations 
within central histaminergic activity in anorexia nervosa patients (Yoshizawa et 
al., 2009). Histamine depolarises select brainstem neurones in the NTS and 
dorsal motor nucleus of the vagus (Poole et al., 2008), which together with the 
hypothalamus, have a fundamental role in the control and regulation of food 
intake (Jelsing et al., 2009). In the GI tract, histamine is considered to regulate at 
least three major functions, firstly the enhancement of gastric acid production 
(Tari et al., 1993), secondly, modulation of GI motility (Bolton et al., 1981), and 
finally the alteration of mucosal ion secretion (Wang et al., 1990). Thus, it seems 
endogenous histamine plays an important role in regulating food intake.  
 
 
1.7 Histamine receptor types  
Histamine exerts its multiple biological activities through the activation of 
at least four distinct receptors: H1R, H2R, H3R and H4R (Leurs et al., 1995, 
Lovenberg et al., 1999, Masaki et al., 2006). All four histamine receptors belong 
to the superfamily of heptahelical seven-transmembrane (7TM), G-protein-
coupled receptors (GPCR) (Govoni et al., 2006). Constitutive activity has been 
shown in all the histamine receptors and is explained in more detail in Chapter 5 
of this thesis.  
Terao et al. suggest that histamine H1R are located post-synaptically with 
high densities of these receptors being apparent in the hypothalamus and other 
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limbic regions (Terao et al., 2004). H2R are also mainly located post-synaptically 
and are found in the hippocampus, amygdala and basal ganglia. Histamine H3R 
are located on the somata and axon terminals of histamine neurones where they 
serve as autoreceptors to modulate histamine synthesis and release, and are 
also located pre- and post-synaptically the brain. Histamine H4R are expressed 
primarily in bone marrow and eosinophils, and are found at very low levels in the 
brain. However, as the H4R are a more recent discovery considerably less 
research has been carried out on these receptors. The H1R is a 486–491 amino 
acid protein encoded by an intronless gene (Yamashita et al., 1991), and is 
coupled to the Gq/11 protein and phospholipase C. Like the H1R, an intronless 
gene encodes the H2R, and the protein consists of 358–359 amino acids. It is 
coupled to Gs and protein kinase A. Several isoforms of the H3R, consisting of 
326–445 amino acids, are derived from a single gene by alternative splicing 
(Lovenberg et al., 1999). The H3 autoreceptor is coupled to Gi/Go, displays 
significant constitutive activity, and controls histamine release and synthesis 
(Morisset et al., 2000). The H3R is highly heterogeneous and its gene structure is 
more complex than that of the H1 and H2 receptors. H3R are coupled to Gi/o and 
high voltage-activated Ca2+ channels, a typical mechanism for the regulation of 
transmitter release (Haas et al., 2003. The H3R is coupled negatively to cAMP 
and activates the mitogen activated protein kinase pathway (Drutel et al., 2001). 
The human H3R gene has four exons and gives rise to six or more alternative 
splice variants (Coge et al., 2001). The H3R regulates the release of several 
transmitters in brain areas such as the substantia nigra, amygdala and cerebral 
cortex (Haas et al., 2003). The gene encoding the H4R has a similar intron–exon 
arrangement as the gene encoding the H3R (Coge et al., 2001). The H4R is a 
390-residue GPCR encoded by three exons and is expressed predominantly in 
bone marrow, eosinophils and mast cells (De Esch et al., 2005). H1 and H2 
receptors have mostly excitatory actions on neurones or potentiate excitatory 
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inputs. Conversely, H3R activation causes autoinhibition of TM neurones and 
inhibition of neurotransmitter release (Haas et al., 2003). As H4R are most similar 
to H3R it could be assumed that they also exhibit inhibitory affects on their target 
cells. The H1 and H2 receptors are found densely throughout the central and 
peripheral nervous system, the H3R is predominantly found within the CNS and 
the H4R is found solely within the PNS. Sander et al. found that H1R, H2R, and H-
4R are expressed in the human GI but found no evidence of H3R expression here 
(Sander et al., 2006). 
 
 
1.7.1 The H1 receptor 
H1R are located post-synaptically and are found in the hypothalamus, 
cerebral cortex, basal forebrain and limbic system (Morimoto et al., 2001) (see 
figure 1.7). H1R mediate excitatory actions on whole-brain activity. The classic 
antihistamines and antipsychotics act as H1R antagonists but H1R-based drugs 
have also been effective in treating depression, anxiety and sleep disorders. 
Stimulation of H1R regulates the level of H1R protein expression through 
activation of H1R mRNA synthesis (Hill et al., 1997). 
Histamine H1R knockout (H1R-KO) mice (Inoue et al., 1996) exhibit a complex 
cognitive phenotype, including both impairments and improvements in a variety of 
learning and memory tasks (Dai et al., 2007, Zlomuzica et al., 2008). The results 
of physiological and pharmacological studies have revealed that brain histamine 
and H1R are involved in the regulation of feeding and obesity in rodents (Masaki 
et al., 2006). The effects of the H1R on weight gain were first witnessed in 
patients taking antipsychotic and antidepressant drugs with H1R antagonistic 
properties which caused drastic and rapid weight gain. Research suggested that 
weight gain caused from taking antipsychotic drugs was through a drug-induced 
decrease in the hypothalamic expression of the H1R, blockade of which is linked 
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to downstream AMPK activation, resulting in increased food intake which, when 
coupled with insufficient locomotion, results in drastic weight gain (Kim et al., 
2007, Han et al., 2008).  
Central administration of histamine can reduce body mass and adiposity in diet-
induced and genetically-obese mice by altering food intake and energy 
expenditure. Endogenous histamine in the brain exerts an inhibitory effect on 
feeding behaviour through the H1R (Fukagawa et al., 1989; Sakata et al., 1994, 
Ookuma et al., 1993, Doi et al., 1994). However, H1R antagonists can stimulate 
other neurotransmitter systems which affect feeding behaviour, such as serotonin 
or noradrenaline (Lidbrink et al., 1971). Therefore, potential effects of H1R 
antagonists on other transmitter systems should always be considered. Through 
site injections of histamine, H1R in the VMN and PVN are implicated in the 
neuronal regulation of appetite (Masaki et al., 2003). A simple, yet clear indication 
that endogenous H1R are important in feeding and body weight regulation is 
provided by the fact that the H1R-KO mouse is obese (Inoue et al., 1996). 
Although it must be noted that H1R are also found in peripheral tissues that are 
concerned with regulating body composition (Masaki et al. 2006). Neuronal 
histamine and the H1R are also involved in the central regulation of energy 
homeostasis through sympathetic influences on uncoupling protein expression in 
brown adipose tissue (Masaki et al., 2001, Takasashi et al., 2002). Consistent 
with these observations, Masaki et al. showed that H1R-KO mice displayed late-
onset obesity and decreased energy expenditure (Masaki et al., 2004). 
Interestingly, the anorectic activity of ICV leptin was significantly attenuated in 
H1R-KO mice (Masaki et al., 2001), suggesting the obese phenotype of H1R-KO 
mice could be explained in part by reduced sensitivity to leptin.  
H1R antagonists are not used pharmacologically for appetite regulation as they 
cause a number of adverse effects due to ubiquitous expression in peripheral 
tissues, including in lymphocytes, heart, and spleen, as well as in the CNS 
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(Kinnunen et al., 1998). The H1R is involved in a number of actions as it is so 
widely found peripherally and centrally and, therefore, it is difficult to make drugs 
that target just one of its many functions and pathways. 
 
 
 
  
 
 
 
 
 
 
 
Figure 1.7.; Illustration based on Hill (1990) showing the interaction between histamine 
(HA) and presynaptic H3 receptors on histaminergic nerve terminals, and H1 and H2 
receptors on postsynaptic cells in the central nervous system. H3-receptor stimulation 
leads to an inhibition of both the synthesis of histamine from histidine (HD) and its release 
into the synaptic cleft. H1- and H2-receptor stimulation leads to physiological responses 
via the action of intracellular messengers diacylglycerol (DG), inositol trisphosphate 
(InsP3) and cyclic 3`,5` adenosine monophosphate (cAMP). 
 
 
 
1.7.2 The H2 receptor 
H2R like H1R are also located post-synaptically (figure 1.7) and occur at 
high densities in the basal ganglia and parts of the limbic system, such as the 
hippocampal formation and amygdala (Masaki et al., 2006). As there are diffuse 
projections of histamine fibres throughout the mammalian brain. Histamine is 
involved in the central control of a large number of behaviours and functions, 
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including neuroendocrine responses (Schwartz et al., 1991) and cardiovascular 
functions (Onodera et al., 1994), motion sickness, sleep and wakefulness cycle 
(Schwartz et al., 1991), stress-induced responses and behaviour, learning 
behaviour and some clinical disorders. Most of these functions in the physiologic 
and pathologic states have been identified to be mediated by H1R and/or H2R in 
the brain.  
H2R are coupled to Gs, adenylyl cyclase and protein kinase, which 
phosphorylates proteins and activates the transcription factor cyclic-AMP-
response element (CRE)-binding protein (CREB). The direct action on neuronal 
membranes is usually excitatory or potentiates excitation (Francis et al., 2007). 
Unlike H1R, H2R are apparently not involved in the control of food intake, since 
injections of H2R agonists do not decrease food intake (Sakata et al., 1988). In 
addition, H2R antagonists do not abolish the feeding suppressive effects of central 
histamine (Lecklin et al., 1998; Morimoto et al., 2001).  
 
 
1.7.3 The H3 receptor 
The H3R differs from the H1 and H2 receptors as it is located pre-synaptically 
(figure 1.7) and is expressed predominantly in the CNS, with high densities being 
found in the cerebral cortex, nucleus accumbens, striatum, olfactory tubercles 
and substantia nigra (Lovenberg et al., 1999). H1R and H3R mRNAs are detected 
in a number of areas within the hypothalamus including the VMN and the ARC 
(Lovenberg et al., 1999). Studies using selective H3R ligand binding have shown 
a high density of H3R in the hypothalamus, striatum and nucleus accumbens 
(Hussain et al., 2002). Although the highest densities of H3R can be found in the 
CNS, they are also present in much lower levels within the PNS, for example, in 
the GI tract, the airways and the cardiovascular system (Celanire et al., 2005). 
The histamine H3R was discovered in 1983 by Arrang and co-workers (Arrang et 
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al., 1983) and later cloned (Lovenberg et al., 1999). H3R are located on the cell 
bodies and axon terminals of histamine-containing neurones, where they serve as 
autoreceptors to modulate histamine synthesis and release (Celanire et al., 
2005). H3R also act as presynaptic heteroreceptors on the terminals of neurones 
that contain other transmitters, such as dopamine, serotonin, noradrenaline, 
GABA and acetylcholine, thus can also negatively regulate the release of a 
number of other neurotransmitters (Schlicker et al., 1994) (figure 1.8). Since H3R 
are located predominantly in the CNS, it has been suggested that H3R mediate 
various CNS functions by modulating brain histaminergic tone and possibly by 
interacting with H1R and H2R. R-alpha-methylhistamine, a selective H3R agonist, 
inhibits the release of endogenous brain histamine (Itoh et al., 1998), while 
thioperamide, a selective inverse agonist, enhances histamine release (Itoh et al., 
1998, Itoh et al., 1999).  
H3R is functionally linked to Gi/o proteins, thus negatively regulates intracellular 
cAMP levels (Lovenburg et al., 1999, Chen et al., 2003). The amino acid 
sequences of H3Rs are highly conserved among humans, monkeys, rats, mice, 
and guinea pigs, thus suggesting that H3Rs play critical roles in numerous 
species (Hancock et al., 2003). Research has shown that several splice variants 
are present in humans, rats, mice and guinea pigs. Drutel et al. reported that rat 
H3R splice variants (H3A, B, and C) showed distinct expression patterns in the 
brain and were differentially coupled to Gi/o proteins when expressed in cultured 
cells (Drutel et al., 2001). Observations suggest that the splicing variants might 
have distinct roles in vivo, but the full extent of which are still unknown. Although 
no major pharmacological differences have yet been noted for these isoforms 
using antagonists, agonists do show increased potencies for the short isoform 
(Wieland et al., 2001). One important point to illustrate is that profound species 
differences in the antagonist pharmacology of the rat and human H3Rs have been 
observed (Ligneau et al., 2000; Lovenberg et al., 2000; Yao et al., 2003).  
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One of the remarkable features of H3R is its high constitutive activity both in 
vivo and in vitro (Morisset et al., 2000) (for a full and detailed description of H3R 
constitutive activity see Introduction in Chapter 6 of this thesis). The high 
constitutive activity of H3R may be critical for its regulatory function in the CNS 
(Morisset et al., 2000, Schwartz et al., 2003). Both native and heterologously 
expressed recombinant H3Rs are constitutively active (Morisset et al., 2000; 
Wieland et al., 2001; Rouleau et al., 2002), and as a result of this several 
previously characterized H3R antagonists have subsequently been shown to be 
inverse agonists, including thioperamide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.; Based on Yoshimoto et al., (2006) illustrating the regulation of H3R on 
appetite. Released histamine acts on H3R located on the presynaptic histamine terinal or 
on non-histaminergic neurones containing noradrenaline, dopamine, serotonin, glutamate, 
and GABA. Released histamine may also activate postsynaptic H3R. 
 
 
 
H3R 
H3R 
H3R 
Histaminergic neurone 
Non histaminergic neurone 
Non-histaminergic receptor 
Food intake 
reduction 
? 
 43 
H3R-specific ligands have been shown to have beneficial effects in animal 
models of obesity, epilepsy, and cognitive diseases such as Alzheimer’s disease 
and attention deficit hyperactivity disorder (Hancock et al., 2003; Passani et al., 
2004; Leurs et al., 2005). Thus, H3R antagonists/inverse agonists are considered 
as potential new therapeutics and are currently undergoing clinical trials (Celanire 
et al., 2005). 
The histaminergic system is well-documented for its involvement in reducing 
food intake through the histamine-induced activation of the H1R, but the histamine 
H3R also plays an important role in food intake and body weight regulation. H3R 
agonists have been shown to increase food intake whereas the H3R antagonists 
and inverse agonists appear to reduce feeding. The role of the H3R in energy 
control are still being elucidated but due to its complexity it could be affecting 
feeding by acting via the H1R or even by controlling the release of other 
neurotransmitters.  
H3R-KO mice display enhanced histamine release when compared with wild-
type (WT) littermates, with increased histamine release being recorded in the 
forebrain, hypothalamus, thalamus, hippocampus, cerebellum and brainstem 
(Takahashi et al., 2002). H3R-KO mice are viable and fertile, but initially their body 
size does not differ significantly from WT littermates, and they show no overt 
abnormalities in the brain or other tissues. The key variation from the WT 
phenotype is that H3R-KO mice display mild hyperphagia, decreased energy 
expenditure and late-onset obesity. The fact H3R-KO mice become obese is a 
paradoxical finding as without the H3R being present it would be expected that 
histamine release would cease to be negatively controlled and, thus, a increase in 
circulating endogenous histamine would be present, resulting in anorexic and 
even a lean mouse phenotype. Takahashi et al., suggest it could be that a lack of 
H3Rs alters neural circuitry during the development stage or sustained increases 
in histamine release may desensitize and/or down-regulate post-synaptic 
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histamine receptors (H1R and H2R), and hence attenuate net histaminergic tone, 
but the evidence for this has yet to be found (Takahashi et al., 2002).  
 
 
1.7.4 The H4 receptor 
The H4R is a post-synaptic receptor and is coupled mainly to Gi/o 
proteins. In either stably or transiently transfected cells, H4R activation leads to a 
pertussis-toxin-sensitive decrease in the forskolin-induced production of cAMP 
and the inhibition of downstream events such as CREB-dependent gene 
transcription in much the same way as the H3R (Lui et al., 2001 b). This 
observation indicates that the H4R, like other histamine receptors expresses 
constitutively activity. The H4R was cloned and found to be over 35% homologous 
to the H3R (Lui et al., 2001 b). 
Research into the H4R suggests it is involved principally in the immune 
system and expressed mainly during allergic reactions or as an inflammatory 
response (De Esch et al., 2005, Nguyen et al., 2001). The H4R is expressed in 
the PNS, but to date there is no consistent observable evidence suggesting H4R 
expression in the brain (Liu et al., 2001 b, Welty et al., 2009). O’Reilly et al. did 
report weak expression in the human brain, but expression has not been 
demonstrated in the brains of rat, mouse or guinea pig (O’Reilly et al., 2002). 
Therefore, if these receptors are expressed in the brain they are expressed at 
minimal levels. No evidence has been found to suggest the H4R has any role in 
the control of energy requisition or expenditure. 
 
 
1.8 Histamine and feeding 
Neuronal histamine is involved in the regulation of food intake (Morimoto et al., 
2001). Changes in endogenous histaminergic tone in the CNS have been 
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associated with genetic models of obesity (Machidori et al., 1992), such as the 
ob/ob mouse (Hancock et al., 2004). L-histidine, the precursor of histamine, 
decreases food intake when it is intraperitoneally (IP) injected (Orthen-Gambill N., 
1988, Sheiner et al., 1985). The ICV infusion of histamine itself (Lecklin et al., 
1998) or the increase of endogenous histamine by the administration of 
metoprine, an inhibitor of histamine catabolic enzyme, suppresses food intake in 
rats (Lecklin 1995). α-FMH the specific suicide inhibitor of histidine HDC, 
inactivates HDC more specifically and potently than any other HDC inhibitors 
(Garbarg et al., 1980). This inactivation of HDC is highly selective, so much so 
that α-FMH depletes neuronal histamine almost completely from the nerve 
terminals therefore increasing food intake (Garbarg et al., 1980). Thus, 
pharmaceutical agents directed at HDC could help regulate the release and 
synthesis of histamine and, thus, be used as a drug to help control appetite. 
H1R and H3R are both important for regulating feeding, and research suggests 
they have opposing affects on food intake. In both humans and rodents, 
treatment with a H1R antagonist or H3R agonist results in hyperphagia (Fukagawa 
et al., 1989), and administration of a H1R agonist or H3R antagonist or inverse 
agonist leads to hypophagia (Attoub et al., 2001, Takahashi et al., 2002). These 
opposing effects on food intake are most simply explained by the fact that the 
H1R is a postsynaptic receptor whereas the H3R is a presynaptic autoreceptor. 
Evidence for histamine’s role in food intake and appetite share the common 
theme that insufficient stimulation of post-synaptic CNS histamine H1R causes 
increased food consumption and/or weight gain (Karlstedt et al., 2001). Studies 
have shown the ability of histamine H3R antagonists or inverse agonists to 
promote weight loss or prevent weight gain (Hancock et al., 2004), with the 
presumed mechanism of action being the resulting enhanced release of 
histamine from histaminergic terminals, leading to the stimulation of postsynaptic 
histamine H1R to reduce appetite. Thus, a presumed CNS mode of action is 
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likely, although findings from recent in situ hybridization histology indicating the 
prominent expression of histamine H3R mRNA in brown adipose tissue (Karlstedt 
et al., 2001) would also support a potential non-CNS role in regulating 
thermogenesis through peripheral sites of action (Hancock et al., 2004).  
The H1R has long been a target of interest in the regulation of food intake. 
ICV application of a H1R agonist (2-(3-trifluoromethylpehenyl)histamine) potently 
suppresses food intake, whilst antagonism of hypothalamic H1R’s results in food 
intake (Sakata et al., 1997; Han et al., 2008). In addition, the H3R is also 
important in the control of food intake. For example, antagonism of H3R’s in the 
hypothalamus reduces food intake and induces weight loss in diet-induced obese 
rodents, as well as rhesus monkeys and pigs (Hancock et al., 2004; Malmlof et 
al., 2005; Malmlof et al., 2007), whilst the H3R agonist, imetit enhances feeding in 
rats (Chiba et al., 2009). Furthermore, the H3R’s localisation in the hypothalamus 
and NTS is supportive of its potential role in the regulation of food intake (Poole et 
al., 2008). The H3R has a distinct role in numerous appetite signaling pathways. 
For example, the H3R inverse agonist, thioperamide, inhibits food intake induced 
by the potent orexigens NPY and PYY (Itoh et al., 1999), whilst H3R agonists, R-
α-methyl-histamine (α-MH) and imetit, decrease bombesin-induced satiety in rats 
(Kent et al., 1997). In addition, H3R activation reduces the anorexigenic effects of 
amylin in fasted rats (Lutz et al., 1996). A study by Attoub et al. found that α-FMH 
dose-dependently inhibited the satiating effects of CCK, whilst thioperamide 
enhanced CCK-induced satiety. They also found that pre-treatment with 
pyrilamine, a post-synaptic H1R antagonist, inhibited CCK-induced satiety (Attoub 
et al., 2001), indicating that whilst the H3R controls pre-synaptic histamine 
concentrations, CCK-induced satiation is also dependent upon the post-synaptic 
activation of the H1R. 
In mice and rats, the activity level of the histaminergic system is relatively 
high at night and low in the day (Mochizuki et al., 1992). However, these animals 
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eat at night for the most part although at this time the histamine activity is high. 
Sakata et al., showed that H1R  (Sakata et al., 1988) and α-FMH (Sakata et al., 
1990) antagonism induced food intake when they were modulated soon after 
lights on, but their effects were attenuated in the dark phase. In addition, they 
also showed that thioperamide reduces food intake in the dark (Sakata et al., 
1990). If this is the case, the abilities of these drugs to affect food intake inversely 
correlates with the histamine level in both the light and dark phase (Morimoto et 
al., 2001).  
 
 
1.9 Histamine and its interactions with other transmitters and peptides 
 As mentioned previously, the histamine H3R can act as a heteroreceptor and 
it is well documented that these receptors are present on the neurones of a 
number of other neurotransmitters. Thus, the H3R not only regulates the release 
of histamine itself but also of other transmitters (Schlicker et al., 1994). Research 
indicates that the H3R’s modulate the release of dopamine, acetylcholine, 
serotonin, GABA and noradrenaline in the brain (Schlicker et al., 1993). Also, 
secretion of these neurotransmitters is inhibited by the activation of H3R (Arrang 
et al., 1995), whilst H3R antagonism disinhibits their release.  
The first effective anti-obesity drugs (fenfluramine, sibutramine) that were 
developed to inhibit food intake and limit weight gain acted upon the synaptic 
availability of dopamine, acetylcholine, serotonin, GABA and noradrenaline. The 
clinical efficacy of these drugs can be attributed to their ability to enhance 
serotonin availability (Tallett et al., 2009), and it has been reported that the H3 
heteroreceptors can inhibit serotonin release resulting in an increase in food 
intake (Cole et al., 1998). Also, the anti-histamines, cyproheptadine and 
promethazine, are non-selective serotonin receptor antagonists, as well as acting 
as histamine receptor blockers that induce food-intake and weight gain in humans 
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and rats (Yoshimatsu et al., 2002). H3 heteroreceptor activity may also play a role 
in atypical antipsychotic-induced weight gain. Antagonism of the H3 
heteroreceptor has been shown to disinhibit neurotransmitter release (Arrang et 
al., 1995), which in the case of H3 heteroreceptors located on noradrenaline and 
acetylcholine neurones, may account for the side-effect of atypical antipsychotic-
induced food intake, as both these neurotransmitters can increase food intake 
(Pratt et al., 2009).  
Histaminergic neurones project fibres to almost all brain areas, albeit to a lower 
extent than the hypothalamus. The hippocampus and the nucleus accumbens 
both receive innervations form histaminergic neurons and both exert some 
physiological control of appetite (Hussain et al., 2002). High densities of H1R and 
H3R have both been found in the striatum (Drutel et al., 2001, Pillot et al., 2002). 
The analysis of histamine receptor distribution has shown that the nucleus 
accumbens also contains high levels of H1R and H3R, and comparably lower 
levels of H2R. Studies have indicated functional interaction between histaminergic 
and dopamine neurotransmission, with histaminergic function regulating at least 
in part dopamine activity in the forebrain (Galosi et al., 2001, Hussain et al., 
2002). Shlicker et al. found that histamine can inhibit striatal dopamine release 
and synthesis via presynaptic H3R (Shlicker et al. 1993). However, the complete 
mechanism by which histamine exerts its effects on dopamine activity is not clear. 
Prast et al. suggested histamine may be acting presynaptically through histamine 
receptors located on dopamine terminals in the nucleus accumbens (Prast et al., 
1999). Alternatively, Galosi et al. propose histamine may act on the output 
neurones of the nucleus accumbens, which via downstream projections may 
indirectly stimulate dopaminergic cells in the ventral tegmental area, resulting in 
dopamine release in the nucleus accumbens. Histamine can also interfere with 
the uptake of dopamine (Galosi et al., 2001), which could also lead to increased 
levels of extracellular dopamine. It may also be possible that histamine affects 
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dopamine release via acting on other inputs to the nucleus accumbens (Prast et 
al., 1999).  
As the histaminergic cell bodies are located only within the TM of the posterior 
hypothalamus (Watanabe et al., 1984), it is possible the signal inputs to the TM 
greatly influence histaminergic function Morphological evidence has suggested 
some of the appetite-stimulating peptides affect the histaminergic system within 
the TM itself (Watanabe et al., 1984). Neurones containing orexin-A and -B 
densely innervate the TM (Peyron et al., 1998), and both of the orexin receptors 
are expressed in the TM (Eriksson et al., 2001). NPY neurones have been shown 
to form synapses with the histaminergic cells directly in the TM (Tomaszuk et al., 
1996). Guan et al. reported strong expression of mRNA for the growth hormone-
secretagogue receptor, for which ghrelin is an endogenous ligand, in the TM 
(Guan et al. 1997). Also, Nakazato et al. reported that ICV injections of ghrelin 
induced the induction of c-fos expression in the TM (Nakazato et al. 2001). Thus, 
ghrelin could affect the histaminergic system directly in the TM. These 
observations indicate a functional relationship between these peptides and the 
histaminergic system (Ishizuka et al., 2006).  
Neuronal histamine plays an important role in leptin signaling in the 
hypothalamus, which controls feeding behaviour and energy metabolism. The 
central administration of leptin increases histamine turnover (Yoshimatsu H., 
2008). Leptin-induced suppression of feeding is attenuated in histamine-depleted 
rats using α-FMH, HDC and in histamine H1R-KO mice (Masaki et al., 2001). All 
these findings indicate neuronal histamine and the H1R could be mediating the 
suppressive effect leptin has on food intake (Morimoto et al., 1999). 
NPY has been demonstrated to potently increase food intake in both WT 
and H1R-KO mice, however the increase in food intake observed in H1R-KO mice 
was much more significant than that seen in WT animals (Ishizuka et al., 2006). 
Ishizuka et al. found NPY increases histamine release although this was very 
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short lived (Ishizuka et al., 2006). Further evidence of NPY and histamine working 
together in the control of food intake is that NPY afferents form direct synaptic 
contacts with the histaminergic cell body, and mRNA of NPY Y1 receptors, which 
has been implicated in feeding (Kanatani et al., 2000), is expressed in the TM 
(Kishi et al., 2005). These observations suggest that NPY could act on the 
histaminergic system directly in the TM via the NPY Y1 receptors. Toftegaard et 
al. have previously shown that the suppression of neuronal histamine synthesis 
by α-FMH stimulates NPY mRNA expression suggesting histamine exerts an 
inhibitory effect on NPY synthesis (Toftegaard et al., 2003). Therefore, NPY may 
inversely affect histamine synthesis and form a feedback loop with the 
histaminergic system in the regulation of food intake.   
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1.10 Summary 
Obesity is clearly a worldwide problem in most developed countries and is 
costing health services around the world millions in treating obesity-related 
illnesses. Thus, it is paramount that treatments are developed which help tackle 
this growing pandemic. Scientific research has advanced over the last few years 
and gained vital knowledge and understanding of the central mechanisms and 
pathways involved in regulating food intake and the control of energy balance. 
One widely accepted discovery is the central role the hypothalamus has in 
regulating energy balance and controlling feeding.  
Histamine is an important neurotransmitter within the CNS that has been 
associated with the regulation of appetite. Histamine has been shown by 
numerous research groups to act as a potent anorexigenic agent (Doi et al., 
1994, Endou et al., 2001, Lecklin et al., 1998, Lecklin et al., 1995). The 
histaminergic system acts via the H1R or H3R to exert its effects on feeding and, 
thus, these receptors could act as possible targets in the development of 
therapies to battle obesity. These receptors have opposing effects on feeding in 
that H1R agonists acts as potent anorexigens and H3R agonists act as powerful 
orexigens. Although the H1R has been more widely investigated as a possible 
target for anti-obesity drug development the fact these receptors are widely 
distributed and are involved in many functions, agonist drugs which target them 
can cause numerous adverse effects. For example, H1R agonists would have 
profound effects on the immune system (note anti-histamines acting on the H1R 
are used to combat hayfever and other allergic reactions). Instead, because H3R 
negatively regulate the release of histamine mainly in the brain, potentially to 
suppress appetite through the activation of only central H1R targets, 
pharmaceutical organisations have turned their focus onto H3R-based antagonists 
and/or inverse agonists, which can be given systemically but will have their 
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effects only centrally. To address the therapeutic potential of H3R ligands as anti-
obesity drugs, several groups have reported the pharmacological profiles of H3R 
inverse agonists in animal studies.  
Although H3R inverse agonists have been seen to potently reduce food 
intake in a number of species (Lecklin et al., 1998), research groups have shown 
varying degrees of their efficacy at changing food intake (Itoh et al., 1998, 
Sindelar et al., 2005). Therefore, although some reports have suggested the 
therapeutic potential of H3R inverse agonists, their anti-obesity effects remain 
controversial. For example, thioperamide, an imidazole-containing H3R inverse 
agonist, has been shown to suppress food consumption in rats and mice (Lecklin 
et al., 1998). However, other studies have shown thioperamide to have no affect 
on food intake either in satiated or in fasted rats (Itoh et al., 1998). Sindelar et al., 
demonstrated that both IP and oral administration of thioperamide enhanced 
histamine release in the brain, while only IP administration caused significant 
reductions in food intake (Sindelar et al., 2004). Furthermore, one group found 
that thioperamide even increased food intake when administered to mice 
(Yoshimoto et al., 2006).  The area of activation of these compounds has not 
been fully elucidated and the specificity of these drugs is not fully known. Thus, it 
is apparent that further investigation into the histaminergic system and in 
particular the H3R is required. 
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1.11 PhD Aims 
My main aims with this PhD were to investigate and determine histamine's 
hypophagic affect on feeding and to determine whether this system could be 
manipulated for the development of potential therapeutic agents that are anti-
obesity targets.  
I aimed to firstly determine the effects histamine had on rodent feeding 
when administered centrally. Once an anorexigenic effect had been elucidated 
we aimed to investigate whether H3R-based drugs, including a H3R agonist and 
two H3R inverse agonists could also alter food intake. Our next aim was to 
investigate where histamine and these H3R drugs were acting within the rodent 
brain and in particular whether the known ‘feeding’ or ‘satiety’ centres are 
involved. Once the areas in which histamine is acting had been established my 
next step was to investigate what effects histamine and histamine-based drugs 
have on neuronal firing within the VMN, a hypothalamic area known to be pivotal 
in the regulation of food intake. We then investigated whether histamine was 
exerting its effects within the VMN via a H1R or a H3R to determine the 
populations of histamine receptors present in this area. My penultimate aim was 
to ensure the effects of the H3R drugs being tested were acting specifically at the 
H3 receptor we co-applied a neutral H3R agonist with an H3R agonist or H3R 
inverse agonist, to ensure the any effects these drugs had on feeding or neuronal 
firing were receptor specific. My final aim was to establish the same populations 
of VMN neurones responding to histamine are also glucose responsive.  
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Chapter 2: 
In vivo effects of histamine and 
H3R drugs on food intake 
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2.1 Introduction 
2.1.1 Pharmaceutical development of histaminergic agents 
Extensive pharmacological experiments have demonstrated that the brain’s 
histamine system plays critical roles in the regulation of feeding and energy 
expenditure and, thus, this system could be manipulated for the pharmaceutical 
control of appetite and body weight. Behavioural studies have revealed histamine 
suppresses food intake when administered centrally or peripherally (Doi et al., 
1994, Endou et al., 2001; Lecklin et al., 1998; Lecklin et al., 1995), therefore, 
Orthen-Gambill et al. (1992) suggested the removal of histamine’s inhibitory effect 
might in turn stimulate feeding. They found that if histamine levels were 
decreased using α-FMH, which is a potent and irreversible inhibitor of HDC, an 
increase in both food intake and body weight is seen in rodents. This inactivation 
of HDC in histamine-containing nerve terminals is highly potent and selective; so 
much so, that FMH depletes neuronal histamine almost completely from the 
nerve terminals (Garbarg et al., 1980). Hence, pharmaceutical agents directed at 
HDC could help regulate the release and synthesis of histamine and be used as a 
drug to help control appetite. However, a problem arises since such drugs would 
affect all histaminergic systems in the body.  
An alternative would be to target specific histamine receptors. H1R and H3R are 
both important for regulating feeding. Their activity has opposing effects on food 
intake. H1R agonists and H3R antagonists decrease food intake, whereas H1R 
antagonists and H3R agonists increase food intake in rodents (Takahashi et al., 
2002). This is most simply explained by the fact that the H1R is a postsynaptic 
receptor, whereas the H3R is normally a presynaptic autoreceptor. In both 
humans and rodents, treatment with an H1R antagonist results in hyperphagia 
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(Fukagawa et al., 1989), whereas administration of H3R antagonists leads to 
hypophagia (Attoub et al., 2001).  
The fact that drugs with H1R-blocking properties stimulate food consumption in 
humans as well as in animals clearly indicates the critical role of endogenous 
histamine and H1R in the regulation of feeding behaviour (Fukagawa et al., 1989). 
However, H1R are widely distributed and are involved in many functions, so 
agonist drugs which target them can cause numerous adverse effects. For 
example, H1R agonists would have profound effects on the immune system (note 
anti-histamines acting on the H1R are used to combat hayfever and other allergic 
reactions). Instead, because H3R negatively regulate the release of histamine 
mainly in the brain, potentially to suppress appetite through the activation of only 
central H1R targets, pharmaceutical organisations have turned their focus onto 
H3R based antagonists and/or inverse agonists, which can be given systemically 
but will have their effects only centrally.  
H3R antagonists have been proposed as drugs for the treatment of several 
CNS disorders such as attention-deficit hyperactivity disorder (Onodera et al., 
1998), Alzheimer’s disease (Passani et al., 2000), epilepsy (Yokoyama et al., 
1994), schizophrenia (Schlicker et al., 1996) and obesity (Takahashi et al., 2002), 
whereas the therapeutic potential of H3R agonists has been shown for myocardial 
ischemia (Levi et al., 2000), inflammatory diseases (McLeod et al., 1998), gastric 
acid-related diseases (Bertaccini et al., 1991), and migraine and sleep disorders 
(Mignot et al., 2002).  
With the cloning of the H3R and the discovery of the high degree of constitutive 
activity of this receptor, many H3R antagonists have been subsequently 
reclassified as inverse agonists because of their ability to reverse basal H3R 
activity. Since H3Rs may inhibit neurotransmitter release in the absence of 
endogenous histamine because of their inherent constitutive activity (Morisset et 
al., 2000), compounds that demonstrate greater inverse agonist efficacy may 
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cause greater enhancement of neurotransmitter release and thus could pose 
greater therapeutic effects. To address the therapeutic potential of H3R ligands as 
anti-obesity drugs, several groups have reported the pharmacological profiles of 
H3R inverse agonists in animal studies. Because H3Rs negatively regulate the 
release of histamine in the brain, H3R inverse agonists are believed to suppress 
appetite through the activation of H1Rs in the post-synaptic areas. Although 
reports have suggested the therapeutic potential of H3R inverse agonists, their 
anti-obesity effects still remain controversial. For example, thioperamide, an 
imidazole-containing H3R inverse agonist, increases histamine neurones activity 
in vivo by removing the normal feedback autoinhibitory control system of both 
histamine synthesis and release at the level of histamine nerve terminals (Arrang 
et al., 1987). Thioperamide has been shown to suppress food consumption in a 
number of animal models, for example Jethwa and colleagues showed that in the 
seasonal hamster administering H3R inverse agonists in the lean state reduced 
food intake (Jethwa et al., 2009). Whilst other studies have shown thioperamide 
to have no effect on food intake either in satiated or in fasted rats (Itoh et al., 
1998, Lecklin et al., 1998, Sakata et al., 1990). Sindelar et al. (2004) 
demonstrated that both intraperitoneal (IP) and oral (PO) administration of 
thioperamide enhanced histamine release in the brain, while only IP 
administration caused significant reductions in food intake (Sindelar et al., 2004). 
Most recently, one influential report witnessed the opposing effects of 
thioperamide in murine studies (Yoshimoto et al, 2006). Here, the group showed 
that the H3R inverse agonist thioperamide increased rather than decreased food 
intake, which opposes the findings of most research groups investigating the 
actions of these histamine-based drugs, but illustrates a need for further 
research. In addition, several reports have demonstrated the possibility that the 
imidazole moiety of thioperamide may be responsible for toxicity through its 
interaction with P450 proteins (Yang et al., 2002; Onderwater et al., 1998), thus 
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suggesting the possibility that imidazole-containing H3R drugs may exert non-
selective adverse effects leading to reduced feeding. In order to address these 
concerns, several pharmaceutical companies have developed non-imidazole H3R 
inverse agonists (Tokita et al., 2006). Among these, Hancock and colleagues 
reported that A-331440 potently suppresses feeding and body weight gain in diet-
induced obese mice (Hancock et al., 2004). However, ABT-239, another 
structurally distinct H3R inverse agonist, showed no anti-obesity activity in the 
same animal model (Tokita et al., 2006). Wulff et al. reported that the H3R inverse 
agonists by Novo Nordisk, NNC-0038-1049 (NNC1049) and NNC-0038-1202 
(NNC1202), reduced body weight in diet-induced obese rats (Wulff et al., 2002). 
Furthermore, NNC1202 reduced food consumption and body-weight gain in pigs 
and obese rhesus monkeys. These varying pharmacological observations 
demonstrate that H3R inverse agonist may possess anti-obesity activity but that 
their efficacy may differ among species (Tokita et al., 2006). Many observations 
highlight potential and as of yet, unknown off-target activity of specific compounds 
that might contribute to their anorectic effects. Although the brain histamine 
system is a highly conserved system among species, it is possible that this 
system plays slightly different physiological roles. Oishi et al. reported that 
histamine content and turnover in several brain areas differ between mice and 
rats (Oishi et al., 1983), thus supporting the notion of species related differences 
in H3R ligand functions. Splicing variants, which differ slightly amongst species, 
would play different roles within the CNS, interacting differently with 
pharmacological reagents and therefore resulting in distinct outcomes in each 
species. Thus, further investigation of the use of H3R compounds as potential 
anti-obesity therapies is required. 
 Imetit was initially characterized as a weak partial H2R agonist (Ganellin R., 
1981), but was later identified in various in vitro and in vivo tests as an extremely 
potent and selective H3R agonist (Garbarg et al., 1992). As an H3R agonist it 
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would be expected that imetit would increase food intake by reducing histamine 
synthesis and release. This has been shown as the case for a number of 
research groups (Garbarg et al., 1992; Leurs et al., 2005; Hancock et al., 2004) 
who all demonstrated imetit produces a increase in food intake in rodent studies. 
However, despite disagreeing with this published material, Yoshimoto et al, 
reported that imetit reduced, rather than increased food intake in mice and 
continual injections even resulted in a body weight reduction (Yoshimoto et al., 
2006). Again, these data emphasise the confused literature and show the need 
for further studies to be carried out to determine the exact actions of H3R drugs 
on food intake.  
Additionally, in mice and rats, the activity level of the histaminergic system 
is relatively high at night and low in the day (Mochizuki et al., 1992). However, 
these animals eat mainly at night when the histamine activity is high. Sakata et 
al., showed that H1R antagonism (Sakata et al., 1988) and α-FMH (Sakata et al., 
1990) induced food intake when they were injected soon after lights on, but their 
effects were attenuated in the dark phase. In addition, they also showed that 
thioperamide reduces food intake in the dark (Sakata et al., 1990). If this is the 
case, the abilities of these drugs to affect food intake inversely correlates with the 
histamine level in both the light and dark phase (Morimoto et al., 2001).  
 
 
2.2 Aims and Objectives 
2.2.1  Does histamine reduce food intake when administered centrally? 
Histamine has many roles in mammalian physiology, one of which is its 
powerful effect on appetite. The hypothalamus is integral in appetite control and 
in order to confirm histamine’s actions in our own models and to lay the 
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foundation for investigating receptor-selective drugs, we carried out a baseline 
study to determine the central action of histamine on food intake.  
 
2.2.2 What effects does the H3R receptor agonist have on food intake? 
 Controversy over the effects of H3R agonist drugs has been raised, thus, we 
aimed to determine the effect of the H3R agonist, imetit, on food consumption in 
the adult rat when administered both centrally and systemically. 
2.2.3 What are the effects on food intake of H3R inverse agonists? 
This same controversy over the effectiveness of H3R agonists also applies 
to the H3R inverse agonists. Thus, we ascertained the effects of the H3R inverse 
agonists, thioperamide and the coded compound from Novo Nordisk, NN1202, on 
food consumption in the adult rat to help establish if these compounds could 
possibly be used pharmacologically to reduce food intake. 
 
 
2.2.4 Do the H3R selective drugs have indirect, adverse effects on food 
intake? 
 Our last objective was to establish if the H3R drugs being considered altered 
only the feeding behaviour, or if other adverse responses, such as malaise or 
sedation, occurred resulting in secondary actions on food consumption. In order 
to determine this, we studied the behavioural satiety sequence of different 
experimental groups. 
 Normally, food intake is controlled by appetitive processes such as hunger or 
satiation. However, many compounds can alter food intake when administered 
exogenously. Although to date it is not fully understood how histaminergic drugs 
affect appetite and alter food intake, one explanation is that they are acting upon 
a specific stage of the natural process where animals match their food intake to 
nutritional requirements (Blundell et al., 1985). A reduction in food intake instead 
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could be due to non-specific, non-physiological interference of eating behaviours, 
such as a reduction in motor function or malaise. Thus, one question is whether 
drug-induced alterations in food consumption actually reflect the natural process 
of satiation (Blundell et al., 1975). To determine this, more data is required than 
simply a change in food consumption. Thus, additionally we can analyse changes 
in the structure of feeding behaviour. The examination of the structure of 
behaviour can be used to identify adaptive responses to “natural” processes or 
altered responses brought about by pathological, physiological or environmental 
conditions, such as administering drugs. Therefore, the structure of behaviour can 
be used to determine whether the effect of a drug on food intake is mediated by a 
natural process or a pathological condition (Blundell et al., 1985). 
 
 
2.2.5 Do imetit and thioperamide have similar effects on food intake in 
mice? 
 The paper published by Yoshimoto et al. (2006) suggested the H3R agonist 
imetit could decrease the food intake in mice, that prolonged administration could 
even cause a loss of body weight, and that the H3R inverse agonist thioperamide 
had the opposite effect to increase food consumption. This paper was very 
influential because, until then, all published research into the effects of these 
drugs on food intake suggested the opposite, with imetit causing hyperphagia and 
thioperamide having an anorectic effect. At face value, because histamine itself is 
anorexic, the results from Yoshimoto and colleagues (2006) are unusual since 
imetit should decrease endogenous histamine release, while thioperamide should 
increase it.  
 
 
 62 
2.3 Methods  
2.3.1 Animals 
Male Sprague-Dawley rats (225 - 275 g) and male CD1 mice (7 weeks old; 
both Charles-River, UK) were kept in a 12 h/ 12 h light-dark cycle (lights on 
08.00-20.00) within The University of Manchester animal facility. All animals were 
maintained in the facility for at least one week prior to the start of the experiment. 
The animals were housed in a temperature-controlled room (~22 ºC ± 1) with a 
relative air humidity of 40-60%. They had free access to food (Beekay, UK) and 
water.  
These and all other experiments conformed with the Home Office (Animals) 
Procedures Act (1986) and local ethical review.  
 
 
2.3.2 Compounds 
Compounds were administered via injection into the lateral cerebral ventricle 
for intracerebroventricular administration (ICV) and into the intraperitoneal cavity 
(IP) for the systemically-injected animals. Histamine (Sigma, Sigma-Aldrich 
Company Ltd, Dorset) and was diluted in isotonic saline to a concentration of 200 
nmol immediately prior to use. Thioperamide (Sigma) was diluted in isotonic 
saline to the required amount for the ICV (100, 200, 400 nmol per rat) and IP (0.5, 
1, 2 mg/kg body weight) injections. Imetit (Sigma) was diluted with isotonic saline 
to the required amount for the ICV (10, 50, 100 nmole per rat) and IP (2.5, 5, 10 
mg/kg body weight) injections. NNC1202 was donated by Novo Nordisk and was 
diluted in isotonic saline to the necessary amounts for the ICV (100, 200, 400 
nmole per rat) and IP (10, 20, 30 mg/kg body weight) injections. 
For the murine experiments drugs were diluted in the same manner as the 
rodent IP studies, but the following amounts were used: thioperamide and imetit 
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were injected at 10 or 20 mg/kg body weight (in a volume of 1 ml/kg of body 
weight).  
 
 
2.3.3 Intracerebroventricular cannulation  
 Rats were anaesthetised with 2 % isofluorane in O2 at 1 l/min. Once the 
head had been shaved, rats were placed securely in the stereotaxic apparatus 
(Stoelting, Illinois, USA). A 2-3 cm incision was made along the midline of the 
cranium, exposing the skull. All connective tissue was displaced from the cranial 
surface before the guide cannula was positioned 0.8 mm posterior and 1.5 mm 
lateral to bregma (co-ordinates determined according to Paxinos and Watson 
1986). A 21-gauge guide cannula was implanted 3 mm into the brain at this co-
ordinate through a 1.5 mm-diameter hole drilled in the cranium so it inserted into 
the lateral ventricle. The guide cannula was fixed to the skull with acrylic dental 
cement (Simplex Rapide; Austental Dental, UK) adhered to two jeweller's screws 
(4 mm long x 2 mm diameter) positioned anterior and posterior to the guide 
cannula. The dental cement was allowed to dry and the skin around the cannula 
and the surrounding skin was then sutured (size 3/0 mersilk, Ethicon, Johnson 
and Johnson International, USA). For post-operative analgesia, rats were injected 
with 10 µl/kg buprenophrine (Vetergesic, Reckitt Benckiser Healthcare, Hull, UK), 
and a bolus of saline to aid recovery. Animals were allowed to recover and then 
maintained for one week post surgery. During this time rats were given food and 
water ad libitum.  A cannula made from the tip of a 23-gauge needle was used to 
inject the drug or vehicle when inserted through the guide cannula to a depth of 
10.5 mm from the surface of the skull which allowed the drug to be injected 
directly into the lateral ventricle. 
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2.3.4 The effect of histaminergic drugs on food intake 
The control groups in the feeding studies show some variation between the 
absolute amounts of food eaten. Rats naturally show much variation in food 
consumption from experiment to experiment, which is probably dependent on 
individual variations, the exact time of day that an experiment was begun, the 
amount of food eaten by different groups in the period immediately before each 
experiment, as well as the immediate pre-history of handling and husbandry. The 
daytime feeding experiments all began between the hours of 8:00 am and 10:00 
am. Although all rats are managed in as similar a way as possible, variations in 
the daily maintenance of stocks by the animal facility staff are difficult to control. 
Variations between experiments are relatively small, but to ensure statistical 
relevance to all experiments, the drug-injected experimental groups and the 
control groups are housed and maintained, as well as treated, in exactly the same 
way. That is every experiment has its own internal controls. 
 
Rats were caged singly and fasted overnight prior to both ICV and IP 
injections. On the day of the experiment for central injections, rats were 
administered 2 µl of the drug being tested (amounts used above) and control rats 
received 2 µl saline ICV. After the injection, the cannula was checked to ensure 
reflux did not occur. For both the rat and mouse systemic injections, on the day of 
the experiment, animals were administered 1ml/kg (body weight) of the drug 
being tested (amounts used above) and controls received 1 ml/kg saline IP. Pre-
weighed food was returned to the animal 2 minutes after receiving the injections. 
Food consumption was measured at 1, 2, 4, 8, and 24 h intervals post-injection 
for the rodent studies and 1, 2, 4, 12 and 24 h for the murine studies.  
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2.3.5 Behavioural satiety sequence (BSS) 
Each experiment was performed at the same time every day to avoid any 
circadian variation. Rats were housed singly, two days before the experiment, in 
transparent observation cages. Food was removed 2 hours before the experiment 
began to ensure no pre-feeding occurred. Animals (n = 8 per treatment) received 
a IP injection of isotonic saline, imetit (10 mg/kg body weight), thioperamide (2 
mg/kg) or NNC1202  (30 mg/kg) at 20:00 h on different days, so each animal 
received one injection of each compound or vehicle over a two-week period. A 
minimum of 3 days were left between each experiment so animals had recovered 
from their last drug treatment. After the drug was administered, rats were given a 
pre-weighed amount of food. Behavioural observations began 90 seconds later. 
The animals were scored every 30 sec for 90 minutes with the behaviour of each 
animal at that instant in time being noted. Their behaviour was scored as one of 
the following: feeding, drinking, grooming, resting, inactive or active (see table 
2.1). The data were collated into 5-minute periods or bins and expressed as the 
mean percentage of total behaviour. The percentage of time the animals spent 
exhibiting each individual behaviour was analysed for all drug or vehicle groups 
and collated into a graph. The overall food eaten for each animal was taken after 
the 90-minute observational period was over. 
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Resting  Sitting or lying in a resting position or asleep. 
Inactive  Not moving or exploring but not lying in resting position and still fully awake. 
Active Walking around cage, exploring or circling. Movements involving 
all four limbs. 
Grooming  Scratching, licking or biting of the coat, whiskers, feet or genitals. Biting of the tail. 
Drinking  Licking the water bottle. 
Feeding Biting, gnawing or swallowing food from dish or from front paws. 
 
 
Table 2.1.; This table was adapted from Halford and Blundell 1993 and illustrates the six 
behavioural categories used for behavioural analysis when carrying out the behavioural 
satiety sequence (BSS) experiments. 
 
 
 
2.3.6 Statistical anaylsis 
 All data are presented as mean ± standard error of mean (S.E.M.). Data from 
feeding and the BSS studies were analysed using an unpaired t test, one-way 
analysis of variance (ANOVA) with Bonferonni post hoc test or a two-way ANOVA 
with repeated measures were carried out depending on the experiment. 
Significance was taken at P < 0.05.  
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2.4 Results 
2.4.1 Histaminergic effects on food intake in rats 
Injection of histamine ICV (200 nmol in 2 µl) caused a significant 
suppression of food intake in rats (P < 0.05) (figure 2.1). It was observed that one 
hour after administration, rats that received histamine had eaten only 0.9 ± 0.3 of 
food, whereas those that received saline had eaten 6.2 ± 0.4 g (P < 0.005), and a 
statistically significant difference in cumulative intake remained until 8 hours after 
ICV injection (P < 0.05). At 24 hours post-injection the cumulative food eaten by 
the two groups was no longer significantly different: histamine injected rats had 
eaten 25.2 ± 0.8 g of food and rats that had received saline had eaten 26.1 ± 1.9 
g. 
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Figure 2.1.; Food consumption measured at 1, 2, 4, 8 and 24 hours after ICV injection 
with histamine (200 nmol, n = 11) or saline (n = 9). Data are expressed as mean ± S.E.M. 
Two-way ANOVA with repeated measures and Bonferonni post hoc test was carried out: 
*** P < 0.005, * P < 0.05.  
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2.4.2 H3R agonist effects on food intake in rats  
We carried out ICV injections using imetit (H3R agonist) at varying 
concentrations (100, 50 and 10 nmol) to determine a dose-response curve (figure 
2.2). We found that giving imetit at a concentration of 10 nmol was not sufficient 
enough to produce a significant increase in food intake. Both 50 nmol and 100 
nmol of imetit caused rats to significantly increase their food consumption 1 hour 
after the initial injection (figures 2.2 and 2.3).  
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Figure 2.2.; Food consumption measured at 1, 2, 4, 8 and 24 hours after ICV injection 
with imetit (10, 50, & 100 nmol) or saline, in 2 µl. n = 7 for saline and 100 nmol imetit 
groups and n = 6 for 10 nmol and 50 nmol imetit drug groups. Data are expressed as 
mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test 
was carried out: ** P < 0.01, * P < 0.05.  
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The group that received 50 nmol of imetit ate 7.08 ± 0.19 g 1 hour after 
receiving the ICV injection whereas control animals ate 5.30 ± 0.56 g. This 
showed a significant increase in food intake (P < 0.05). This increase in food 
intake was not a long-term effect as by 2 hour the significance was lost, with the 
50 nmol imetit group having cumulatively eaten 7.79 ± 0.52 g and the control 
groups having cumulatively eaten 7.67 ± 0.99 g (figure 2.3). Out of the 
concentrations tested, we found that giving imetit at a concentration of 100 nmol 
gave the most significant results. An ICV injection of 100 nmol imetit caused a 
significant, though short-term, increase in food intake in rats (figure 2.3). It was 
observed that one hour after treatment, rats that received imetit had eaten 7.5 ± 
1.3 g of food whereas those that received saline ICV had eaten 5.3 ± 1.9 g (P < 
0.01; figure 2.3). The significance was lost between 1 and 2 hours post injection 
with rats receiving ICV imetit injections having a cumulative food intake of 8.4 ± 
1.2 g compared with the saline-treated group 7.67 ± 0.99 g (figure 2.3).  
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Figure 2.3.; Food consumption measured at 1 & 2 hours after ICV injection with imetit at 
50 & 100 nmol or saline, in 2 µl. n = 7 for saline and 100 nmol imetit groups and n = 6 for 
50 nmol imetit drug group. Data are expressed as mean ± S.E.M. Two-way ANOVA with 
repeated measures and Bonferonni post hoc test was carried out: ** P < 0.01, * P < 0.05.  
 
 
We also carried out a dose response curve for imetit (H3R agonist) given IP at 
varying amounts (10, 5 and 2.5 mg/kg, see figure 2.4). We found that imetit when 
given at 2.5 mg/kg and 5 mg/kg there was no significant change in food intake, 
although the lower amount (2.5 mg/kg) did surprisingly show some trend towards 
reducing food intake, but this did not enter significance. Alternatively, when we 
administered imetit IP at 10 mg/kg a significant increase in food intake in rats was 
observed (figures 2.4 and 2.5).  
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Figure 2.4.; Food consumption measured at 1, 2, 4, 8 and 24 hours after IP injection with 
imetit (2.5, 5 & 10 mg/kg, n = 6) or saline (n = 7) in 1 ml/kg. Data are expressed as mean 
± S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test was 
carried out: ** P < 0.005, * P < 0.05.  
 
 
It was observed that at one hour after treatment, rats that received imetit had 
eaten 8.77 ± 0.27 g of food, whereas those that received saline IP had eaten 6.75 
± 0.32 g (P < 0.005; figure 2.5). At 2 hours rats that received IP injections of imetit 
were still eating significantly more, with cumulative food intake at 9.77 ± 0.69 g 
compared with 8.09 ± 0.35 g for control rats (P < 0.05; figure 2.5). This significant 
difference in cumulative food intake continued up to 4 hours post injection, with 
the imetit group eating 10.28 ± 0.44 g and the saline group consuming 8.49 ± 
0.48 g (figure 2.5). The statistical significance was lost between 4 and 8 hours 
post injection with rats receiving IP imetit injections having eaten 12.28 ± 0.64 g 
compared with 11.60 ± 1.01 g for the control group (figure 2.5).  
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Figure 2.5.; Food consumption measured at 1, 2, 4, 8 and 24 hours after IP injection with 
10 mg/kg imetit (n = 6) or saline (n = 7) in 1 ml/kg. Data are expressed as mean ± S.E.M. 
Two-way ANOVA with repeated measures and Bonferonni post hoc test was carried out: * 
P < 0.05.  
 
 
 
2.4.3 H3R inverse agonist effects on food intake in rats  
After carrying out a dose response curve for thioperamide (an H3R inverse 
agonist) given ICV at varying concentrations (400, 200, 100 nmol, figure 2.6), we 
found that a concentration of 400 nmol was the only concentration that we tested 
that gave a significant result (figures 2.6 and 2.7).  
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Figure 2.6.; Food consumption measured at 1, 2, 4, 8 and 24 hours after ICV injection 
with thioperamide (100, 200 & 400 nmol, n = 5) or saline (n = 5) in 2 µl. Data are 
expressed as mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferonni 
post hoc test was carried out: * P < 0.05. 
 
 
The ICV injection of 400 nmol thioperamide caused a significant decrease 
in cumulative food intake in rats compared with saline (figure 2.7), however, the 
difference was only significant at the 4- and 8-hour time points. At four hours, IP 
thioperamide-injected rats had eaten 5.80 ± 0.26 g and those that had received 
saline had eaten 7.43 ± 0.93 g (P < 0.05; figure 2.7). The significant difference in 
cumulative food intake between thioperamide and control rats was maintained at 
8 hours, with control rats eating 11.35 ± 0.70 g whereas thioperamide-treated 
animals ate 7.79 ± 0.93 g. This significance was lost between 8 and 24 hours 
(figure 2.7). At 24 hours, the cumulative food intake of thioperamide-treated rats 
was 30.52 ± 1.43 g and for the saline-treated rats was 34.25 ± 0.56 g. These 
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feeding experiments suggest that the H3R inverse agonist may have a delayed 
effect on feeding. 
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Figure 2.7.; Food consumption measured at 1, 2, 4, 8 and 24 hours after ICV injection 
with thioperamide (400 nmole, n = 5) or saline (n = 5). Data are expressed as mean ± 
S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test was 
carried out: * P < 0.05.  
 
 
We then went on to determine the effect on food intake that thioperamide 
(H3R inverse agonist) has when administered systemically at varying amounts by 
carrying out a dose response curve. The amounts investigated were, 2, 1, 0.5 
mg/kg (figure 2.8). We found that giving thioperamide at all three amounts gave 
significant results at some time points post injection, with the highest 
concentration (2 mg/kg) giving the highest significance (figures 2.8 and 2.9).  
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Figure 2.8.; Food consumption measured at 1, 2, 4, 8 and 24 hours after IP injection with 
thioperamide (0.5, 1 & 2 mg/kg, n = 5) or saline (n = 5) in ml/kg. Data are expressed as 
mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test 
was carried out: ** P < 0.005, * P < 0.05. 
 
 
 
 The IP injections at 2 mg/kg caused a significant decrease in food intake in 
rats in the same way as the ICV study. One hour post injection, thioperamide-
treated rats had eaten 5.89 ± 0.18 g and those treated with saline had eaten 7.22 
± 0.44 g (P < 0.05; figure 2.9). 2 hours post injection the significance of the 
difference increased to P < 0.005, and thioperamide-treated rats ate 6.80 ± 0.25 g 
compared with saline-treated rats that consumed 9.47 ± 0.63 g of food (figure 
2.9). 4 hours post injection, rats that received a injection of thioperamide ate 
significantly less than rats receiving vehicle, with thioperamide-treated animals 
having eaten 7.39 ± 1.63 g and control animals consuming 13.22 ± 1.59 g of food 
(figure 2.9). The statisitical significance in difference in cumulative food intake 
was lost between 4 and 8 hours, with the H3R inverse agonist-treated rats 
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consuming 11.09 ± 1.35 g and those that received saline eating 12.64 ± 0.51 g 
(figure 2.9).  
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Figure 2.9.; Food consumption measured at 1, 2, 4, 8 and 24 hours after IP injection with 
thioperamide (2 mg/kg, n = 5) or saline (n = 5). Data are expressed as mean ± S.E.M. 
Two-way ANOVA with repeated measures and Bonferonni post hoc test was carried out: 
*** P < 0.0001, ** P < 0.005, * P < 0.05. 
 
 
The i.p injections of thioperamide at 0.5 and 1 mg/kg also cause a significant 
reduction in food intake compared with control injections, but these doses appear 
to have a delayed affect on feeding, as significance was apparent only at 4-hours 
post injection (figure 2.8). This significance was lost for the 0.5 mg/kg dose by the 
8-hour time point but rats that received a injection of 1 mg/kg thioperamide ate 
significantly less 8 hours post injection. Food intake normalised levels somewhere 
within the 8 and 24 hour time points. These feeding experiments correlate with 
the ICV thioperamide study showing the same effect on feeding. 
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A dose-response experiment for NNC1202 (an H3R inverse agonist) given ICV 
at varying concentrations (100, 200 and 400 nmol, figure 2.10) was then carried 
out. We concluded that giving NNC1202 at all the concentrations tested showed 
no significant change in food intake (figure 2.10). There was no overall trend or 
change in food consumption suggesting that, when given ICV, NNC1202 has no 
effect on rodent appetite. 
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Figure 2.10.; Food consumption measured at 1, 2, 4 and 24 hours after ICV injection with 
NNC1202 (100, 200 & 400 nmol, n = 6) or saline (n = 8). Data are expressed as mean ± 
S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test was 
carried out: non significant. 
 
 
We then carried out a dose-response curve for NNC1202 using IP injections 
(30, 20, 10 mg/kg, figure 2.11) to determine if the drug can affect food intake in 
rats when given systemically. We found that giving NNC1202 at all three doses 
showed a reduction in food intake, with the highest concentration (30 mg/kg) 
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showing the highest and most prolonged significance in food intake reduction 
(figures 2.11). The IP injections (30 mg/kg) caused a significant decrease in food 
intake in rats that lasted for a prolonged time and was still apparent 24 hours after 
the injection. One hour after injection, NNC1202-treated rats had eaten 1.03 ± 
0.30 g and those that received saline IP had eaten 6.14 ± 0.55 g (P < 0.0005; 
figure 2.11). The significant difference between NNC1202-treated and saline-
treated rats was still apparent after 24 hours, with rats injected IP with NNC1202 
IPconsuming between 28.00 ± 0.91 g of food compared with saline treated rats 
that consumed 34.27 ± 0.93 g (P < 0.0005; figure 2.11). These results suggest 
that the H3R inverse agonist NNC1202 given IP at 30 mg/kg and 20 mg/kg has a 
dramatic affect on the food consumption of rats causing a much reduced food 
intake that is prolonged and still apparent after 24 hours post injection. 
We noted that NNC1202 given at 20 mg/kg also caused a significant reduction 
in food intake at 1, 2, 4 and 24 hours post injection. Also our results also indicate 
that when NNC1202 is administered at 10 mg/kg a significant reduction is 
apparent after 1 and 2 hours post injection. These data suggests that even at the 
lower doses NNC1202 has a significant effect on food consumption in rats.  
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Figure 2.11.; Food consumption measured at 1, 2, 4, 8 and 24 hours after IP injection 
with NNC1202 (10, 20 & 30 mg/kg, n = 7) or saline (n = 7). Data are expressed as mean ± 
S.E.M. Two-way ANOVA with repeated measures and Bonferonni post hoc test was 
carried out: *** P < 0.0005, ** P < 0.005, * P < 0.05.  
 
 
2.4.4 The effect of the H3R compounds on the behavioural satiety sequence 
Similar to the earlier experiments described in this chapter, animals ate 
significantly more food when given the H3R agonist imetit (figure 2.12) compared 
with all other groups. When given either of the H3R inverse agonist drugs, 
thioperamide or NNC1202, rats significantly reduced their food intake (figure 
2.12). Measurements of food intake were made at the end of the 90-minute 
observation period. As mentioned, food intake was measured 90 minutes into the 
lights off period showing that the changes in food intake seen after administering 
these drugs occurs both in pre-fed and fasted animals in both lights on and lights 
off periods.  
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Figure 2.12.; Food consumption measured at 90 minutes after IP injection with imetit (10 
mg/kg), thioperamide (2 mg/kg), or NNC1202 (30 mg/kg) or saline (n = 8 for all groups). 
Data are expressed as mean ± S.E.M. One-way ANOVA with Bonferronni post hoc test 
was carried out: * P < 0.05, *** P < 0.0005. 
 
 
Figure 2.13 shows the BSS control group animals display a normal sequence 
of behaviour. They initially showed episodes of feeding interspersed with 
episodes of activity, before progressing to extended periods of grooming and rest, 
as they became satiated. Apart from an initial increase in eating behaviour in the 
first few bin points, the imetit-treated animals showed a similar pattern to the 
control animals. Also, the pattern of behaviours was similar in the thioperamide-
treated animals apart from slightly less time spent eating over the first few time 
bins. These results show that no unusual behaviours, e.g. immobility, malaise or 
sickness behaviour were noted in these treated groups. This was not the case for 
the NNC1202-treated group which showed a very different pattern of behaviours. 
Rats treated with NNC1202 showed prolonged episodes of inactivity where they 
were observed as quiet, motionless and unresponsive, although with eyes open, 
leading to assumption they are suffering from malaise. They appeared to recover 
slightly towards the latter part of the 90 minutes post injection and were even 
seen to start feeding in the last few bin time points. These results suggest that the 
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drug is having an effect on the animals that is making them feel unwell or 
unmotivated and as a result of this they are not eating as much as the other 
groups.  
 
 
 
 
 
 
 
Figure 2.13.; Behavioural satiety sequence – animals were IP injected with, A. saline, B. 
imetit, C. thioperamide, or D. NNC1202 and introduced to food 90 seconds post-injection. 
Their behaviours were scored every 30 seconds for 90 minutes according to the 
categories mentioned in the method section. Data are collated into 5 min time bins and 
expressed as mean percentage of total behaviour.  
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 Saline Imetit Thioperamide NNC1202 
Feeding 31% 34% 24% 13% 
Drinking 6% 5% 4% 2% 
Grooming 18% 21% 20% 1% 
Active 29% 26% 33% 28% 
Inactive 4% 2% 7% 54% 
Resting 13% 12% 12% 2% 
 
 
Table 2.2.; The overall average percentage of time spent in each behaviour over the 90-
minute observational period whilst carrying out the behavioural satiety sequence after 
animals were injected with either, saline, imetit, thioperamide, or NNC1202.  
 
 
 Animals that received an injection of imetit at lights out spent a slightly longer 
percentage of their time eating compared with control animals over the 90 
minutes observation period. Imetit treated animals spent 34 ± 3% of their time 
eating, whereas control animals spent 31 ± 3% (table 2.2). All time spent carrying 
out other behaviours corresponded with control animals. Thioperamide-treated 
subjects also showed similar behaviours as controls and spent a similar 
percentage of time in each behaviour. The one behaviour to deviate from control 
levels was the time spent feeding. Thioperamide-treated animals spent 24 ± 3% 
of their time feeding over the 90 minutes they were observed. Conversely, 
NNC1202-treated subjects spent a large percentage of their time in different 
behaviours during each time bin compared with the control animals and the 
thioperamide- and imetit-treated animals. Firstly, the NNC1202 group showed a 
much lower percentage of time feeding compared with controls or thioperamide-
treated subjects, with only 13 ± 2% of their time being spent feeding.  Also, 
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animals that received an injection of NNC1202 spent the majority of their time 
during the 90 minute observation period inactive with signs of malaise (54 ± 4%). 
When compared with control animals, which spent only 4 ± 1% of the 90 minutes 
showing inactivity, it is apparent that the NNC1202 animals are clearly showing a 
very different pattern of behaviours, as they are when compared with animals that 
received either the imetit or thioperamide injections.  
A measure of the induction of satiety may be inferred from the time during the 
observational period when resting overtakes feeding as the dominant behaviour. 
The control saline-, imetit- and thioperamine-treated animals all showed similar 
times taken for rest to become the dominant behaviour. The point of transition or 
‘cross over’ took place in time bins 8 to 11 for animals on the three groups (figure 
2.15). The NNC1202 treated animals showed a very different BSS compared to 
all other groups. It was noted that these animals were highly inactive for 
prolonged periods of time following injection and only started feeding towards the 
end of the 90 minutes. There was no real transition from feeding to resting with 
the animals spending very little time resting or feeding.  
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Figure 2.15.; This figure illustrates the observational period when resting overtakes 
feeding as the dominant behaviour after animals were injected with, A. saline, B. imetit, C. 
thioperamide, or D. NNC1202. Where the two lines first overlap is known as the ‘cross 
over’ point. The purple line indicates feeding behaviour and the blue line indicates resting. 
Each time bin represents 5 minutes. 
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2.4.5 Do imetit and thioperamide have similar effects on feeding in mice? 
 Using similar concentrations to those used by Yoshimoto et al. (2006), we 
administered two doses of imetit to determine whether this H3R agonist had the 
same effects on food intake that we and others have reported in rats or whether it 
had the opposite effects noted by Yoshimoto et al. (2006). We gave 10 or 20 
mg/kg of imetit IP to mice, 10 mg/kg had no effect on food intake either at 1 hour 
or 2 hours post injection. 20 mg/kg did have a significant effect on food intake 
resulting in significantly less food being eaten by imetit-treated mice compared 
with the saline-treated animals (figure 2.16). This significance was only apparent 
in the first hour post the imetit injection with the imetit treated group only eating 
0.41 ± 0.05 g compared to control animals that ate 0.74 ± 0.11 (P < 0.01) (figure 
2.16). This significance was lost by two hours post injection, with control animals 
eating 1.14 ± 0.11 g and imetit treated mice eating 0.08 ± 0.11 g (figure 2.16). 
Thus, we found in contrast to what we noted in rats, imetit reduce food intake in 
mice. 
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Figure 2.16.; Food consumption measured at 1 & 2 hours after IP injection with 10 & 20 
mg/kg imetit or saline (n = 5). Data are expressed as mean ± S.E.M. Two-way ANOVA 
with repeated measures and Bonferonni post hoc test was carried out: ** P < 0.01. 
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We then wanted to determine whether the H3R inverse agonist thioperamide 
had opposing effects on food intake in mice and rats. We administered both 10 
and 20 mg/kg of thioperamide, and measured food intake for two hours after the 
injection (figure 2.17). We found both doses resulted in a significant reduction in 
food intake. 10 mg/kg of thioperamide resulted in anorexia in mice for the first 
hour post injection. Here we found that control animals ate 0.74 ± 0.11 g of food, 
whereas thioperamide-treated animals ate 0.51 ± 0.06 g of food (P < 0.01). This 
significance was lost between 1 and 2 hours post injection with mice 
administered, with imetit mice ate 1.14 ± 0.11 g of food whereas the control 
grouped ate 0.90 ± 0.09 g of food 2 hours post injection (figure 2.17). Mice given 
a dose of 20 mg/kg of thioperamide showed significant hypophagia at both the 1 
and 2 hour time points. Mice given 20 mg/kg ate 0.027 ± 0.06 g of food 1 hour 
post injection, which is significantly less food (P < 0.001) than animals that 
received a injection of saline, which ate 0.74 ± 0.11 g. This significance was still 
apparent at two hours post injection, with the control group having eaten 1.14 ± 
0.11 g of food compared with thioperamide-treated animals that ate 0.68 ± 0.10 g 
(figure 2.17). Thus, we found thioperamide to be a powerful and effective 
anorexic inducing drug in mice. 
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Figure 2.17.; Food consumption measured at 1 & 2 hours after IP injection with 10 & 20 
mg/kg thioperamide or saline (n = 13). Data are expressed as mean ± S.E.M. Two-way 
ANOVA with repeated measures and Bonferonni post hoc test was carried out: *** P < 
0.001, ** P < 0.01. 
 
 
 
2.5 Discussion 
2.5.1 Histamine causes a reduction in feeding in rats 
In the first experiments described, histamine was injected into the lateral 
ventricle of the rat brain, close to the hypothalamus, an area associated with 
appetite. It has been shown previously by a number of research groups that 
histamine can decrease food intake in rodent models following ICV, IP and 
intravenous (IV) injections (Doi et al. 1994; Endou et al. 2001; Lecklin et al. 1998), 
and we aimed to confirm these studies by determining if we could also cause a 
decrease in food intake in male Sprague-Dawley rats. We found that ICV 
histamine injection caused a significant decrease in food intake for up to 8 hours 
post injection. 200 nmol histamine caused a reduction in the food eaten by rats 
 88 
compared with rats receiving a saline vehicle injection. Intake was normalised by 
24 hours post injection. That is, histamine-injected rats compensated with an 
increase in consumption at later time points, indicating that the histamine did not 
have long-term deleterious effects.  
According to the literature, H1R and H3R can mediate effects on feeding 
behaviour in rodents, with H1R agonism causing a reduction, and H3R agonism 
causing an increase in food intake, respectively. As our ICV histamine injections 
cause a reduction in food intake, the simplest explanation is that histamine is 
acting directly on postsynaptic H1R, perhaps within the hypothalamus. H1R are 
highly concentrated in the hypothalamus (Ookuma et al., 1993; Doi et al., 1994), 
and direct injections of histamine or H1R agonists into either the VMN or PVN can 
reduce feeding (Kinnunen et al. 1998).  
However, it remains possible that histamine’s actions could be indirect and not 
the result of activating hypothalamic H1Rs. H3R occur densely within the 
hypothalamus and can act as heteroreceptors. Thus, giving injections of 
histamine could activate H3R heteroreceptors present on neurones containing 
other transmitters to affect the release of these transmitters, which could indirectly 
affect the food consumption of the animals being tested (Schlicker et al., 1993, 
Yoshimatsu et al., 2008).   
 
 
2.5.2 H3R agonism effects on food intake in rats and mice  
Our findings, on the effects of the H3R agonist imetit on food intake in rats is in 
agreement with the vast majority of the literature already published. Many studies 
have been carried out that suggest H3R agonists, including imetit, cause an 
increase in food consumption (Garbarg et al., 1992; Leurs et al., 2005; Hancock 
et al., 2004). We too found that the H3R agonist imetit, when administered either 
centrally or systemically caused a significant increase in food intake in male 
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Sprague-Dawley rats. The majority of H3R are expressed centrally (Lovenberg et 
al., 1999) and, therefore, these results support the assumption that imetit can 
cross the blood-brain barrier to affect central H3R receptors to affect feeding 
(Lecklin et al., 1998). We could assume that administering a H3R agonist would 
increase the auto-regulatory nature of H3R autoreceptors and, thus, endogenous 
circulating histamine would be reduced resulting in an increase in food intake.  
However, one study has found imetit to have opposite effect on food intake in 
mice (Yoshimoto et al., 2006). This study suggests imetit causes a decrease 
rather than an increase in food intake in mice and that continual administration 
can result in body weight reduction. Thus, our next aim was to carry out a feeding 
study in mice to determine whether this research groups finding are in 
disagreement with the rest of the literature, or whether species related difference 
in the effects of this H3R drug actually causes it to have an alternative effect in 
mice. Our results agreed with the findings of Yoshimoto and colleagues with 
imetit causing a significant reduction in food intake in mice when given 
systemically. These data supports the controversial findings of Yoshimoto et al. 
(2006) and suggest imetit can have opposing effects in rats and mice and again 
illustrates the possible differences in effects H3R drugs can have amongst 
different species.  
Histamine is known to play a crucial role in sleep-wake control and it has been 
reported (Parmentier et al., 2002; Lamberty et al., 2003) that several H3R 
agonists, including imetit, increase slow-wave sleep by inhibiting histamine 
release. Thus, it has been suggested that H3R agonists might have hypnotic 
actions, and could possibly explain the hypophagic effects of imetit reported 
(Parmentier et al., 2002). However, Yoshimoto et al. found that imetit did not 
significantly reduce locomotor activity compared with vehicle (Yoshimoto et al., 
2006). Likewise, the hyperphagic effects seen in rats given imetit and our BSS 
findings, which showed no significant alterations in any behaviour other than 
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feeding, suggests movement and/or wakefulness was not seriously affected. It 
would be important to carry out the BSS study in mice too.  
 
 
2.5.3 H3R inverse agonism decreased food intake in rats and mice  
Although some research groups have found thioperamide to have varying 
effects (Itoh et al., 1998; Sindelar et al., 2004), it is a widely investigated H3R 
inverse agonist and has been shown to decrease food intake by a number of 
research groups (Lecklin et al., 1998; Sakata et al., 1990). NNC1202, on the 
other hand, is a more recently developed H3R inverse agonist and has been 
much less widely investigated, yet it is reported to have robust inhibitory effects 
on food intake (Wulff et al., 2002).  
We carried out feeding studies to determine how these H3R inverse agonists 
would affect food intake in male Sprague-Dawley rats when administered either 
centrally or sytemically. By both routes of administration, thioperamide caused a 
significant decrease in food intake in rats. By 24 hours post injection of 
thioperamide by either route, cumulative food intake was no longer significantly 
different compared with vehicle controls, suggesting that the drug is not having a 
long-lasting effect on food intake and no major adverse actions. This is backed up 
by our BSS results which showed that the sequence of post feeding behaviours 
did not greatly differ from those seen in control animals, with the only difference in 
behaviour being seen in the feeding behaviour. Although we found the behaviours 
of the rats that received thioperamide did not greatly deviate from those given 
saline there was no shift in the sequence, which might suggest thioperamide is 
not affecting satiation directly. 
The H3R inverse agonist, NNC1202, a compound donated by our industrial 
partners, Novo Nordisk, has been shown to decrease food intake in rodent and 
primate studies when given systemically (Wulff et al., 2002). We were able to 
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confirm this. However, to date there is no evidence that shows the compound to 
have the same effects when given by the ICV route, which would narrow its 
effectiveness to a central site of action. We found NNC1202 to have no 
observable effect on food intake at any of three doses tested (100, 200 or 400 
nmol) when injected ICV. No data are available to indicate the efficacy of 
NNC1202 compound when given ICV, and it is possible that insufficiently high 
doses were chosen. Since the hypothesis set out by the company is that the 
compound is crossing the blood-brain barrier to cause anorexia when 
administered peripherally, it is surprising that NNC1202 is ineffective at any of our 
tested doses. However, NNC1202 did cause a dramatic reduction in food intake 
when injected IP and cumulative food intake was still significantly reduced at 24 
hours post injection. This suggests this compound has longer-term effects on 
feeding. We did not measure food intake after the 24 hour period and thus can 
not define when, if at all, cumulative food intake normalised. However, we did 
note that the rats did not lose weight and showed comparable weight gain to 
control rats over the next seven days. However, a question remains whether it is 
achieving a reduction in appetite through the hypothesized mode of action (i.e. 
the central release of endogenous histamine) or whether it is creating an adverse 
reaction within the periphery that leads indirectly to hypophagia. Our BSS 
experiments show NNC1202 treated animals eat very little and are inactive for the 
majority of the 90 minutes they were observed, suggesting NNC1202 is indirectly 
affecting appetite and may be affecting other behaviours causing a lack of food 
intake. Unfortunately, our BSS studies do not distinguish between possible 
causes for the recorded inactivity (e.g. malaise, sedation etc). An alternative 
study to carry out would be a conditioned taste aversion test to investigate the 
development of aversion and, thus, malaise or nausea induction after the 
administration of a drug. Suffice to say that the enormous disruption of the BSS 
and the lack of effect when given centrally but dramatic affect when peripherally 
 92 
administered, suggests that NNC1202 is having undesirable adverse actions and, 
thus, we decided not to continue with our studies using this drug. In fact, Novo 
Nordisk have since stopped its development programme on this and other small 
molecule drugs in this field.  
It has certainly been shown that a number of H3R inverse agonists have 
opposing effects on food intake in different animal models (Lecklin et al., 1998; 
Hancock et al., 2004; Jethwa et al., 2009). Hancock et al. Showed that the H3R 
antagonist, A-133144, decreased weight and body fat when given orally over a 
28-day period, although surprisingly minimal food intake consumption changes 
were observed (Hancock et al., 2004). Lecklin et al. (1998) found that giving 
thioperamide centrally had no affect on food intake, whereas Jethwa and 
colleagues showed that in the seasonal hamster administering H3R inverse 
agonists in the lean state reduced the animals food intake (Jethwa et al., 2009). 
Alternatively Yoshimoto et al. found that thioperamide given to mice resulted in 
significant weight gain and hyperphagia (Yoshimoto et al., 2006). 
After determining that the H3R agonist imetit can cause an increase in food 
intake in rats and yet produces anorexia in mice we wanted to determine whether 
thioperamide could also have these differing effects in different animal species as 
shown by Yoshimoto et al. (2006). We found, when given systemically, the H3R 
inverse agonist thioperamide caused a significant decrease in food intake in mice 
at both 10 and 20 mg/kg. These findings support our data from our rodent studies 
which also suggest thioperamide acts as a potent hypohagic agent, but oppose 
the results previously published by Yoshimoto and colleagues. The difference in 
our findings and the findings of Yoshimoto et al. (2006) are not entirely surprising 
as thioperamide has long been controversial in its effectiveness with varying 
effects seen by a number of groups being published. Some suggest it causes 
anorexia (Arrang et al., 1987), whilst others suggest it has no effects on food 
intake (Itoh et al., 1998), and others suggesting its effects are determined by the 
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route of administration (Sindelar et al., 2004). We used CD-1 mice whereas 
Yoshimoto and colleagues carried out their experiments on C57BL/6J mice. The 
differences in mouse strains could explain the differences in our findings 
especially as a number of other H3R inverse agonists have shown different effects 
in their actions depending on the species being tested (Oishi et al., 1983; 
Hancock et al., 2004; Tokita et al., 2006). 
 
Our results from systemic injections suggest that imetit and thioperamide could 
be crossing the blood-brain barrier as they have strong effects on food intake. 
This is useful for the development of pharmaceutical agents as it would be 
impossible to administer drugs centrally to human patients. Furthermore, since 
H3R are found in abundance centrally, the release of endogenous histamine or 
other transmitter modulation within the brain is unlikely to have “off-target” effects 
in the periphery. It is interesting that we found no evidence for adverse actions of 
either drug from our BSS. Altogether our evidence suggest, although more 
research needs to be carried out, H3R might still be worthy of consideration as a 
useful target for the treatment of obesity or other eating disorders.  
 
 
2.6 Future work and directions 
The H3R can act as an autoreceptor to modulate histamine synthesis and 
release or as a heteroreceptors on the terminals of other transmitter-containing 
neurones (Schlicker et al., 1994). From the studies carried out we are not able to 
define whether the increase in food intake seen in rats with imetit or the decrease 
in feeding seen with thioperamide was due to effects on the presynatic H3R 
autoreceptor or the H3R heteroreceptor. This could be determined by carrying out 
feeding studies where the H3R based drugs are given along with antagonists for 
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post-synaptic histamine receptors or for other transmitters. The situation is further 
complicated by the fact that histamine can also co-localise with other transmitters 
that have effects on feeding and appetite, such as dopamine (Fulton S., 2010, 
Campbell et al., 2007), GABA (Gruninger et al., 2007, Patel et al., 2010) and 
serotonin (Ebenezer et al., 2007, Halford et al., 2010).  
To determine that diurnal influences are not having effects on drug 
administration and determining different behaviours, we also could examine the 
behavioural satiety sequence following histamine injection at different times of the 
day. Any disruption of the sequence would indicate unusual actions of a treatment 
that might be affecting food intake indirectly, for example of aversion, nausea or 
sedation. Future work might also include the use metabolic cages to determine 
how histamine can affect energy metabolism. 
 
 
These feeding studies allowed us to determine how the drugs affected food 
intake in adult rats but didn’t give us any information on where the drugs were 
acting. Thus, our next step was to carry out immunohistochemistry studies to 
measure the induction of c-fos, a neuronal marker for activation, to determine 
exactly where in the adult rat brain the H3R drugs are acting. 
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Chapter 3: 
Neuronal activation by 
histaminergic receptor ligands 
 96 
3.1 Introduction 
3.1.1 Histamine and its neuronal projections throughout the rat brain 
Histamine is a central neurotransmitter and, as mentioned previously, is 
involved in many behavioural and physiological functions. The histamine 
neurones are found solely in the TM of the posterior hypothalamus (Schwartz et 
al., 1991), from here the histaminergic nerve fibres project to almost the entire 
areas of the brain through dorsal and ventral pathways, with the highest density 
of projections being found within the hypothalamus, in particular to the VMN. 
Although all brain regions receive some histaminergic innervations, some receive 
a much denser input than others. An over-simplified description would be to say 
that that structures innervated by the ventral ascending pathway receive a 
powerful input whereas those innervated by the dorsal ascending pathway tend to 
have a much lower density of fibres (Brown et al., 2001). The cerebral cortex of 
the rat brain has a moderate density of fibres, whilst the histaminergic innervation 
of the thalamus is concentrated upon the periventricular nuclei. Although the 
hippocampus receives only a moderate innervation by histamine neurones, 
histamine has strong effects on excitability in this area (Haas et al., 1983; Haas et 
al., 1986; Panula et al., 1989; Greene et al., 1990). Also a low to moderate level 
of innervation is present in the striatum and nucleus accumbens (Brown et al., 
2001). Projections to the midbrain, brain stem, cerebellum and spinal cord are 
lower concentration than the ascending projections. All of the other aminergic cell 
groups receive at least a moderate density of fibres, with the substantia nigra and 
ventral tegmental area being strongly innervated. In addition, prominent 
projections have been noted in the inferior and superior colliculi, periaqueductal 
gray, nucleus of the trigeminal nerve and nucleus of the tractus solitarius (Brown 
et al., 2001). 
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Histaminergic axons do not in general form synaptic specialisations, 
instead histamine is released from varicosities (swellings containing synaptic 
vesicles) located periodically along the axon (Takagi et al., 1986). Thus, 
histamine release sites and histamine receptors are not always directly apposed 
to one another. Therefore, histamine can function like a local hormone, acting on 
neurones, glial cells and blood vessels in a concerted manner (Wada et al., 1991, 
Brown et al., 2001). Although some brain regions receive only a low density of 
histaminergic fibres there is a considerable inconsistency between histaminergic 
fibre density and histaminergic receptor density in various brain regions 
(Schwartz et al., 1991) and the prominence of electrophysiological effects (Takagi 
et al., 1986). This suggests that all brain regions can be affected to a lesser or 
greater degree depending on the situation. For example, areas with a high 
histaminergic density of fibres will probably be affected tonically during waking, 
whilst areas with lower histamine fibre density may only be affected under certain 
behavioural situations when histamine neurones fire more rapidly.  
There is accumulating evidence that histaminergic neural circuits arising in the 
TM and projecting into the satiety centres of the hypothalamus participate in 
regulation of energy homeostasis. The central function of neural histamine in 
regulation of food intake is further underlined by the fact that leptin, amylin and 
bombesin have been suggested to exert at least some of their anorectic effects 
through the histaminergic circuitry (Malmlof et al., 2005). Also, histaminergic 
neurones project into hypothalamic centres known to be involved in food intake 
regulation, these include the PVN and VMN, where the anorectic effect is thought 
to be mediated by the postsynaptic histamine H1R. Malmlof et al. suggest the 
density of the H1R, together with the H3R-mediated control of the intrasynaptic 
concentration of histamine, are both crucial in determining the strength of the 
anorectic signal (Malmlof et al., 2005).  
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Although there are only two histamine receptors (H1R and H3R) known to 
influence feeding behaviour there are a number of other histamine receptors that, 
like H1R and H3R, are found widely both peripherally and centrally. The ubiquitous 
nature of histamine receptors is one of the main reasons that histamine has such 
diverse and widespread effects. For this reason we began by giving histamine 
i.c.v. to determine the exact effects it has acting purely upon the brain. This stops 
any peripheral receptors being stimulated and potentially causing secondary 
actions in the brain through afferent projections. We then went on to determine 
the effects of the histamine agonist and histamine antagonists by carrying out 
both i.c.v. and i.p. injections. We carried out i.p. injections as wanted to see the 
effects the drugs would have if given systemically and we needed to determine if 
the drug was able to cross the blood-brain barrier. This is important in considering 
the possible route of administration in a clinical setting. 
 
 
3.1.2 The neuronal activation marker c-fos  
Immediate-early genes (IEG) show rapid and transient expression, are 
activated upon cell stimulation, and their expression cannot be prevented by 
protein synthesis inhibitors (Sheng et al., 1990). IEG’s are believed to encode 
transcription factors which modify the expression of other target genes (Sheng et 
al., 1990). The induction of these genes by neuronal activity can result in long-
lasting changes and even modify the phenotype of the cell. One of the more 
commonly studied and understood IEG is c-fos (Herrera et al. 1996). A number of 
studies have demonstrated that increased neuronal activity in vivo induces c-fos 
expression (Morgan et al., 1987, Hunt et al. 1987, Ons et al., 2010), leading to c-
fos expression commonly being used to determine which neuronal populations 
are activated following different stimuli (Dragunow et al., 1989), such as drug 
administration.  
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C-fos is the most widely used functional anatomical marker of activated 
neurones within the CNS, mainly because it is expressed at relatively low levels 
under basal conditions; it is induced in a stereotypical manner in response to 
extracellular signals; the response is transient; detection of c-fos expression is 
relatively basic and it can be easily combined with a number of other markers 
(Elias et al., 1999; Zhang et al., 2000). C-fos and its protein product c-Fos are 
generally thought to act as reliable markers for identifying activated cells (Kovas 
KJ., 2008), but it must be noted that the lack of a Fos response does not rule out 
the involvement of the cell group or tissue area being investigated (Ericsson et 
al., 1994). Although, if depolarisation alone regulated c-fos expression, its 
detection would be observed in neurones throughout the brain, even under basal 
conditions. Thus, it is likely that only changes in afferent inputs and changes in 
external stimuli induce c-fos expression (Scott et al., 2007; Kovas et al., 2008; 
Dodd et al., 2009).   
In most cell types, c-Fos protein levels are relatively low under basal 
conditions (Curran et al., 1988). However, stimuli linked to cell division, such as 
serum and polypeptides can stimulate c-fos expression (Curran et al., 1985; 
Greenberg et al., 1986; Greenberg et al., 1984; Sheng et al., 1990). Other signals 
associated with neuronal excitation can also elicit, albeit temporary, c-Fos 
expression. For example, voltage-dependent Ca2+ channel activation and 
neurotransmitter release (Greenberg et al., 1986). Activation of c-fos in the brain 
can be induced by a diverse group of stimuli and therefore c-fos has been used 
as a tool to study neuronal activation in a number of different systems in the brain 
(Herrera et al., 1996). Hence, C-fos is an important tool in science and its 
detection has led to a further understanding of different systems in the CNS and 
allows the mapping of neuronal populations activated by a variety of external 
stimuli. 
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3.2 Objectives 
3.2.1 Where does i.c.v. injection of histamine activate cells within the rat 
brain? 
A number of brain areas are known to be central in the control of appetite 
and feeding behaviour. Thus, using c-Fos immunohistochemistry, we aimed to 
determine which brain areas were activated when histamine was administered 
centrally and to establish how widespread the activation was.  
 
 
3.2.2 Do i.p. injections of a histamine agonist and inverse agonist cause 
activation of cells in similar areas to that of histamine? 
Due to the significant changes on feeding behaviour caused by the 
administration of the H3R agonist, imetit, and the H3R inverse agonists, 
thioperamide and NNC1202, we also wanted to determine if the same brain areas 
were activated when these drugs were given systemically.  
 
 
 
3.3 Methods 
3.3.1 Animals 
Male Sprague-Dawley rats (250-280 g; Charles-River, UK) were adapted 
to a 12 h/ 12 h light-dark cycle (lights on 08.00-20.00) a week before surgery or 
before their intraperitoneal (i.p.) injections. These and all other experiments 
conformed with the Home Office Scientific (Animal) Procedures Act of 1986 and 
local ethical review.  
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3.3.2 Compounds 
Histamine (200 nmol) was administered via injection into the lateral 
cerebral ventricle (intracerebroventricular administration, i.c.v.), thioperamide (2 
mg/kg body weight), imetit (10 mg/kg) and NCC-0038-1202 (NNC1202, 30 mg/kg) 
were administered intraperitoneally. All compounds were diluted in isotonic saline 
to the required concentration. Histamine, thioperamide and imetit were purchased 
from Sigma-Aldrich Company Ltd (Dorset) and NNC1202 was donated by Novo 
Nordisk. 
 
 
3.3.3 Experimental procedures for i.c.v. cannulation 
Rats were anaesthetised with 2 % isofluorane in O2 at a rate of 1 l/min. 
Once their heads had been shaved, rats were placed securely in the stereotaxic 
apparatus (Stoelting, Illinois, USA). A 2-3 cm incision was made along the midline 
of the cranium exposing the skull. All connective tissue was displaced from the 
cranial surface before a 21-gauge guide cannula was positioned 0.8 mm posterior 
and 1.5 mm lateral to bregma (co-ordinates determined according to Paxinos and 
Watson 1986). The guide cannula was inserted to a depth of 3 mm through a 1.5 
mm diameter hole drilled in the cranium. It was fixed to the skull with acrylic 
dental cement (Simplex Rapide; Austental Dental, UK) adhered to two jeweller's 
screws (4 mm long x 2 mm diameter) positioned anterior and posterior to the 
cannula. Once the dental cement was dry, the skin around the cannula was 
sutured (size 3/0 mersilk, Ethicon, Johnson and Johnson International, USA). For 
post-operative analgesia, rats were injected with 10 µl/kg buprenophrine 
(Vetergesic, Reckitt Benckiser Healthcare, Hull, UK) and a bolus intramuscular 
injection of saline to aid recovery. Animals were allowed to recover for one week 
and during this time rats were given food and water ad libitum. 
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3.3.4 Fos immunocytochemistry following i.c.v. histamine administration or 
i.p. administration of a H3R agonist and H3R inverse agonists  
I.c.v. histamine administration or i.p. administration of thioperamide, imetit 
or NNC1202 was repeated in animals that had not been fasted overnight, in order 
to examine brain areas activated. On the day of the experiment, rats were 
administered with histamine or isotonic saline (2 µl injection volume) i.c.v., or with 
the thioperamide, imetit, NNC1202 or isotonic saline injections (1ml/kg) i.p. After 
the injection, the cannulae were checked to ensure reflux did not occur. 90 min 
following injection, the rats were deeply anaesthetised with sodium 
pentobarbitone (100 mg/kg (B. Braun, Sheffield, UK) and perfused transcardially 
with heparinised (10,000 I.U./l, Leo Pharma, Denmark) isotonic saline (0.9 % 
NaCl, B. Braun, Sheffield, UK) for 8 min, followed by 4 % paraformaldehyde in 0.1 
M phosphate buffer (PB) for 15 min. Perfused brains were post fixed and 
cryoprotected in the same fixative with 15 % sucrose added, followed by 
immersion in 30 % sucrose in 0.1 M PB. 30 µm coronal sections throughout the 
rostro-caudal extent of the brain were cut using a freezing-sledge microtome and 
collected into 0.1M PB. Endogenous peroxidase activity was deactivated by 
incubating sections in a 1.5 % hydrogen peroxide, 20 % methanol and 0.2 % 
Triton X-100 in 0.1 M PB for 30 minutes at room temperature, followed by three 
10 min washes in 0.1 M PB. To block non-specific staining, slices were incubated 
for 1 hour at room temperature in 2 % normal goat (NGS) blocking serum (0.1 M 
PB, 0.3 % Triton X-100, 2 % NGS). Slices were then incubated for ~24 hours at 
4°C in goat anti-rabbit c-Fos antibody (SC052, Santa Cruz Biotechnology Inc., 
USA) diluted 1:1000 in the NGS blocking serum. Excess antibody was removed 
by washing sections three times in 0.1 M PB with 0.3 % Triton X-100 before the 
sections were incubated in goat anti-rabbit immunoglobulin (IgG) peroxidase 
complex (Vector Laboratories Inc., USA) diluted 1:500 in blocking serum. 
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Following three washes in 0.1 M PB the slides were incubated for 1 ½ hours at 
room temperature in streptavidin-biotinylated horseradish peroxidase complex 
(source) 1:400 in 0.1M PB. Following three further washes in 0.1 M PB, the 
bound antibody-peroxidase complex on the sections was visualised using nickel-
intensified diaminobenzidine (DAB). Sections were washed in 0.1 M acetate 
buffer (1.64 % sodium acetate, adjusted to pH 6 with glacial acetic acid) 
incubated in nickel-DAB solution (5 % nickel sulphate in 0.1 M acetate buffer, 
0.25 mg/ml DAB, 0.4 % glucose, 0.08 % ammonium chloride and 0.003 % 
glucose oxidase). The reaction was followed using a microscope and terminated 
by rinsing the sections in acetate buffer, followed by 0.1 M PB three times, once a 
strong black precipitate was formed. 
Sections were mounted from distilled water onto glass microscope slides 
using a xylene-based mountant (Ralmont, BDH UK), left to dry and observed 
using a microscope. 
 
 
3.3.5 Analyses 
Neurones were determined to be c-Fos positive if their nuclei were stained 
a dark black colour. A qualitative analysis of the whole brain was made to 
determine regions of interest (i.e. that contained significant c-Fos staining). 
Regions of interest were then counted bilaterally for each tissue section with the 
observer blinded to the treatment group. The average number of cells per section 
was calculated for each animal and averaged to provide a treatment group mean. 
All sections collected were analysed and each section is 120 µm further than the 
last. One way analysis of variance (ANOVA) with Bonferonni post hoc test was 
carried out to determine statistical significance between saline and histamine 
treated animals. Two way ANOVA with Bonferonni post hoc test was carried out 
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to determine statistical significance between saline treated animals and imetit, 
thioperamide or NN1202 treated animals. 
 
 
3.5 Results  
Examining the brains collected from each of the drug treatments, we found 
that all had induced c-Fos. There was not a global activation of the brain, but 
instead, activity was distributed within clearly-identifiable regions. The staining 
patterns of c-Fos were found to be similar for the different drug treatments and, 
therefore, these regions of interest were focused on in our quantitative analyses. 
The regions of interest were the paraventricular nucleus (PVN), ventromedial 
nucleus (VMN), dorsomedial nucleus (DMN), arcuate nucleus (ARC) in the 
hypothalamus, anterior hypothalamic area (AHC), lateral hypothalamic area (LH), 
medial amygdala (AMYm), anterior amygdala (AMYa), central amygdala (AMYc), 
tuberomammillary nucleus (TM) and the dorsal raphe nucleus (DR). As all 
staining patterns were similar for histamine and all the drug groups a example of 
the staining for only the histamine versus control group have been illustrated. 
 
 
3.5.1 The effect of i.c.v. injections of histamine on neuronal activation 
Examination of brains showed that animals that received i.c.v. injections of 
200 nmol histamine displayed the induction of c-Fos. Four hypothalamic nuclei 
known to be involved in feeding and appetite had high numbers of c-Fos-positive 
neurones. These included the PVN, VMN, DMN and the ARC. We found that 
these areas had significantly increased numbers of c-Fos-positive neurones in 
rats that received histamine, compared with control rats (figure 3.1). For the PVN 
there were a high number of c-Fos-positive cells per section (50 ± 5) compared 
 105 
with the control rats (7 ± 2; P < 0.0001). The PVN was seen to have a high 
number of c-Fos-positive cells that were close together and with nuclei of varying 
sizes suggesting different types of neurone and potentially non-neuronal cells 
were activated in this area (figure 3.2). The VMN had significantly more c-Fos-
positive cells in animals that received i.c.v. histamine injections (27 ± 4) compared 
with control animals (2 ± 1, P < 0.0001) (figure 3.1). The DMN had a large 
number of c-Fos-positive cells in the histamine-treated rats (120 ± 20) compared 
with vehicle-treated animals (46 ± 20, P < 0.0001) (figure 3.1). These cells were 
more spaced out throughout the DMN rather than a close group of cells as seen 
in the PVN. The ARC also had increased number of Fos-stained neurones in rats 
that received histamine injections (30 ± 3) compared with those that received 
saline vehicle (9 ± 3; P < 0.0005) (figure 3.1). The TM was found to have an 
increased number of c-Fos-positive cells in the brains collected from rats that 
received histamine injections compared with those that received vehicle. There 
were 50 ± 12 c-Fos-positive cells per section found within the histamine-treated 
animals with only 12 ± 5 c-Fos-positive cells being found in the saline-treated 
control animals (P < 0.05) (figure 3.1). 
 There was also a high amount of staining within the central amygdala 
(AMYc) of rats treated with histamine. Rats treated with histamine were found to 
have significantly higher neuronal activation (45 ± 29) as compared with control 
rats (12 ± 9, P < 0.05) (figure 3.1). These c-Fos-positive cells were tightly grouped 
together suggesting they could be a specific population of cells within the AMYc. 
The other areas of the amygdala did not show significant differences between 
histamine and control groups. 
 After examining the DR of both the histamine- and saline-treated animals we 
counted a significant difference between numbers of neurones activated. The 
saline-treated animals had a much lower level of staining than the histamine-
treated group (figure 3.1). The histamine-treated group had an average of 121 ± 5 
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positive cells per section whereas as the saline-treated group had 46 ± 5 (P < 
0.05) c-Fos positively stained cells. 
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Figure 3.1.; The effect of histamine administration on c-Fos immunoreactivity in the rat 
brain. Animals received an injection of histamine (200 nmol) or saline into the 
intracerebral ventricle 90 minutes before transcardial perfusion. Data are expressed as 
mean ± SEM. Two way ANOVA with Bonferonni post hoc test was carried out to 
determine statistical significance, * P < 0.005, ** P < 0.0005, *** P < 0.00005. 
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Figure 3.3.; Representative photomicrographs of the cortex of saline treated and 
histamine treated animals. These photomicrographs illustrate that c-fos staining was not 
universally found in all regions throughout the brain but was specific to certain brain 
areas. In particular those regions of interest known to be integral in appetite control. 
Animals received an injection of histamine (200 nmol) or saline into the intracerebral 
ventricle 90 minutes before transcardial perfusion. A. Represents animals that received an 
injection of saline, B & C represent a animal that received a injection of histamine. A 
similar a pattern of staining was also observed in these areas for each of the H3R 
compounds tested. 
 
 
Figure 3.2. (see previous page); Representative photomicrographs of regions of interest 
known to be integral in appetite control that display significantly high level of activation 
following histamine administration. Animals received an injection of histamine (200 nmol) 
or saline into the intracerebral ventricle 90 minutes before transcardial perfusion. A, D & 
G represent saline treated animals, B, C, E, F, H & I represent histamine treated animals. 
A – C illustrates c-fos staining in the PVN, D - F represents c-fos staining in the VMN and 
G – I represents c-fos staining in the ARC. 3V = third ventricle. A similar a pattern of 
staining was also observed in these areas for each of the H3R compounds tested.  
200 µm 200 µm 800 µm 
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3.5.2 The effect of i.p. injections of H3R compounds on neuronal activation 
I.p. injections of 10 mg/kg imetit, 2 mg/kg thioperamide or 30 mg/kg 
NNC1202 significantly increased c-Fos-positive neurones in a number of areas 
within the hypothalamus compared with control rats (figure 3.4). Overall there 
were also similar patterns of c-Fos staining between the separate drug groups. A 
significantly higher number of cells were stained for c-Fos within the DMN of 
imetit-, thioperamide- and NNC1202-treated animals (99 ± 9, 88 ± 14, 90 ± 9, 
respectively; P < 0.001 for all groups) compared with saline-treated rats (51 ± 6) 
(figure 3.4). The VMN also had a large number of c-Fos-positive cells within the 
brains of imetit-, thioperamide- and NNC1202-treated animals (32 ± 4, 36 ± 3, 44 
± 4, respectively; P < 0.001 for thioperamide and NNC1202, P < 0.01 for imetit), 
with a significantly lower number within the brains of animals that received saline 
injections (15 ± 3) (figure 3.4). There were also differences in neuronal activation 
within the PVN between the drug and vehicle groups. The H3R agonist, imetit, 
and H3R inverse agonists, thioperamide and NNC1202, treated brains were found 
to have a significantly increased number of c-Fos positive cells (78 ± 16, 126 ± 
12, 120 ± 9, respectively; P < 0.05 for all groups) compared with the saline-
treated group (26 ± 3) (figure 3.4). The ARC was also an area that we discovered 
differences between the H3R agonist-, the H3R inverse agonist- and the saline-
treated-controls (figure 3.4). The imetit-treated animals had 49 ± 7 c-Fos-positive 
cells whereas those that received saline had significantly less cells stained for c-
Fos (26 ± 3; P < 0.001). The rats that received thioperamide and NNC1202 also 
had significantly higher c-Fos counts (33 ± 5, 56 ± 3, P < 0.001). Interestingly, the 
H3R antagonists were less potent at causing neuronal activation that the H3R 
agonist within the ARC.  
Two other areas within the hypothalamus were also seen to have 
differences in neuronal activation between drug-treated and vehicle-treated 
groups. These areas included the AHC and the LH (figure 3.4). The AHC of 
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control animals had 48 ± 19 c-Fos-positive cells whereas those that received 
imetit, thioperamide and NNC1202 showed a dramatic increase in neuronal 
activation, with, 184 ± 25, 147 ± 7, 158 ± 16 (P < 0.001) c-Fos-positive cells, 
respectively (figure 3.4). H3R agonist- and H3R inverse agonist-injected animals 
were also seen to have an increase in neuronal activation within the LH. c-Fos-
positive cells were more numerous within the LH in imetit, thioperamide and 
NNC1202 treated animals (170 ± 14, 146 ± 8, 124 ± 14, respectively; P < 0.001), 
than in saline control animals (57 ± 14), suggesting all three drugs cause a 
increase in neuronal activation in this area. The TM, the source of histaminergic 
neurones, was also found to show differences in activation (figure 3.4). Brain 
slices from rats that were treated with saline had 23 ± 6 c-Fos-positive cells per 
section, whereas those that received imetit injections had 93 ± 6 c-Fos-positive 
cells (P < 0.001), those that received NNC1202 showed 100 ± 10 (P < 0.001) 
cells positive for c-Fos and those that received thioperamide were calculated to 
have 107 ± 22 c-Fos-positive cells (P < 0.001). Thus, all three treatments caused 
a significant increase in neuronal activation with increased numbers of c-Fos-
positive cells compared with saline controls in much a similar way seen when rats 
received a histamine injection (for comparison see figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
 
PVN VMN ARC DMN LHA AHC TM
0
100
200
300
400
500
600
700
800
900
1000
1100
1200 Vehicle
Imetit
Thio
NNC1202
***
***
***
******
***
*****
***
*
*
*
**
***
***
#
***
***
***
#
##
***
***
***
Av
e
ra
ge
 
c-
fo
s 
po
si
tiv
e
 
ce
lls
 
pe
r 
br
a
in
 
sl
ic
e
 
 
Figure 3.4.; The effect of the H3R agonist imetit and the H3R inverse agonists, 
thioperamide and NNC1202 administration on c-Fos immunoreactivity in the 
hypothalamus of the rat brain. Animals received an injection of imetit (10 mg/kg), 
thioperamide (2 mg/kg) or NNC1202 (30 mg/kg) or saline into the intraperitoneal cavity 90 
minutes before transcardial perfusion. Data are expressed as mean ± SEM. One way 
ANOVA with Bonferonni post hoc test was carried out to determine statistical significance. 
* indicates change from control animals. # indicates change from different drug group. # / 
* P < 0.05, ** P < 0.01, *** P < 0.001. 
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The AMY was another area seen to have variances in neuronal activation 
between the drug- and saline-treated groups (figure 3.5). The AMYm showed a 
significant increase in c-Fos-positive cells in brain sections from animals that 
received imetit (214 ± 20, P < 0.01), thioperamide (231 ± 18, P < 0.01) and 
NNC1202 (281 ± 45, P < 0.001), compared to those that received saline (77 ± 15) 
(figure 3.5). The pattern of staining here was evenly spaced out, covering the 
entire AMYm. The AMYa showed a similar pattern of staining for c-Fos-positive 
cells. There was a significant increase in c-Fos-positive cells in animals treated 
with imetit (235 ± 19, P < 0.001), thioperamide (163 ± 12, P < 0.01) and NNC1202 
(151 ± 10, P < 0.01), compared with control animals (81 ± 16) (figure 3.5). Again 
the staining pattern was seen to be evenly spread throughout the entire AMYa. 
The cells stained positive for c-Fos showed a much more compact pattern in the 
AMYc compared to the other areas of the AMY (figure 3.5). The AMYc from 
animals that received imetit and thioperamide showed a significant increase in c-
Fos positive cells (187 ± 16, 200 ± 33, respectively; P < 0.001) compared with 
saline controls (40 ± 5) (figure 3.5), suggesting this area was activated due to the 
effects of the drug. The NNC1202 treatment however showed no significant 
difference in neuronal activation with only 68 ± 5 c-Fos positive cells being 
detected. This suggests that the NNC1202 compound does not cause activation 
within the AMYc, despite the H3R inverse agonist thioperamide showing a 
significant increase in neuronal activation in this area. 
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Figure 3.5.; The effect of the H3R agonist imetit and the H3R inverse agonists, 
thioperamide and NNC1202 administration on c-Fos immunoreactivity in the amygdala 
regions of the rat brain. Animals received an injection of imetit (10 mg/kg), thioperamide (2 
mg/kg) or NNC1202 (30 mg/kg) or saline into the intraperitoneal cavity 90 minutes before 
transcardial perfusion. Data is expressed as mean ± SEM. One way ANOVA with 
Bonferonni post hoc test was carried out to determine statistical significance. * indicates 
change from control animals. # indicates change from different drug group. * P < 0.05, ** 
P < 0.005, ### / *** P < 0.0005.  
 
 
 
The dorsal raphe nucleus (DR) contained a significantly increased number 
of c-Fos-positive cells in brain slices from rats that had been treated with imetit, 
thioperamide and NNC1202 (81 ± 6, 115 ± 15, 110 ± 12, respectively; P < 0.05, P 
< 0.05, P < 0.01 respectively), compared to rats that had received saline (35 ± 9) 
(figure 3.6). This staining was seen in more anterior DR areas, with the amount of 
neuronal activation decreasing more caudally. 
 114 
0
50
100
150
Vehicle
Imetit
Thio
NNC1202
*
**
*
DR
Av
e
ra
ge
 
c-
fo
s 
po
si
tiv
e 
c
el
ls
 
pe
r 
br
ai
n
 
sl
ic
e
 
Figure 3.6.; The effect of the H3R agonist, imetit, and the H3R inverse agonists, 
thioperamide and NNC1202, on c-Fos immunoreactivity in the dorsal raphe nucleus (DR) 
of the rat brain sections. Animals received an injection of imetit (10 mg/kg), thioperamide 
(2 mg/kg) or NNC1202 (30 mg/kg) or saline into the intraperitoneal cavity 90 minutes 
before transcardial perfusion. Data is expressed as mean ± SEM. One way ANOVA with 
Bonferonni post hoc test was carried out to determine statistical significance. * P < 0.05, 
** P < 0.005.  
 
 
3.6 Discussion 
We found that Fos was induced only in certain areas within the rat brain (see 
comparison between figure 3.2 and figure 3.3). Thus, there was no blanket effect 
of neuronal activation therefore suggesting only certain areas are activated upon 
administration with histamine. Presence of Fos shows which areas of the brain 
have been activated but not the process through which it occurs (for example, 
directly or indirectly). Although c-Fos shows certain areas of the brain that are 
activated at the time of brain collection it gives no indication if histamine is 
actually being released endogenously in these areas. Also, c-Fos immunopositive 
neurones are found in areas that have been activated but this can be due to 
excitation or a disinhibition (that is due to the local inhibition of otherwise 
inhibitory neurone/inputs).  
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3.6.1 Histamine- and H3R receptor drug-induced neuronal activation within 
the hypothalamus 
Histamine neurones project from the TM to all areas of brain, with the densest 
projections to nuclei in the hypothalamus. Thus, one might have predicted, a high 
level of neuronal activation, though not an exclusive activation in these areas. 
Although, it is noteworthy to add that the activation was confined mainly to areas 
involved in the regulation of appetite. It is well established that the hypothalamus 
is essential for controlling appetite (see review King 2006). In particular the VMN, 
PVN, ARC, LH and DMN play pivotal roles in regulating food intake. We 
determined that the numbers of c-Fos-immunopositive neurones in the VMN, 
PVN, ARC, LH and DMN were significantly higher in rats that received an i.c.v. 
injection of histamine, or i.p. injections of the H3R agonist, imetit, or the H3R 
inverse agonists thioperamide and NNC12302.  
The hypothalamus is crucial in appetite control with the VMN, PVN, LH,  ARC, 
DMN and SCN nuclei all playing pivotal roles. Grouped together these areas form 
complex networks that regulate energy intake and expenditure (Beck et al., 
2000). For example, the VMN has direct links with the PVN and DMN and via 
these it connects indirectly with the LH (Harrold et al., 2004) illustrating the 
complex circuitry involved in regulating food intake within the hypothalamus. All 
the hypothalamic areas we found to have increased numbers of c-Fos-
immunopositive neurones are known to play important roles in regulating food 
intake. The VMN and PVN are satiety centres and the LH is a feeding centre and, 
thus, inform the brain when the animal is full or hungry, respectively. The ARC 
has a high co-expression of the orexigenic peptides NPY and AgRP (Dhillo, 2007) 
and also expresses a large population of anorectic signalling cells (Elias et al., 
1998) and therefore is extremely important in regulating both hunger and satiation 
in the animal. These orexigen- and anorexigen-producing neurones project from 
the ARC onto the VMN, DMH, LH and PVN (Harrold JA., 2004), again illustrating 
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the complex appetite regulating networks within the rodent brain. Within the DMH, 
microinjection of orexigenic compounds elicits feeding (Li et al., 1998), and the 
inhibition of NPY-induced feeding, enhances neuronal c-Fos (Yokosuka et al., 
1998). DMH efferents project to both the VMN and PVN, and the DMH receives 
prominent ARC input. Studies have shown that high densities of c-Fos-positive 
neurones have been shown within the PVN in response to administration of both 
orexigenic and anorexigenic signal molecules (Dhillo, 2007). All these areas were 
shown to increase their neuronal activation in response to histamine, imetit, 
thioperamide or NNC1202 application suggesting their involvement in controlling 
food intake at least in part through the histaminergic system.  
Fos induction within the hypothalamus might be due to direct activation by 
histamine itself through the activation of H1Rs. H1Rs are located throughout the 
rodent brain but are known to be high in density in the hypothalamus, including 
discrete neurones involved in regulating food intake, such as in the VMN and 
PVN (Sakata et al., 1988). Morimoto et al (2001) and Masaki et al. (2006) suggest 
that histamine acts on the H1R in the VMN and PVN to decrease food intake. As 
the H1R is distributed throughout the hypothalamus, histamine may also be acting 
directly within the ARC, LH and/or DMN. The H1R causes a reduction in food 
intake when activated, so administering histamine could have caused an 
activation of the H1R within these feeding centres of the rat brain, thus causing 
the reduction in food intake observed in previous experiments. This also applies 
to the H3R inverse agonists, as their actions would have led to the inactivation of 
the H3R’s ability to regulate the release of histamine and thus resulting in a 
increase in neuronal histamine with would than cause the same effects seen on 
food intake or neuronal activation witnessed when histamine itself was 
administered. 
A significantly high number of c-Fos-immunopositive cells were also evident 
within the TM of the rat hypothalamus. This is not surprising as the TM is the sole 
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origin of the histaminergic neurones. Also, accumulating evidence suggests 
histaminergic neural circuits arising within the TM and projecting into the satiety 
centres of the hypothalamus participate in regulation of energy homeostasis. For 
example, histaminergic neurones have been found to project from the TM the 
PVN and VMN. Here the anorectic effect is again thought to be mediated by 
postsynaptic histamine H1R. But the density of the H1R, together with H3R-
mediated control of endogenous histamine concentrations is thought to be crucial 
for anorectic potency (Malmlof et al., 2005). H3Rs are present on the cell bodies 
of the histamine neurones in the TM (Brown et al., 2001). Thus, histamine and the 
H3R drugs could be directly acting upon these histaminergic cell bodies causing 
neuronal activation within this area and this would induce Fos. Equally the 
histamine may activate H1R within or around the TM causing the increase in c-
Fos-immunopositive neurones being seen. Also, histamine, imetit, thioperamide 
or NNC1202 could be acting upon the histaminergic nerve endings from the TM. 
This itself may not induce Fos, but the H3R inverse agonists may block the ability 
of the H3 autoreceptor to negatively regulate the release and synthesis of 
histamine thus resulting in an inevitable increase of endogenous circulating 
histamine. This increase in endogenous histamine could be binding to the H1R in 
the hypothalamus causing an increase in neuronal activation. As all the 
substances tested could be acting through the H1R by altering histamine levels, 
this could explain the similar patterns of Fos staining seen after the application of 
histamine and the H3R agonist and inverse agonists suggesting similar neuronal 
activation occurs. 
The H3R agonist imetit increased neuronal activation within the same 
areas as histamine and the H3R inverse agonist even though it would inhibit 
histamine release and thus be unlikely to be activating H1R in these areas. 
Therefore, imetit could have activated H3R present or that project to these 
regions. Alternatively, the H3R agonist might have acted on H3 heteroreceptors 
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and affected the release of other transmitters which in turn is causing an increase 
in c-Fos staining due to neuronal activation in this area. This applies to the H3R 
inverse agonists as well who could have equally been activating H1Rs via H3 
autoreceptor directed histamine release, or directly activating H3 heteroreceptors 
present on other transmitter terminals.  
 
 
3.6.2 Histamine and H3R-drug induced neuronal activation within the medial, 
central and anterior amygdala 
Another area showing a significant increase in neuronal activation after 
histamine or the H3R drug application was the amygdala. The medial, central and 
anterior amygdala all showed increased neuronal activation. Krettek et al. (1978), 
illustrated how individual amygdalar cell groups in rat project to the 
hypothalamus. This work revealed that the medial, basomedial, and posterior 
amygdalar nuclei project to the VMN, that these same nuclei project to the 
premammillary nuclei, and that the central and basolateral nuclei also project 
sparsely to the rostral lateral hypothalamic zone (Petrovich et al., 2001). Central 
amygdala lesions robustly potentiate feeding. Thus, activation in this area might 
be involved in the sharp reduction in feeding seen. In addition, the amygdala has 
anatomical connections with neural circuits in the hypothalamus that are known to 
control feeding behaviour (Swanson LW., 2000, Petrovich et al., 2001).  
The H1R is expressed abundantly in the amygdala (Haas et al., 2003) and, 
thus, could have been activated after the application of histamine. The H3R 
inverse agonists would have also increased endogenous histamine, which could 
have then acted upon the H1R. These connections and the presence of H1R could 
explain why significant c-Fos staining was observed within the amygdala after 
histamine administration and the injections of the H3R inverse agonists, 
thioperamdie and NNC1202.  
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The H3R agonist imetit was also proven to increase neuronal activation 
and although it would result in a reduction in histamine, it could have, like the H3R 
inverse agonist drugs, activated H3Rs that are present or project to the amygdalar 
regions. Alternatively, all three compounds might have acted on H3R 
heteroreceptors. Imetit, thioperaminde or NNC1202 could have acted on H3R 
heteroreceptors, such as those that have been found on glutamatergic terminals. 
There are a large number of glutamate neurones within the amygdala which have 
been shown to project onto the LH (Swanson et al., 1998). Thus, our H3R drugs 
may be affecting the release of glutamate within the amygdala causing an 
increase in c-Fos staining due to neuronal activation in this area.  
 
 
3.6.3 Histamine- and H3R- drug induced neuronal activation within dorsal 
raphe nucleus 
The dorsal raphe nucleus (DR) also had an increase in c-Fos-positive cells 
after both histamine and H3R drugs were given. H1R rather than H3R have been 
found within the DR (Barbara et al., 2002) and, thus, could again be activated by 
the increase in endogenous histamine either after the administration of histamine 
or the H3R inverse agonists.    
There is a large serotonergic neurone population within the DR (Barbara et al., 
2002). Serotonin is involved in the control of feeding behaviour (Blundell JE., 
1977, Simansky KJ., 1996, Kaye et al., 1998, Schuhler et al., 2005) and is 
especially linked to hunger and satiety (Blundell et al., 1987). Serotonergic 
transmission from the DR (Fletcher et al., 1993; Ohliger-Frerking et al., 2002) to 
the VMN has been proven to regulate feeding (Fernández-Galaz et al., 2010). 
H3R, when acting in their heteroreceptor form, can control the release of serotonin 
by acting presynaptically (Schlicker et al., 1988, Threlfell et al., 2004). For 
example, thioperamide has been shown to increase serotonin release (Threfell et 
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al., 2004). Also a number of atypical H3R antipsychotic drugs affect food intake 
and appetite by influencing serotonin release via the H3R. Thus, the H3R drugs 
could have been not only affecting histamine release and synthesis but also other 
neurotransmitter release such as serotonin caused an increase in neuronal 
activation and hence shown a significant increase in Fos production in this area. 
 
 
 To conclude we have demonstrated that only specific areas within the rat 
brain are activated upon receiving the compounds tested. We have shown some 
areas within the rodent brain histamine, imetit, thioperamide and NNC1202 act 
upon, and have determined that each drug group produces very similar patterns 
in neuronal activation. In particular, we have illustrated that all the known key 
feeding or satiety centres showed a significant increase in c-Fos-immunopositive 
neurones, suggesting activation of these areas by histamine and the H3R drugs is 
causing the changes on food consumption that these drugs exhibit. 
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Chapter 4: 
Modulation of neuronal activity 
within the VMN by 
histaminergic receptor ligands 
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4.1 Introduction 
4.1.1 The VMN and appetite 
For a number of decades, discrete nuclei in the basal hypothalamus have 
been accepted as crucial in the regulation of daily energy homeostasis, especially 
those sites connected with neural mechanisms affecting appetite and energy 
homeostasis (Kalra et al., l999). These hypothalamic sites include the VMN, 
DMN, PVN, and LH. The belief these regions contained neurones affecting 
ingestive behaviour was based on the results of numerous lesions studies or 
surgical transections of neural pathways in these hypothalamic regions (Anand et 
al., 1951; Bray GA 1984). With the exception of lesions in the LH, these 
experimental manipulations within the brain disrupted the daily food intake pattern 
to produce permanently enhanced hyperphagia, suggesting appetite-regulatory 
mechanisms may be confined to a small number of morphologically well-defined 
regions within the hypothalamus (Kalra et al., 1999). The VMN is one of the most 
important sites known to regulate appetite and food intake and is commonly 
referred to as the satiety centre. The satiety centre hypothesis was first proposed 
in 1950 (Kennedy GC., 1950.). Here Kennedy (1950) suggested that the VMN 
was the brain’s satiety centre, as when active, feeding behaviour is inhibited and 
when disrupted or ablated feeding greatly increases, indicating its main role is to 
tell the brain when the body is full. 
There is evidence that suggests the VMN is receptive to several appetite-
regulating signal molecules, including orexigenic and anorexigenic signals. For 
example, microinjection into the VMN of NPY (Stanley et al., 1985), galanin 
(Kyrkouli SE., 1990; Kyrkouli et al., 1986; Schick et al., 1993), GABA (Grandison 
et al., 1977; Kelly et al., 1979), and β-endorphin (Grandison et al., 1977) all 
stimulate hyperphagia, whereas injections of leptin reduces feeding (Munzberg 
H., 2010; Velkoska et al., 2003). This suggests that receptors for each of these 
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signals exist in the VMN and each of these compounds have valuable roles in 
appetite and feeding control. Further, the VMN is neurally linked with several 
hypothalamic sites implicated in the control of ingestive behaviour. 
Brobeck (Brobeck JR 1956) and Kennedy (Kennedy GC 1950) observed 
that even small lesions around the ventrolateral borders of the ventromedial 
hypothalamus and extending to the base of the brain can have affects on feeding 
behaviours. Anand and Brobeck (Anand et al., 1951) later reported that obesity 
could be produced by either ventromedial hypothalamus lesions or by small 
lesions just lateral to the ventromedial hypothalamus. Lesions posterior to the 
ventromedial hypothalamus and dorsolateral to the mammillary body also cause 
obesity (Graff et al., 1962). Although researchers have observed weight gains in 
rodents with lesions just ventrolateral or just posterior to the ventromedial 
hypothalamus, lesions directed at the VMN cause the greatest obesity (King BM., 
2006). Ventromedial hypothalamus lesion-induced hyperphagia and obesity have 
been observed in a variety of species besides rats, including ground squirrels, 
mice, dogs, cats, pigs, monkeys and even birds (Mrosovsky N. 1974; Romaniuk 
A. 1962; Rozkowska et al., 1971; Brooks et al.,  1946), illustrating the species 
wide importance of this brain area in the regulation of feeding. Hypothalamic 
obesity has been documented in humans as well when damage has occurred in 
the hypothalamic brain area due to injury or other outside causes (Bray et al., 
1975). Although, I believe it important to note here that it is difficult to interpret the 
results of such physical lesions as the damage can be indiscriminate, involving, 
cell bodies or fibre pathways, and not be specific so that they include other 
surrounding brain regions.  
A number of studies have demonstrated that more selective knock out models 
or disruption in peptide signalling within the VMN can also cause hyperphagia 
resulting in weight gain and obesity. BDNF is highly expressed within the VMN, 
and its expression is dramatically reduced by food deprivation (Xu et al. 2003). 
 124 
Mice with reduced BDNF receptor expression or decreased BDNF signalling 
significantly increase food intake and thus have elevated body weight (Rios et al. 
2001; Xu et al. 2003). The VMN has also been identified as a key target for leptin, 
which acts on the hypothalamus to inhibit feeding and stimulate energy 
expenditure (Dhillon et al. 2006). It is also rich in glucose-responsive neurones 
(GRN) which respond to a rise in blood glucose that may help to cease feeding 
(Levin et al., 1999; Borg et al., 1995). Zhao et al. demonstrated the targeted 
deletion of the VMN transcription factor steroidogenic factor 1 (SF-1) results in 
agenesis of the VMN and obesity (Majdic et al., 2002; Zhao et al., 2004). 
Additionally, SF-1-driven deletion of the signalling form of the leptin receptor, lepr-
B, can also results in an obese phenotype (Dhillon et al., 2006). These studies all 
illustrate the importance of the VMN in controlling food intake and show that not 
only disruption in the neuronal structure within this area disrupts feeding but also 
alterations in the signalling of a number of peptides or hormones affecting energy 
homeostasis regulation. 
 
 
4.1.2 The VMN and histamine signalling 
The rat VMN has long been divided on cytoarchitectonic grounds into 
ventrolateral, central and dorsomedial parts (Canteras et al. 1994). McClellan et 
al. (2006) suggest the VMN contain a bilateral cell group that have an 
elliptical shape. In coronal sections, the anterior region consists of a circular 
aggregate of densely packed perikarya, whereas the middle and posterior VMN 
are formed by two regional cell masses, dorsomedial and ventrolateral, separated 
by a diagonal cell-poor zone (Canteras et al. 1994). The VMN has been thought 
of as a collection of heterogenous cell types, some of which have been identified 
but most of which have not (McClellan et al. 2006). Cell identity is an important 
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characteristic of brain organization and the VMN cell population has been 
somewhat unidentified thus far. Cell sizes have been seen to differ greatly, 
ranging from between 5 – 20 µm. Sakuma et al. (1983) observed differences 
in the spike duration and amplitude between groups of neurones with different 
sizes within the VMN. The larger surface area of the larger neurones allows a 
greater peak current flow, and the action potentials in these cells are finished in 
a much shorter period. The amplitude of the extracellular spikes has also been 
shown to vary directly with the transmembrane current flow (Sakuma et al. 
1983). Thus as a rule, large neurones will generate larger spikes of shorter 
duration, and their extracellular fields will be detected over great distances 
(Humphrey, 1978). Two main neuronal types, large and small, exist in the VMN. 
(Murphy et al. 1969; Ono et al. 1982). Ono et al. (1982) found small neurones 
are restricted to the medial border of the nucleus. On the other hand, Murphy & 
Renaud (1969) described a cluster of small neurones at the lateral edge of the 
VMN. Ono et al. (1982) illustrated the presence of large neurones in the core of 
the VMN and scattered distribution of small neurones all over the nuclear region. 
Larger neurones have thicker axons, which conduct action potentials faster than 
thinner ones (Paintal, 1966). Sakuma et al. (1983) found a the lack of any 
systematic difference in the antidromic spike latency between the two groups of 
VMN neurones with different sizes suggesting the conduction distance may not 
be consistent for all VMN neurones. Murphy & Renaud (1969) suggest small 
VMN neurons are interneurones which transmit inhibitory amygdala effects to 
the VMN, and they propose the large neurones are the major effector cells of 
the VMN.  
As shown in the previous chapters, there is abundant evidence to support 
a role of brain histamine in food intake and energy metabolism. An early 
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iontophoretic:extracellular recording study in anaesthetised rats found that 
histamine could either increase or depress firing in the VMN, ARC, DMN and LH 
(Renaud LP., 1976). There is also evidence to suggest histamine acts within the 
VMN to cause shifts in feeding. In fact, the VMN is reported to be the preferential 
site of histamine-mediated suppression of food intake in the mammalian brain 
(Haas et al., 2008). The regional distribution of histaminergic fibres and H1R is 
uneven, but is most dense in the hypothalamic nuclei related to food intake, such 
as the VMN and PVN (Palacios et al., 1981). Ookuma et al. (1993) suggest that 
as the H1R has a suppressive role on feeding it could be explained by the fact 
these receptors are distributed more densely in the nuclei involved in the 
suppressive function of food intake. Thus, histamine, through H1R, conveys 
signals for suppression of food intake to the satiety centre in the VMN (Ookuma 
et al., 1993; Sakata et al., 2003). Evidence for the VMN H1R suppressive effects 
on feeding come from studies demonstrating that microinfusion of H1R 
antagonists directly into the VMN but not PVN or LH elicits feeding responses and 
increases both meal size and duration (Fukagawa et al., 1989; Sakata et al., 
2003). Likewise, electrophoretic application of H1R antagonists suppresses the 
firing of glucose-responsive units in the VMN but not the PVN or LH (Fukagawa et 
al., 1989). Also, feeding rhythms are disrupted in H1R-deficient mice (Masaki et 
al., 2001), and H1R antagonists given selectively in the VMN but not other regions 
induces feeding and suppress the firing of glucose-sensitive neurons (Fukagawa 
et al., 1989; Haas et al., 2008).  
There is little or no research suggesting the H3R is present within the VMN 
but what is known is that the H3R can regulate histamine release within the 
ventromedial hypothalamus through its autoinhibitory pathways. H3R within or 
around the ventromedial hypothalamus can alter the release of endogenous 
histamine locally, thus could be affecting histamine’s ability to bind to H1R within 
the area and cause changes in appetitive behaviour. 
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4.2 Objectives 
4.2.1 How does histamine affect the firing rate of cells within the VMN? 
 We have determined that histamine can affect the feeding behaviour of rats 
when administered centrally. We have also demonstrated that injections of 
histamine and H3R based drugs increase c-Fos induction, which is a marker of 
cellular activation, within the feeding centres of the rat brain, including the VMN.  
The VMN has also been shown by a number of research groups (see Chapter 5 
introduction) to not only play a pivotal role in controlling feeding behaviours in the 
rat but also to be highly innervated by histamine neurones, and to contain H1R 
within and around it. Thus, we wanted to determine what was happening at the 
neuronal level within the VMN. Little research has looked at histamine’s affects 
using the extracellular electrophysiology technique, therefore, our aim was to 
determine firstly what changes were seen when histamine was introduced to a rat 
brain slice, and specifically to determine whether histamine had an inhibitory or 
excitatory affect on the firing rate of cells in this area. 
  
 
4.2.2 Is the increase in neuronal firing via a H1R?  
Whilst a number of research groups (Palacios et al., 1981; Ookuma et al., 
1993; Sakata et al., 2003) suggest the presence of the H1R within and around the 
VMN, little has been published about the presence of the H3R. It is widely 
accepted that the H3R can control the endogenous histamine levels within the rat 
brain and, therefore could possibly affect histamine’s release and actions within 
the VMN. Once we had determined how histamine affected the firing rate of cells 
within the VMN, we then wanted to determine the role of H1R and H3R. To do this 
we aim to administer H1R and H3R drugs to determine how they affect the local 
actions of histamine.  
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4.2.3 Are H3R in the VMN autoreceptors or heteroreceptors? 
 As mentioned previously, the evidence of H3R presence within the VMN is 
scarce. We determined using extracellular electrophysiology that histamine was 
acting via both H1R and H3R within the VMN, thus suggesting the presence of the 
H3R in this area. After demonstrating that the H3R is present within the VMN, we 
then wanted to determine whether these are H3 heteroreceptors or autoreceptors. 
To do this we co-administered an H1R antagonist after blocking H3R. If H3R are 
autoreceptors, then H1R antagonism would block the actions of an H3R inverse 
agonist. Whereas if H3R were heteroreceptors, then co-administering an H1R 
antagonist would have no additional effect.    
 
 
 
4.3 Methods 
4.3.1 Animals 
Male Sprague-Dawley rats, aged 6-8 weeks (Charles River, UK) were 
housed within The University of Manchester animal facility in a temperature-
controlled room (22°C ± 1°C), under a 12:12 h light/dark cycle (lights on 08.00-
20.00), with a relative air humidity of 45 ± 10 % and had free access to food and 
water (Beekay, UK). All animals were maintained in the facility for at least one 
week prior to the start of the experiment. These and all other experiments 
conformed with the Home Office (Animals) Procedures Act (1986) and local 
ethical review.  
Animals were culled using a UK Home Office recommended Schedule 1 
procedure (see below).  
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4.3.2 Drugs 
Histamine, thioperamide, pyrilamine and imetit (all Sigma) were the drugs used 
for this study. All drugs were dissolved in sterile water to stock concentration, 
aliquoted and stored at -20oC. Immediately before use, an aliquot was thawed, 
diluted to the appropriate working concentration in artificial cerebrospinal fluid 
(aCSF) and bath applied to the slice via the perifusion line. Concentrations were 
determined following review of the literature. 
 
 
 
4.3.3 Artificial Cerebrospinal Fluid (aCSF) 
2 l of aCSF was prepared fresh each day with the following constituents: NaCl: 
124.0 mM; NaHCO3: 25.5 mM; KCl: 3.3 mM; KH2PO4: 1.2 mM; MgSO4: 1.0; 
CaCl2: 2.5 mM and D-glucose; 5 mM (all Sigma). In order to determine whether 
the response of neurones to peptides was direct, we used a low CaCl2 and high 
MgSO4 solution to block pre-synaptic activation from other neurones. Only the 
amount of CaCl2 and MgSO4 was changed, using 0.3 mM and 9.0 nM, 
respectively. The aCSF was adjusted to pH 7.4 and constantly perifused with 
95% O2/5 % CO2.  
 
4.3.4 Slice preparation  
Rats were killed by cervical dislocation and decapitation under isofluorane 
anaesthesia. The brain was rapidly removed and dissected to form a tissue block 
containing the hypothalamus. Coronal brain slices 400 µm thick were cut in ice-
cold aCSF using a Vibroslicer (Campden Instruments, Loughborough, UK). 
Usually, three slices that included the VMN were obtained from the 
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hypothalamus, and the slices not used immediately were stored in oxygenated 
aCSF through the day.  
 
 
 
4.3.5  Electrophysiological Rig 
Brain slices were transferred to a PDMI-2 submerged slice microincubator 
(Figure 3.1) (Medical Systems Corp., NY, and USA). The slice sits in a culture 
dish surrounded by a 350 µm thick spacer and is stabilised using a nylon ladder 
attached to a collar, which sits on the spacer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 4.1.; A schematic 
representation of the 
electrophysiological experimental 
arrangement.  
The diagram illustrates the flow of 
10mM glucose aCSF, via a 
peristaltic pump, through the 
bubble trap, warmed at the heat 
exchange (via a TC-202 bipolar 
temperature controller) and 
superfused over the oxygenated 
brain slices contained in the 
PDMI-2 micro-incubator 
chamber; waste solution is 
removed via a suction line.  
Modified from Forsythe & Coates 
(1988). 
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Diagram 4.2.; A schematic 
representation of the 
electrophysiology recording 
chamber. 
A top down view of the brain slice 
recording chamber showing the 
input locations of the perfusion 
line, background electrode, 
suction line, and the orientation of 
the nylon ladder which stabilises 
the brain slice and allows 
unrestricted microelectrode 
manipulation.  
Modified from Forsythe & Coates 
(1988). 
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Slices were maintained for 8-12 h by perfusion (approximately 1.5ml/min) with 
oxygenated aCSF. The tissue bath and perfusion solutions were warmed to 
approximately 35°C using a TC-202 temperature controller (Medical Systems 
Corp.). Slices were allowed to equilibrate for at least 1 h before 
electrophysiological recordings began. 
 
4.3.6  Electrophysiological Recording 
Single unit activity of hypothalamic neurones was recorded extracellularly with 
borosilicate glass electrodes (Harvard Instruments, Herts, UK) filled with 2 M 
NaCl (resistance approximately 5 MΩ). Action potential spikes were amplified (× 
20,000) filtered (bandwidth 300 Hz to 3 kHz) and visualised using an 
oscilloscope. Amplification, filtering and spike discrimination were performed 
using a NeuroLog modular system (Digitimer Ltd, Herts, UK). Data were collected 
and plotted as integrated histograms on a PC running Spike 2 software 
(Cambridge Electronic Design, Cambridge, UK). The size of the spikes recorded 
was between 10-100 mV. Only spikes at least two times the size of the 
Diagram 4.3.; A diagram of the 
insert assembly showing the collar 
(A), the nylon ladder (B) and 
perspex spacer (C) which sit in 
the 35 mm tissue culture dish. The 
underside of the collar (D) 
illustrates the location of the inlet 
port. 
 
inlet port
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background noise were recorded and the cell firing rate was recorded for 10 
minutes to obtain a stable baseline firing rate, prior to a change in aCSF or drug 
treatment.  
 
4.3.7 Treatment 
Once a stable baseline firing rate was established, the drug was applied via the 
perifusion line. To identify histamine-responsive neurones, 5 µM histamine was 
applied for 4 minutes.  Normal aCSF was then applied for 20 minutes to allow the 
histamine to be washed off, before either 20 µM thioperamide or 20 µM 
pyrilamine was applied for 4 minutes. Again normal aCSF was then applied for 20 
minutes to wash off the drug treatment. For experiments using low CaCl2/ high 
MgSO4, this aCSF was applied for 10 minutes before the drugs diluted in low 
CaCl2/ high MgSO4 aCSF were applied at the concentrations and times shown 
above. A return to stable baseline firing was re-established for 10 minutes in low 
CaCl2/ high MgSO4 aCSF before application of the drug, and then a recovery 
period of 20 minutes was allowed for the firing rate to return to basal levels before 
the next drug application. 
 
4.3.8 Identification of Neurones and Analysis 
Recordings were only taken from the neurones in the dorsomedial region 
of the VMN. A VMN neurone was considered to have responded if the firing rate 
increased or decreased by 20 % relative to the initial 5 min baseline recording, 
following and during a change in aCSF or drug application. Responses are given 
as a mean firing rate ± S.E.M. and statistical significance was accepted when P < 
0.05 using an unpaired t-test. 
4.4 Results 
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4.4.1 Histamine increases neuronal firing rate in the VMN 
In this study a total of 197 spontaneously firing VMN neurones were tested 
for their responsiveness to bath application of 5 µm histamine. The cells showed 
an average basal firing rate of 1.91 ± 1.73 Hz and a range of 3.55 – 0.97 Hz.  122 
out of 197 cells (62 %) showed an increase in firing when histamine was applied, 
whilst four decreased firing (2 %) and 71 had no response (36 %). Those that 
increased in firing had an average rate of 3.47 ± 2.01 Hz following application of 5 
µm histamine. Those that decreased firing whilst histamine was applied showed 
an average neuronal firing of 0.62 ± 0.46 Hz. Finally, the 71 cells recorded that 
were classed as unresponsive to histamine showed an average neuronal firing 
rate 1.10 ± 1.20 Hz whilst histamine was present. All changes in firing of 
individual neurones were shown to return to basal levels within 20 minutes post 
the application of histamine. 
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Figure 4.1.; This graph illustrates the differences in the response that cells have to 
histamine when it is applied to a brain slice in vitro. As can be seen the majority of cells 
showed an increase in neuronal firing when histamine was applied. Around a third of the 
cells we recorded from were not responsive suggesting around two-thirds are able to 
respond to histamine, and almost 97 % of these do so with an excitatory response. Only 4 
out of 197 cells showed an inhibitory response to histamine. 
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The increase in neuronal firing seen in 122 of the cells we recorded was 
very rapid following the introduction of histamine, bearing in mind a slight delay is 
incurred as the drug is introduced into the bath via the perifusion line (estimated 
at around 60 seconds). Figure 4.2 shows a typical electrophysiology trace of a 
VMN neurone responding to histamine application. The increase in firing rate is 
almost instant and there is a period of constant rapid firing spikes before a graded 
decrease in response. The neurone takes around 15 minutes to return to basal 
firing rate. The return to its basal firing rate indicates that the neurone has not 
been irreversibly altered by the application of histamine.  
 
Figure 4.2.; An electrophysiology trace showing a typical rat VMN neuronal response to 
histamine application. The trace indicates that almost immediately after histamine is 
administered the spikes fired per second increase from 3 spikes per second to 7 spikes 
per second.  There is a gradual decrease in firing rate after histamine is removed and a 
return to basal rate after ~ 15 minutes. The purple band indicates when histamine was 
applied. 
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Our results suggest that of the two thirds of VMN neurones that respond to 
histamine application, they do so with an increase in firing (97 %), illustrating that 
the majority of VMN neurones are excited by the transmitter histamine. The other 
third of VMN neurones recorded show no change in firing suggesting they are 
histamine unresponsive. Very few cells were found to decrease their neuronal 
firing rate after histamine was applied (only 4 out of 197 cells) suggesting a very 
small percentage of histamine neurones within the VMN are inhibited by the 
transmitter.  
 
 
4.4.2 Histamine causes an increase in neuronal firing via the H1R 
In this study, a total of 31 VMN neurones that were responsive to the 
application of 5 µm histamine, were then tested by the co-application of 5 µm 
histamine and 50 µm pyrilamine, an H1R antagonist. These cells showed, on 
average, a basal firing rate of 1.87 ± 0.93 Hz and a range of 2.76 – 0.89 Hz.  Only 
2 out of 31 cells (7 %) showed an increase in firing when the histamine and 
pyrilamine were applied together, whilst only 1 cell (2 %) decreased to below 
basal neuronal firing. In the majority of cells, 50 µm pyrilamine blocked the effects 
of histamine (28 out of 31 cells; 90 %). The two cells that increased firing rate in 
the presence of histamine and pyrilamine, showed an average firing rate of 3.45 ± 
1.35 Hz, which is in the range of histamine alone. The one cell that decreased in 
neuronal firing whilst 5 µm of histamine and 50 µm pyrilamine were applied 
showed a neuronal firing rate of 0.51 Hz. Finally the 28 cells recorded from that 
were unresponsive to the histamine when pyrilamine was present, showed an 
average firing rate 1.28 ± 1.15. All changes in neuronal firing returned to basal 
levels 20 minutes after the application of the drug solution. 
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Figure 4.3.; This graph illustrates the differences in the response that cells have when a 
solution of histamine and pyrilamine was applied to a brain slice in vitro. As can be seen, 
the majority of cells showed no response, suggesting the H1R antagonist pyrilamine is 
blocking histamine actions. 
 
 
Figure 4.4 which illustrates a typical extracellular electrophysiology trace 
response to the application of 5 µm histamine and then the application of a 
solution of 5 µm histamine and 50 µm pyrilamine. As can be seen, when the 
histamine and pyrilamine were added together there was no change in neuronal 
firing (seen in over 90 % of the cells). To ensure pyrilamine was not causing long-
lasting effects on the slice preparation, when possible, we added 5 µm histamine 
again by itself. In these cases, the neurones again responded to histamine alone.  
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Figure 4.4.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of the 50 µm pyrilamine and 5 µm histamine solution. This trace illustrates 
that after firstly recording a typical histamine neuronal response, when pyrilamine is 
added along with histamine the increase in neuronal firing is blocked. The purple band 
indicates when histamine was applied alone and the blue band indicates when the 
pyrilamine and histamine were co-administered. 
 
 
4.4.3 Histamine signalling in the VMN is modified by H3R 
In this study, a total of 49 histamine-responsive VMN neurones were 
tested for how they reacted to the application of a solution containing 20 µm 
thioperamide. These cells showed on average basal firing rate of 1.29 ± 1.37 Hz 
and a range of 2.78 – 0.74 Hz.  43 out of 49 cells (88 %) showed an increase in 
firing when thioperamide was applied, whilst 1 decreased (2 %) firing and 5 had 
no response (10 %). Those that increased activity in response to thioperamide, 
showed an average firing rate of 3.15 ± 2.01 Hz. The one cell that decreased in 
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neuronal firing whilst thioperamide was applied showed a neuronal firing 
response of 0.29 Hz. Finally, the five cells recorded from that showed no changes 
in neuronal firing during the application of thioperamide showed an average 
neuronal firing rate 1.57 ± 1.18. All changes in neuronal activity were shown to 
return to basal levels within 20 minutes post the application of the drug solution. 
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Figure 4.5.; This graph illustrates the differences in the response that cells have when the 
H3R inverse agonist, thioperamide, was applied to a brain slice in vitro. As can be seen, 
the majority of cells showed a similar response as to histamine application itself, with 88 
% of cells showing a increase in neuronal firing. This suggests the H3R is present within 
the VMN and that their blockade can produce an excitatory increase in neuronal firing. As 
with histamine, very few cells showed an inhibition following the application of 
thioperamide (2 %) and, in the case of thioperamide, a relatively small number of cells 
also had no response in neuronal firing rates (10 %).  
 
 
Figure 4.6 illustrates a typical trace response recorded after histamine and 
then thioperamide were separately applied to the brain slice. The majority of cells 
recorded from within the VMN illustrated that thioperamide not only caused an 
increase in neuronal firing, but that the response almost mimicked that to 
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histamine itself. The cells exposed to thioperamide showed an almost immediate 
increase in neuronal firing with a gradual decrease back to basal firing rates.  
 
 
 
 
Figure 4.6.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of 20 µm thioperamide. This trace illustrates that the typical histamine 
response is mimicked by 20 µm thioperamide. In a similar pattern to histamine, 
thioperamide causes a almost immediate increase in neuronal firing with a gradual return 
to basal levels over a 15 minute period. The purple band indicates when histamine was 
applied and the pink band indicates when the thioperamide was added. 
 
 
Our results suggest that the H3R is present within or near the vicinity of 
the VMN of the rat hypothalamus, since when the H3R inverse agonist, 
thiopereamide, was applied there was an increase in firing in 88 % of cells we 
recorded from. Thioperamide may be causing an increase in endogenous 
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histamine release by stopping the negative regulation by H3R autoreceptors. This 
might explain why similar responses were seen after histamine and thioperamide 
applications.  
 
 
We have also carried out some preliminary studies to determine if 
the increase in firing rate that the VMN neurones were showing in response to 
histamine application was a presynaptic or postsynaptic event we carried out 
electrophysiology recordings that used low Ca2+
 
/ high MgSO4 aCSF (figure 4.7). 
Once a neurone had shown an increase in firing in response to histamine and 
returned to basal firing, we then place the brain slice under low Ca2+
 
/ high MgSO4 
aCSF and applied histamine again. In the majority of neurones that received 
histamine diluted in low Ca2+
 
/ high MgSO4 aCSF there was no change in 
response (66 % of neurones showed no response to histamine when under a low 
Ca2+ / high MgSO4 aCSF solution, n=4). During and after the application of 
histamine it was noted that the basal firing rate of neurone remained constant and 
thus suggests that application under low Ca2+
 
/ high MgSO4 aCSF blocks the 
neurones response to histamine (figure 4.7).  
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Figure 4.7.; An electrophysiology trace showing a typical rat VMN neuronal response to 
histamine application under low Ca2+/high MgSO4 aCSF. The trace indicates that almost 
once histamine is added under low Ca2+/high MgSO4 aCSF there is no increase in 
neuronal firing as seen when histamine is applied under the common aCSF solution. 
Purple band indicates where histamine was applied. Orange band indicates low Ca2+/high 
MgSO4 aCSF application.  
 
 
 
4.4.4 Histamine activates H3R autoreceptors within the VMN 
In this study a total of 15 histamine-responsive VMN neurones were tested 
for their responsiveness to the application of a solution containing 20 µm of 
thioperamide, an H3R inverse agonist, with or without 50 µm pyrilamine, an H1R 
antagonist. These cells showed on average basal firing rate of 1.18 ± 1.29 Hz and 
a range of 0.89 – 2.63 Hz. All 15 cells recorded, also responded to 20 µm 
thioperamide with an increase in firing, however this response was lost when 50 
µm pyrilamine was co-administered. The cells were shown as histamine 
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responsive by displaying an increase in neuronal firing when the 5 µm solution of 
histamine was applied to the slice. We then ensured the cell being recorded from 
also showed an increase in neuronal firing when thioperamide, the H3R inverse 
agonist, was applied. All 15 cells showed increases in neuronal firing when either 
histamine or thioperamide were applied alone, but when pyrilamine was co-
applied with thioperamide it was found that pyrilamine blocked the increase in 
neuronal firing. This suggests that the H3R in this system is an autoreceptor as 
the H1R antagonist pyrilamine is able to block the actions of the H3R inverse 
agonist thioperamide. All changes in neuronal firing were shown to return to basal 
levels 20 minutes post the application of the drug solutions. 
          Figure 4.8 shows increases in neuronal firing after firstly applying 5 
µm histamine and then, secondly, applying 20 µm thioperamide. Once this had 
been determined we then added a solution containing 20 µm thioperamide and 50 
µm pyrilamine, the H1R antagonist, and found that the excitation was lost.  
 
 
 
 
 
 143 
 
 
Figure 4.8.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of a solution of 20 µm thioperamide plus 50 µm pyrilamine. This trace 
illustrates firstly a typical neuronal response when histamine is added to the slice 
preparation and then a typical response to the introduction of thioperamide. As can be 
seen, though, if pyrilamine is co-administered with thioperamide, the increase in neuronal 
firing was lost and neuronal firing remained at basal levels. This suggests that pyrilamine 
is able to block the actions of thioperamide resulting in the loss of the increase in neuronal 
firing. The purple band indicates when histamine was applied, the pink band indicates 
when the thioperamide was added and green band indicates when thioperamide and 
pyrilamine were co-administered. 
 
 
 
Our results suggest we are recording the effects of thioperamide at an H3 
autoreceptor as opposed to a H3 heteroreceptor, as when the effects of 
thioperamide were blocked on each occasion by the H1R antagonist, pyrilamine. If 
thioperamide was acting on H3 heteroreceptors to block the release of other 
transmitters, pyrilamine would have no effect on its actions. We also carried out 
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some recordings (results not shown) where we applied thioperamide alone after 
the co-treatment of thioperamide and pyrilamine to ensure that applying 
thioperamide alone didn’t release all available endogenous histamine. This further 
concludes the ‘no response’ recording seen with the co-application of 
thioperamide and pyrilamine was a real result and not due to no available 
histamine.  
 
 
4.4.5 The H3R agonist imetit has an inhibitory effect on VMN neuronal firing 
 Here 22 histamine-responsive cells were recorded to determine their 
response to the application of 5 µm imetit. After establishing a cell was histamine 
responsive, we then applied imetit to establish how the cell reacts to the H3R 
agonist. We found that the 22 histamine-responsive cells had an average basal 
firing rate of 1.86 ± 1.33 Hz and a range of 1.19 – 3.09 Hz. We found 19 (86%) of 
the 22 cells tested cells showed a reduction in firing rate when imetit was applied, 
suggesting imetit has mainly an inhibitory effect on neuronal firing within the rat 
VMN. The cells that responded with an inhibition in neuronal firing showed a 
average firing rate of 0.47 ± 0.42 Hz during and immediately post the application 
of the H3R agonist. Imetit had no effect on 3 of the 22 cells (13%) we recorded, 
which showed an average firing rate of 1.67 ± 1.22 Hz during imetit application. 
No cells responded with an excitation following the application of imetit.  
 Figure 4.9 illustrates that after the initial excitatory histamine response is 
recorded and imetit is then applied, the cell then significantly reduces its neuronal 
firing rate almost immediately. After around 10 minutes post application of the 
H3R agonist the neuronal firing rate then returns to basal levels showing this is a 
reversible response. 
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Figure 4.9.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of the 20 µM imetit. This trace illustrates that after firstly recording a typical 
histamine neuronal response, when imetit is added the firing rate of the cell being 
recorded from decreases suggesting imetit has an inhibitory effect on VMN neuronal 
firing. Purple band indicates where histamine was applied and the green band illustrates 
where imetit was applied. 
 
 
 
Our results suggest the majority of cells (86 %) within the rat VMN showed very 
similar response to that seen in figure 5.9, with most exhibiting an inhibitory 
response to imetit. An important point to illustrate is that imetit did not always 
completely block firing within the VMN when applied, but the majority of cells 
recorded from significantly reduced their firing rate. Only a small minority of cells 
(14 %) were unresponsive to the application of imetit and no cells showed an 
excitatory neuronal firing response, suggesting imetit has an inhibitory response 
on cells within the rat VMN.  
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Although all our drug applications resulted in similar responses from the VMN 
neurones it must be noted that the overall firing pattern we observed from the 
neurones we recorded from within the VMN was quite irregular with bursts of 
spikes occurring every minute or so. 
 
   
4.5 Discussion 
4.5.1 Histamine can cause an increase in neuronal firing via the H1R within 
the VMN 
Our results suggest that the increase in neuronal firing seen in a histamine 
responsive cell after the application of histamine can be blocked when the H1R 
antagonist pyrilamine is co-applied. This suggests that the increase in neuronal 
firing seen when histamine is applied to the slice is caused by activating a H1R 
within the VMN or at least within the confines of the slice. We have shown that 
histamine causes neuronal excitement in approximately two thirds of rat VMN 
neurones. The remaining cells were non responsive. It is likely that the two 
neurones that responded to application of histamine with a decrease in firing may 
have been doing so following an indirect action through other neurones within the 
slice, though this was not proven in the current studies. Relatively few 
electrophysiology studies have been carried out on the effects of histamine, but 
those that have been published suggest histamine can cause both the inhibition 
and excitation of neuronal firing rates depending on the area being investigated 
(Chen et al., 2003; Haas et al., 1977; Haas et al., 1975; Haas et al., 1983; Reiner 
et al., 1987).  
In some studies, histamine has been applied microelectrophoretically to 
the immediate environment of single cells (Haas HL., 1974; Phillis et al., 1968). In 
most brain regions, including the cerebral cortex, brain stem and the thalamus, a 
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depressant effect has been demonstrated. In contrast, neurones within the 
hypothalamus, where the highest levels of histamine are found, an excitement in 
neuronal activity is often found (Haas et al., 1977). In rat and cat brains, 
histamine caused neuronal excitement in almost 70 % of hypothalamic neurones. 
Chen et al., (2003) also found histamine, when given at varying concentrations 
(1-100 µm), caused a dose-dependent increase in the firing of most hypothalamic 
neurones. 
As mentioned previously, histaminergic neurones are found only within the 
TM of the posterior hypothalamus, and from here the histaminergic fibres project 
to most regions of the brain (Panula et al., 1984; Watanabe et al., 1984). The 
actions of histamine occur through the functioning of four types of receptors 
(Schwartz et al., 1986). The H1R mediates the excitation of cortical, thalamic and 
brainstem neurons; and are mainly responsible for the arousal actions of the 
histaminergic system (Diewald et al., 1997). Haas et al., (1975) showed the H1R 
had an inhibitory action in the rat hippocampus and suggest this is probably down 
to an elevation of the intracellular Ca2+ levels. H2 receptors have also been shown 
to be inhibitory in action (Haas et al., 1975). However, the H1R has also been 
proven to excite neurones, such as in the hippocampus (Haas et al., 1983). 
Histamine potentiates excitation in neurons by blocking the long-lasting after 
hyperpolarization that follows action potentials and the accommodation of firing 
(Diewald et al., 1997). The H3R negatively controls the synthesis and release of 
transmitter (Reiner et al., 1987). The H4R is primarily expressed in hematopoietic 
cells indicating their function in immunomodulation (Tiligada et al., 2009) and are 
not found within the brain. 
In the results section of this chapter, we described how when histamine 
was applied to a rat brain slice, of the 66 % of cells that were histamine 
responsive, 97 % of these showed a almost immediate increase in neuronal firing 
rate. We have concentrated on the VMN as this is a leading feeding centre within 
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the rat brain, is known to contain histamine receptors and a number of research 
groups have suggested that when histamine is applied to a brain area within the 
hypothalamus an excitement in neuronal firing is recorded. As we found only four 
of the responding cells to show an inhibitory response to the application of 
histamine we too can suggest that histamine causes an excitation within the rat 
VMN. This response could be resulting in the animal’s behavioural response to 
food intake after histamine is administered, suggesting histamine excites 
receptors within the VMN which in turn affect the appetite of the animal causing 
reduction in food intake.  
 
 
4.5.2 Histamine signals via the H1R causing a excitatory neuronal response 
within the VMN  
 After determining that histamine causes an excitatory response in the 
majority of rat VMN neurones when applied to a slice preparation, we wanted to 
determine if this was, as others had suggested, a H1R-dependent response. As 
shown in the results section we illustrated that when pyrilamine, an H1R 
antagonist was co-applied with histamine the increase in neuronal firing was 
blocked. This suggests that the excitatory response that histamine has on cells 
within the VMN is via a H1R.  
The H1R is involved in numerous actions and is widely distributed both 
peripherally and centrally. Centrally, the H1R is found post-synaptically in almost 
all areas of the rat brain and has been found to be involved in the regulation of 
appetite and feeding. Pharmacological, behavioural and knock out studies all 
suggest the H1R has inhibitory effects on food intake (Fukagawa et al., 1989; 
Sakata et al., 1994; Ookuma et al., 1993; Doi et al., 1994; Inoue et al., 1996). In 
particular, H1R within the VMN are implicated in the neuronal regulation of 
appetite (Masaki et al., 2003). However, Kow et al. (1989) found that histamine 
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effected PVN neurons with an almost exclusive excitatory action, and this 
excitatory action was blocked by H1R receptor antagonists. Li et al. (1996) 
confirmed using whole-cell patch recording techniques that bath-applied 
histamine depolarizes membrane potential and increases firing rate in many SON 
neurons and that the depolarization can be blocked by H1R antagonists and is 
mimicked by H1R agonists. Electrophysiological studies have demonstrated the 
excitatory effect of histamine on neuronal activity in the SCN, SON and ARC is 
mediated by H1R (Armstrong et al., 1985, Jorgenson et al., 1989, Stehl et al., 
1992). Zhou et al. (2007) used whole cell patch-clamp recording to investigate the 
effect of histamine on VMN neurons. They found that histamine increased the 
excitability of VMN neurons as indicated by membrane depolarization and 
increased firing rate. They suggest this effect is produced by the inhibition of 
potassium leakage currents through the H1R. 
 
 
 
 
 
Figure 4.10.; This schematic diagram illustrates how histamine induces an excitatory 
response on neurones within the rat VMN via the H1R. Histamine alone results in an 
increase in neuronal firing within the VMN but when the H1R agonist pyrilamine is added 
this increase in neuronal firing is lost suggesting histamine is exciting cells within the VMN 
via a H1R. 
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The majority of studies carried out that have focussed on the effects of 
histamine on neuronal activity within the hypothalamus have shown histamine to 
cause a excitation in neuronal activation as implicated by a increase in the firing 
rate of the neurones being recorded. These studies all found that the H1R to be 
implicated in the production of this excitatory response by using selective 
agonists and antagonists. Thus figure 4.10, illustrates the possible pathways that 
histamine could be inducing its excitatory response on a VMN neurone via a H1R.  
 
 
4.5.3 Histamine can act via an H3R to affect neuronal firing within the VMN 
 The H3R has been less widely studied than the H1R in relation to its affects 
on feeding behaviours, in part because it was discovered much later than the 
H1R. Also the H3R is much more complex in its physiology than the H1R as it is a 
presynaptic receptor and can act as either an autoreceptor, negatively regulating 
the synthesis and release of histamine, or as a heteroreceptor, regulating the 
release of other transmitters such as serotonin and dopamine. H3R activation 
inhibits the release of serotonin in the CNS, of dopamine in the CNS and the 
retina, and of noradrenaline in the CNS, in blood vessels and in the heart (Stark 
et al., 1996). H3R is found predominantly within the CNS, which makes it a good 
target for manipulation, avoiding the unwanted effects on peripheral systems.    
 H3R mediate reduction of transmitter release (Philippu et al., 1991; Schlicker 
et al., 1994) and have been found to inhibit the firing of histaminergic neurons 
(Reiner et al., 1987). Little research has been carried out on H3R in the 
hypothalamus including the VMN and so no evidence has been gathered as to 
their effect in this area. We have now shown that H3R blockade can lead to an 
increase in neuronal firing within the VMN of the rat brain. We have demonstrated 
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in the results section of this chapter that the H3R inverse agonist thioperamide 
mimicked the actions of histamine when applied to a brain slice containing the 
VMN. Our results illustrate that not only are H3R present within the VMN but also 
they can mediate an excitatory response within VMN neurones. When histamine 
and thioperamide are applied either centrally or peripherally a decrease in food 
intake is observed and an increase in neuronal activation has been demonstrated 
within the VMN. As the VMN is an integral player in the control of food intake we 
could suggest that the H3R present in this area have roles in the regulation of 
appetite. Figure 4.11 illustrates how histamine can induce an excitatory response 
on a VMN rat neurone via the H3R. 
 
 
 
 
 
Figure 4.11.; This schematic diagram illustrates how histamine also can induce an 
excitatory response on neurones within the rat VMN via the H3R. Histamine results in an 
increase in neuronal firing within the VMN and the H3R inverse agonist thioperamide 
mimics this response also resulting in a excitatory increase in neuronal firing. This is the 
first evidence to date that not only suggests H3R are present within the rat VMN but that 
they also cause excite neurones within this area resulting in a increase in neuronal cell 
firing.  
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4.5.4 Histamine can act via an H3R autoreceptor to affect neuronal firing 
within the VMN 
Our studies proved that H3R are present within the VMN, so our next step 
was to determine whether these H3R were autoreceptors or heteroreceptors. 
Histamine is known to have many different actions depending on the histamine 
receptor involved. The two receptors associated with histamine’s effects on food 
intake are H1R and H3R. H1R is located postsynaptically and H3R is located 
presynaptically, and both are found within and act upon the hypothalamus. 
However, H1R and H3R have opposing effects on food intake, with the H1R 
agonism decreasing and the H3R agonism increasing food intake. By applying low 
Ca2+/ high MgSO4 aCSF, it is possible to determine whether a compound is acting 
postsynaptically or presynaptically. We found that of the small number of 
neurones tested in this way, 66% of histamine-responsive neurones did not 
respond to histamine when it was applied in low Ca2+/ high MgSO4 aCSF. If 
histamine is affecting the target neurone directly on postsynaptic receptors, we 
would expect the neurone to still respond in low Ca2+/ high MgSO4 aCSF. The 
lack of response in these neurones could suggest histamine is acting via 
presynaptic receptors within the VMN. Although tempting at this point to suggest 
the applied histamine may be acting on presynaptic H3R, but the modulation of 
this receptor would be masked in low Ca2+/ high MgSO4 aCSF, it is equally likely 
with this crude experiment that the with high Ca2+/ low MgSO4 aCSF recordings, 
histamine could be acting on other neurones within the slice which then act to on 
the VMN neurones from which we are recording. These presynaptic neurones 
may themselves contain excitatory transmitters that stimulate the downstream, 
recorded neurone. If the presynaptic neurones contain inhibitory transmitters, 
then histamine may inhibit these, leading to disinhibition of the downstream, 
recorded neurone. In this context, it is important to note that the VMN is 
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surrounded by a dense network of GABAergic neurones which could potentially 
project into the nucleus and be affecting the response of VMN output neurones.  
Thus using the co-application of the H3R inverse agonist thioperamide and 
the H1R antagonist pyrilamine we were able to establish that H3 autoreceptors 
within the VMN could be exerting the excitatory response produced by VMN 
neurones after the application of thioperamide. We found that pyrilamine blocked 
the excitatory increase in neuronal firing by thioperamide, suggesting the H3R we 
observed within the VMN are autoreceptors. If the H3R were heteroreceptors, 
pyrilamine would have had no effect on the firing response to thioperamide in a 
majority of neurones.  
 
 
4.5.5 H3R agonism inhibits the excitatory response of histamine 
 We have also demonstrated that the H3R agonist imetit can have an 
inhibitory effect on VMN neuronal firing. Our results suggest 86 % of the VMN 
cells showed very similar response to the application of imetit, with most 
exhibiting an inhibitory response by showing a significant reduction in neuronal 
firing whilst and immediately after the application of the H3R agonist. These 
results show imetit have the opposite effects on neuronal firing within the rat 
VMN. As thioperamide, which is a H3R inverse agonist, and imetit, a H3R agonist 
have opposing effects on the H3R it is not surprising they have opposite effects on 
the neuronal firing of VMN neurones. Thioperamide blocks the autoinhibitory 
actions of the H3R and, thus, allows an increase of endogenous histamine 
release. Imetit activates the H3R and, thus, encourages its autoinhibitory effects, 
halting the release of histamine in the slice. Consequently, thioperamide can 
mimic the actions of histamine whereas imetit produces opposite results. As 
mentioned previously, the H3R negatively controls the synthesis and release of 
histamine and has been shown to inhibit the firing of histaminergic neurons 
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(Reiner et al., 1987), which could be what we are observing in our recordings. 
Also, Vanni-Mercier et al. (2003) have reported that imetit caused a significant 
decrease in cell discharge and neuronal firing rate when applied to the posterior 
hypothalamus, but our slices did to include the TM. 
 
 
It is important to note that one major drawback with extracellular 
electrophysiology, is that the response that we are recording could be a direct 
response of the drugs on that cell within the VMN or an accumulative response to 
a number of inputs which might themselves have histamine receptors. Due to 
this, it can be difficult to verify whether the response we see is a direct or indirect 
neuronal response to histamine and histamine receptor drugs, but the cumulative 
data suggests a direct action. 
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Chapter 5: 
Proxyfan – an H3R neutral 
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5.1 Introduction 
5.1.1 GPCRs and constitutive activity 
G-protein coupled receptors (GPCRs) are a large family of 
transmembrane receptors that sense molecules outside the cell and activate 
intracellular signal transduction pathways resulting in cellular responses (Gbahou 
et al., 2003). Activation of some GPCRs results in fast chemical synaptic 
transmission through neurotransmitter-gated ion channels. Additionally, 
neurotransmitters acting on GPCRs can also have slower, longer-lasting and 
more diverse post-synaptic actions. Transmitter action involves three steps. 
Firstly, the neurotransmitter molecules bind to receptor proteins embedded in the 
post-synaptic membrane (Fong TM., 1996). The receptor proteins then activate 
small protein molecules, called G-proteins (guanosine triphosphate (GTP)-binding 
proteins), that move freely along the intracellular face of the post-synaptic 
membrane. The activated G-proteins activate "effector" proteins, which can be G-
protein-gated ion channels in the membrane or enzymes that synthesize second 
messengers that diffuse away in the cytosol and regulate ion channel function 
and alter cellular metabolism (Fong TM., 1996). 
GPCRs are allosteric proteins that adopt inactive and active conformations 
in equilibrium. The active conformation can be promoted by agonists or can occur 
spontaneously, leading to constitutive activity of the receptor. Alternatively, 
inverse agonists promote an inactive conformation and decrease constitutive 
activity (Gbahou et al., 2003). Gbahou et al (2003) suggest constitutive activity is 
the synthesis of a protein or enzyme at a constant rate regardless of physiological 
demand or the concentration of a substrate. In pharmacology, an agonist is a 
substance that binds to a specific receptor and triggers a response. It does so by 
mimicing the action of an endogenous ligand that binds to the same receptor. 
Agonist ligands stabilize or increase the fraction of the active state of a GPCR, 
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allowing it to interact with and activate a G protein. Milligan and colleagues 
propose that basic thermodynamics define there must be a finite probability that 
this active state also occurs in the absence of the agonist (Milligan et al., 2003). If 
agonists enhance such active states, then ligands (inverse agonists) that stabilize 
or enrich the inactive state should be able to be identified. Therefore, an inverse 
agonist is able to bind to the same receptor-binding site as an agonist for the 
receptor, but it exerts the opposite pharmacological effect.  
Heterologous expression of many GPCRs has resulted in the uncovering 
of ligand-independent signal transduction that increases with increasing levels of 
GPCR expression (Tiberi et al., 1994). Many traditional 'antagonists', that block 
the constitutive activity of expressed GPCRs, have been reclassified as inverse 
agonists after establishing the constitutive activity of the GPCR is not linked to the 
presence of low concentrations of endogenous agonists (Milligan et al., 1995). 
Inverse agonists are effective against only certain types of receptors, such as the 
histamine receptors, which have intrinsic activity without the action of a ligand 
upon them (Daeffler et al., 2000).  
Compounds that are able to bind to GPCRs without altering the balance 
between active and inactive states of the receptor are described as neutral 
antagonists and are much less common (Milligan et al., 2003). An antagonist is a 
ligand of a receptor that blocks the ability of an agonist or inverse agonist to bind 
to the receptor and thus inhibits their function. Milligan et al. suggests that within 
such models, efficacy ranges from 1 (full agonism) to -1 (full inverse agonism) 
and neutral antagonists possess 0 efficacy (Milligan et al., 1995). 
Takahashi et al. (2003) suggest GPCRs play a major role in signal 
transduction and are the targets of a large number of therapeutic drugs. As 
mentioned before, traditional models of GPCRs require an agonist to bind to the 
receptor to activate the signal transduction pathways. A model used to describe 
agonist activation of GPCRs is referred to as the ternary complex model, which 
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accounts for the interactions between receptor, G-protein and agonist (De Lean et 
al., 1980). This model has since been extended to include the observations that 
several GPCRs can activate G-proteins in the absence of agonists due to 
constitutive activity. Therefore the ternary complex model was modified to the 
“extended ternary complex model” or ETC (Samama et al., 1993). In this model, 
Samama et al. (1993) suggest the receptor exists in an equilibrium between an 
inactive state (R) and an active state (R*) in the absence of a drug. Binding of an 
agonist to the receptors stabilizes the R* causing G-protein-coupling and 
activation of cellular responses. Conversely, binding of an inverse agonist 
stabilizes the R at the expense of R*. Takahashi et al. propose the primary 
structure and expression levels of the receptor determine the equilibrium between 
active and inactive receptor states and therefore determine the intrinsic basal 
activity of the GPCRs (Takahashi et al., 2003). For wild-type receptors, R 
predominates, thus minimal receptor activity is present in the absence of an 
agonist. Alternatively, a high level of receptor expression or specific mutation in 
receptors can increase the concentration of R*, therefore resulting in increased 
activities in the absence of agonists and the enhanced susceptibility to inverse 
agonists. Thus the level of constitutive activity depends on both the number of 
spontaneously active conformations and their coupling efficiency to G proteins 
(Arrang et al., 2007). Inverse agonists therefore abrogate constitutive activity by 
promoting inactive conformations of the receptor. 
Protean agonists are a theoretical class of ligands that produce receptor 
activation but at a lower degree than that derived from spontaneous receptor 
constitutive activity (Kenakin T., 2001). Protean agonists are unique in that they 
can produce positive agonism in some GPCR systems, and inverse agonism in 
others, when the receptor conformation induced by an agonist shows an efficacy 
lower than that of the constitutively active receptor conformation (Kenakin T., 
2001). For example, if the ligand produces activity in the receptor greater than 
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spontaneous constitutive activity, it will act like an agonist. Conversely, if the 
system were constitutively active and, thus, had a high number of spontaneously 
active sites, the ligand might reduce the activity by changing this active site to the 
less efficacious active site and therefore act as an inverse agonist (Kenakin T., 
2001). Consequently, a protean agonist could act as either an agonist or an 
inverse agonist at the same GPCR, depending on the level of constitutive activity. 
With an none constitutively active system the ligand would be act as an agonist 
and in a constitutively active system it would be an inverse agonist (Arrang et al., 
2007. The observation of protean agonism in a system gives some evidence that 
the ligand being investigated produces a receptor active state of lower intrinsic 
efficacy than the naturally occurring constitutively active state and therefore is 
suggestive of selective receptor states which are a useful tool for discovery of 
ligand-specific receptor active-states and thus could be a useful tool in our 
investigations to determine the ligand-specific nature of our H3R agonist, imetit, 
and H3R inverse agonist, thioperamide.  
 
 
5.1.2 Constitutive activity and the H3R 
The H3R belongs to the class of G-protein coupled receptors which 
contain seven putative transmembrane domains, with an extracellular N-terminus 
and an intracellular C-terminus (Strakhova et al., 2008). Arrang et al. (2007) have 
reviewed how the H3R has become a GPCR of choice for studies of constitutive 
activity and protean agonism as H3Rs present in the brain have been shown to 
exhibit high constitutive activity. Liedtke et al. (2003) suggest the mechanisms 
underlying constitutive activity might involve the carboxyl terminus of the third 
intracellular loop of the H3R and is conserved among species (Lovenberg et al., 
1999, Hancock et al., 2003). However, the functional H3R isoforms, which all 
contain this sequence, show different degrees of constitutive activity. Constitutive 
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activity of the recombinant H3R is, therefore, dependent on species, isoform, cell 
line and signaling pathway, but all of the collected data are consistent in showing 
the high constitutive activity of both the rat and human H3R. Most of the 
compounds originally classified as H3R antagonists are, in fact, inverse agonists, 
such as thioperamide, and abrogate the signaling changes generated by 
constitutive activity of the recombinant H3R (Arrang et al., 2007, Liedtke et al., 
2003).  
The H3R has been shown to signal without agonist stimulation in several 
recombinant receptor systems (Wieland et al., 2001; Wulff et al., 2002), as well as 
in in vivo systems (Morisset et al., 2000), by means of constitutive activity. 
Pharmacological agents with high inverse efficacy would be a benefit if the clinical 
need is to lower basal receptor activity. Thus, inverse agonists open the 
possibility for a new therapeutic strategy for the H3 receptor (Takahashi et al., 
2003). However, the level of H3R constitutive activity in each specific system, 
such as that controlling feeding, needs to be fully determined as species 
differences and drug effectiveness of the H3R agonists and inverse agonists have 
all been brought into question, suggesting the need for a careful evaluation of the 
drugs used to fully define H3R involvement. 
 
 
5.1.3 Proxyfan and its potential to act as a neutral antagonist at the H3R 
Interest in the drug proxyfan began after the discovery that the H3R shows 
a high degree of constitutive activity. Several of the classical H3R antagonists, 
such as thioperamide and ciproxifan, actually behave as potent inverse agonists, 
as they block the intracellular pathways associated with active H3R in 
heterologous transfected cells (Morisset et al., 2000; Rouleau et al., 2002). 
Alternatively, the high-affinity H3R ligand, proxyfan, acts as a protean agonist 
which can display the full spectrum of pharmacological activities from full agonism 
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to full inverse agonism (Gbahou et al., 2003).  
Research on proxyfan has confirmed the competition between a ligand-
directed active receptor state (LR*) and a constitutively active receptor state (R*) 
for G proteins, predicted by Kenakin’s model (Kenakin T., 2001). This model 
suggests the intrinsic activity of proxyfan is that of an agonist when the agonist 
state promoted by proxyfan (LR*) has an higher efficacy than that of the 
constitutively active state (R*). When both states show the same efficacy, 
proxyfan alone will have no apparent activity on the system and therefore here 
proxyfan will act as a neutral antagonist (Arrang et al., 2007). Alternatively, when 
the state promoted by proxyfan has a lower efficacy than that of constitutive 
activity, proxyfan behaves as an inverse agonist (Arrang et al. 2007).  
Constitutive activity of a native GPCR can be established when its putative 
activation by an endogenous agonist has been excluded, which can only be 
achieved using a neutral antagonist (Arrang et al., 2007). In the presence of 
constitutive activity, neutral antagonists have no effect alone, but will block the 
effects of agonists and inverse agonists. Constitutive activity at H3 autoreceptors 
inhibits histamine release (Morriset et al., 2000). By suppressing H3R constitutive 
activity, inverse agonists such as thioperamide enhance histamine release, 
whereas agonists such as imetit inhibit its release. Here, proxyfan alone would 
have no effect on histamine release, but will blocks the effects of both 
thioperamide and imetit, and therefore act as a neutral antagonist (Clark et al., 
1996). The lack of effect of proxyfan alone illustrates antagonism of endogenous 
histamine does not contribute to the histamine-releasing effect of thioperamide or 
other drugs (Clark et al., 1996, Meier et al., 2004). Fox and colleagues 
demonstrated that H3 autoreceptors that inhibit histamine synthesis in brain also 
show constitutive activity (Fox et al., 2002). Histamine released from histamine 
neurons is metabolized to tele-methylhistamine (t-MeHA). Levels of t-MeHA are, 
thus, a reliable indication of histamine neuron activity (Schwartz et al., 1991). H3R 
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inverse agonists enhance t-MeHA levels by abolishing the constitutive block 
caused by H3 autoreceptors (Clark et al., 1996). Proxyfan acts as a neutral 
antagonist by antagonizing the increase in t-MeHA levels induced by 
thioperamide or ciproxifan and the decrease induced by imetit (Clark et al., 1996; 
Meier et al., 2004). Proxyfan also has been shown to act as a neutral antagonist 
in H3R-mediated intake of water. Here Fox et al. (2002) showed that proxyfan 
attenuates both agonist and inverse agonist effects on drinking behaviour in mice. 
One issue with proxyfan is that it appears to be very species and organ 
dependent in its actions and ability to act as a protean agonist. Where inverse 
agonists, such as ciproxifan, induce arousal in all species (Ligneau et al. 1998), 
the effect of proxyfan on the sleep–wake cycle depends on the species. In the 
mouse, proxyfan increases wakefulness, decreases sleep, and therefore behaves 
as a full inverse agonist (Morisset et al., 2000). Conversely, in the cat, proxyfan 
increases sleep and shows the same effect as the H3R agonist (R)-α-
methylhistamine (Morisset et al. 2000). In the rat, proxyfan acts as an inverse 
agonist on histamine neuron activity (Morisset et al., 2000), but as a full agonist 
on fear memory (Baldi et al., 2005). Here, Baldi et al. (2005) reported that rats 
that received systemic administrations of proxyfan showed a stronger response to 
the footshock-context association. Proxyfan can mimic the memory-enhancing 
effect of H3R agonists administered in the amygdala (Cangioli et al., 2002) or in 
the hippocampus (Giovannini et al., 2003), in contextual fear conditioning. Full 
agonism of proxyfan has also been observed in the cat, where it significantly 
increases deep slow-wave sleep, without affecting wakefulness, whereas in the 
mouse proxyfan behaves as a full inverse agonist (Gbahou et al., 2003), 
mimicking the arousal effect of ciproxifan (Parmentier et al., 2002). Proxyfan has 
also acted as a partial agonist in a murine dipsogenic model (Fox et al., 2002), as 
mentioned above. Gbahou et al. (2003) suggest competition between the active 
and inactive forms of the H3R receptor may be responsible for the variety of 
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pharmacological responses observed in different brain regions and in different 
species. The pharmacology of H3R is very complex, and Passani and colleagues 
suggest that receptor polymorphism with differential splice variant distribution in 
the CNS, potential coupling to different G protein signaling pathways and 
heterogeneity contributes to the numerous effects of histaminergic ligands when 
tested in different brain regions and across animal species allowing a range of 
behavioural responses to be observed (Passani et al., 2004). Therefore, protean 
agonism indicates that a single drug might produce different responses, 
depending on the constitutive activity of the system.  
Morriset et al. (2000) suggest the pharmacological profile of proxyfan 
depends on the system being tested. Thus it depends on the equilibrium between 
the active and inactive conformations of the receptor and/or the stoichiometric 
ratio of the receptor to the various G proteins. Thus, Gbahou et al. 2003, suggest 
that a single drug such as proxyfan may belong to all of the classical classes of 
ligands (full agonists, partial agonists, neutral antagonists, partial inverse 
agonists, and full inverse agonists). Therefore, proxyfan could be used as a tool 
to discover ligand-specific receptor active-states and, thus, could be used in our 
investigations to determine the ligand-specific nature of our H3R agonist, imetit, 
and H3R inverse agonist, thioperamide. 
 
 
5.2 Aims and Objectives 
5.2.1 Does proxyfan alone affect feeding in Sprague Dawley rats? 
 Proxyfan has been shown by a number of research groups to act in 
differently in various models, including as a H3R agonist, inverse agonist, protean 
agonist and neutral antagonist (Clark et al., 1996, Morisset et al., 2000, Gbahou 
et al., 2003, Baldi et al., 2004, Passani et al., 2004, Meier et al., 2004). Fox et al. 
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(2002) published a paper illustrating how proxyfan can block the actions on 
drinking behaviour of ciproxifan, a H3R inverse agonist, and to attenuate R-α-
MeHA effects on water intake. As proxyfan has not been investigated into its 
effects on food intake and appetite behaviour, we wanted to determine whether 
alone it would act as a H3R agonist, inverse agonist, a protean agonist or a 
neutral antagonist. 
Levels of endogenous histamine in the whole brain may vary greatly 
across the time of day, and also in regions of the brain specifically involved in 
appetite regulation. Thus, we measured the effects on normal food intake of 
proxyfan at both lights out in animals that were fed ad libitum and at lights on in 
overnight fasted animals, ensuring a spectrum of endogenous histamine 
concentrations would be tested. 
 
 
5.2.2 Can proxyfan attenuate the actions on food intake of other H3R drugs? 
 Once we had established whether proxyfan had any effect on food intake 
alone, we then wanted to determine whether proxyfan could act as a neutral 
antagonist at the H3R and attenuate the actions on food intake of both the H3R 
agonist, imetit, and the H3R inverse agonist, thioperamide, when co-administered. 
Proxyfan has been seen to act in a number of ways, to attenuate the actions of 
some H3R drugs and not others (Fox et al., 2002), and have effects on some 
behaviours in certain species and not in others (Morisset et al., 2000, Gbahou et 
al., 2003). Therefore, we aimed to determine whether proxyfan could indeed 
attenuate or block the effects that imetit and thioperamide have on food intake in 
male Sprague Dawley rats. 
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5.2.3 Can proxyfan act as a neutral antagonist on feeding-related neurones 
in vitro? 
 Once we determined if proxyfan affects food intake when administered alone 
or when co-administered with H3R drugs, we aimed to determine the effects 
proxyfan has at a neuronal level in an in vitro slice preparation using single-unit 
extracellular electrophysiology. Here we plan to determine the effects proxyfan 
has on neurons within the VMN when applied via a perifusion line. We then aim to 
determine whether, when co-applied, proxyfan can block or attenuate the actions 
of imetit or thioperamide on neuronal firing rates of neurons within the VMN. 
 
 
5.3 Methods 
5.3.1 Animals 
 For the feeding studies, male Sprague-Dawley rats (225 - 275 g, Charles 
River, UK) were used and for the electrophysiology studies male Sprague-Dawley 
rats, aged 6 - 8 weeks (Charles River, UK) were used. All animals were adapted 
to a 12 h/ 12 h light-dark cycle (lights on 08:00 - 20:00), at least one week prior to 
the experiments starting. Rats were housed in a temperature-controlled room (~ 
22 ± 1 oC) with relative air humidity 40 - 60 %. Rats had free access to food 
(Beekay, UK) and water unless otherwise stated. Animals used in the 
electrophysiology studies were culled using a UK Home Office recommended 
Schedule 1 procedure. These and all other experiments conformed with the 
Home Office (Animals Procedures Act of 1986 and local ethical review. 
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5.3.2 Compounds  
 Compounds used in the behavioural studies were administered via injection 
into the intraperitoneal cavity (i.p.) of the rat. Imetit and thioperamide (both 
Sigma) were diluted with isotonic saline to allow injection of 10 mg/kg and 2 
mg/kg of body weight, respectively. Proxyfan (Tocris) was made up to 5, 2, 0.5 
and 0.2 mg/kg body weight for the feeding experiments and to 5 mg/kg body 
weight when co-administered with either imetit or thioperamide. All drugs were 
diluted to their required concentrations immediately prior to use. 
 For the extracellular electrophysiology procedures compounds were used at 
the following concentrations: histamine 5 µM; thioperamide 20 µM; imetit 5 µM; 
proxyfan 20 µM. For all compounds an aliquot was thawed, diluted to the 
appropriate concentrations in fresh aCSF (see previous chapter for details on 
how to make aCSF solution) and bath applied to the brain slice being recorded 
from via a perifusion line immediately before use. 
 All concentrations were determined following a review of the literature (Fox 
et al. 2002). 
 
 
 
5.3.3 Proxyfan and its effects on food intake 
 Rats were caged singly 24 hours before i.p. injections we administered. 
Drug-treated rats were given 5 mg/kg of body weight of proxyfan in a volume of 
1ml/kg of body weight and control rats received a volume of 1 ml/kg of body 
weight of saline, i.p. Satiated rats given the i.p. injection of proxyfan at lights on 
(08:00 h) were allowed free access to food until they were injected with proxyfan. 
Rats receiving an i.p. injection of proxyfan at lights off (20:00 h), had their food 
removed 2 hours before lights out to ensure no pre-feeding was carried out 
before the experiment. Pre-weighed food was returned to the rat 2 minutes after 
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receiving the injections and food consumption was then measured at 1, 2 and 4 
hours post injection. 
 
 
5.3.4 Does proxyfan act as a neutral antagonist in the feeding model? 
 Again, rats were caged individually 24 hours before any injections or 
experiments were carried out. All injections were i.p. and in a volume of 1 ml/kg 
body weight. Rats being tested for their food behaviour response to imetit 
received an injection of 10 mg/kg body weight of imetit at lights off (20:00 h) 15 
minutes after receiving an injection of 5 mg/kg body weight of proxyfan. Rats 
being tested for their feeding response to thioperamide received an injection of 2 
mg/kg body weight of thioperamide 15 minutes after receiving an injection of 5 
mg/kg body weight of proxyfan, again at lights off (20:00). Pre-weighed food was 
returned to the rat 2 minutes after receiving both injections and food consumption 
was then measured at 1, 2 and 4 hours post injection. 
 
 
5.3.5 The effects of proxyfan on neurones within the VMN 
 An account of how our extracellular rig is set up and how our slices are 
prepared and recorded from is detailed in the previous chapter. 
 Once a neurone was identified and a stable baseline firing rate was 
established, 5 µM histamine was applied by perifusion for 4 minutes. If an 
excitatory histamine response was recorded, histamine was washed off during 20 
minute application of normal aCSF. Proxyfan was then applied via the perfusion 
line for 4 minutes and the cells response was recorded. Normal aCSF was then 
applied for 20 minutes to again allow the cell’s firing to return to baseline levels. 
Thioperamide was then co-applied with proxyfan for 4 minutes to determine 
whether proxyfan would block the excitatory effects that thioperamide has been 
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shown to produce (see previous chapter). Again, normal aCSF was the applied 
for 20 minutes to wash off the effects of the drugs and baseline levels of firing 
were returned. Thioperamide was then applied alone for 4 minutes to check the 
effects when applied alone. Finally normal aCSF was again administered for 20 
minutes to allow neuronal firing to return to baseline levels. 
 For the imetit electrophysiology study, after an excitatory response to 
histamine was recorded and neuronal firing was allowed to return back to basal 
levels after 20 minutes of normal aCSF application, imetit was appled for 4 
minutes and the response recorded. Normal aCSF was then applied to allow the 
drug to wash off and neuronal firing to return to normal levels. A solution of imetit 
and proxyfan was then applied over a 4 minute period and the response was 
recorded to determine whether proxyfan could block the actions that imetit alone. 
Finally, normal aCSF was again administered for 20 minutes to allow neuronal 
firing to return to baseline levels. 
 
 
5.3.6 Statistical analysis 
 All data are presented as mean ± SEM. Data from feeding groups were 
analysed using a two-way analysis of variance (ANOVA) with repeated measures. 
Significance was taken at P < 0.05. 
 Recordings were only taken from the neurones in the dorsomedial region of 
the VMN. A VMN neurone was considered to have responded if the firing rate 
increased or decreased by 20 % relative to the firing rate 5 minutes prior to 
application of proxyfan, imetit, thioperamide or a combination of these drugs. 
Responses are given as a mean firing rate ± S.E.M. and show significance at P < 
0.05 using an unpaired t-test. 
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5.4 Results 
5.4.1 Proxyfan alone has no effect on food intake in rats 
 Firstly, we determined whether different doses of the H3R drug proxyfan 
affect the feeding behaviour of Sprague-Dawley rats that had free access to food 
at the beginning of the light phase. We found that an injection of proxyfan at 0.2, 
0.5, 2 and 5 mg/kg body weight had no significant effects on food consumed at 1, 
2 or 4 hours post injection (figure 5.1). Rats that received the saline injection 
cumulatively had eaten 0.12 ± 0.08 g at 4 post injection, which is very similar to 
the rats that received either 0.2, 0.5, 2 or 5 mg/kg body weight of proxyfan (0.65 ± 
0.8 g, 0.75 ± 0.9 g, 0.1 ± 0.1 g and 0.13 ± 0.07, respectively). These results 
suggest both high and low doses of proxyfan have little effect on the food intake 
of satiated rats. 
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Figure 5.1.; Cumulative food consumption measured at 1, 2 and 4 hours after i.p. 
injection with proxyfan (n = 4) or saline (n = 4) during the day time (08:00 h). Food intake 
over this period is very low in these nocturnal animals. Data are expressed as mean ± 
S.E.M. Two-way ANOVA with repeated measures and Bonferronni post hoc test was 
carried out. Significance = n/s. 
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We then determined whether these same doses of proxyfan (0.2, 0.5, 2 and 5 
mg/kg body weight) had any effects on food intake of rats when fed at normal 
night time feeding (20:00 h). We found that an injection of proxyfan at any of the 
concentrations tested had no effect on food intake, with all animals within the 
drug groups eating similar amounts to the control group (figure 5.2). Rats that 
received an injection of saline ate on average 9.4 ± 1.8 g at 4 h post injection, 
whereas rats receiving an injection of 0.2, 0.5, 2 and 5 mg/kg body weight of 
proxyfan ate 9.9 ± 1.3 g, 9.0 ± 0.6 g, 9.6 ± 0.5 g and 8.8 ± 1.1 g of food, 
respectively. 
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Figure 5.2.; Cumulative food consumption measured at 1, 2 and 4 hours after i.p. 
injection with proxyfan (n = 4) or saline (n = 4) given at lights out (20:00 h). Data are 
expressed as mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferronni 
post hoc test was carried out. Significance = n/s. 
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5.4.2 Proxyfan blocks imetit-induced hyperphagia in rats 
As none of our concentrations of proxyfan had shown any affects on rat 
food intake alone, we decided to use the highest concentration of proxyfan tested 
(5 mg/kg body weight), which is similar also to concentrations used by other 
research groups. Our research showed that when an injection of imetit was given 
after an injection of proxyfan, no increase in food intake was noted from control 
levels whereas when an injection of imetit was administered after an initial 
injection of saline a significant increase in food intake was observed 1 hour post 
the injection of imetit. This suggests proxyfan is blocking the effects imetit has on 
rodent feeding. We found rats that received a double saline injection ate on 
average 3.89 ± 0.72 g of food 1 hour post the first injection. Rats that received a 
proxyfan injection and then an injection of saline 15 minutes later ate on average 
3.37 ± 1.11 g of food 1 hour post the first injection, rats that received a injection of 
saline and then an imetit injection ate on average 4.89 ± 0.56 g of food and rats 
that received an injection of proxyfan and then an imetit injection 15 minutes later 
at on average 3.58 ± 0.67 g of food. Only rats that received the injection of saline 
and then later were administered a second injection containing imetit were found 
to eat significantly more (P < 0.05) than the control group and the proxyfan-
vehicle or proxyfan-imetit group. Significance was lost by two hours after the first 
injection. 
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Figure 5.3.; Cumulative food consumption measured at 1 and 2 hours after i.p. injections 
with; saline (S) or proxyfan (P) followed by saline (S) or imetit (I) (n = 6). There are four 
different drug groups tested and rats received two injections 15 minutes apart. These 
groups include; saline-saline, proxyfan-saline, saline-imetit and proxyfan-imetit. Data are 
expressed as mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferronni 
post hoc test was carried out. P < 0.05. 
 
 
 
 
 
 
5.4.3 Proxyfan blocks thioperamide-induced hypophagia in rats 
 We found that when an injection of thioperamide is administered prior to an 
injection of saline rats consumed significantly less food than when thioperamide is 
injected after receiving an injection of proxyfan suggesting proxyfan is able to 
block the anorexic effects of thioperamide. We found that when we administered 
a double injection of saline rats ate on average 1 hour post the first injection 3.89 
± 0.72 g of food. Rats that were given a proxyfan injection and then administered 
with an injection of saline 15 minutes later, ate on average 3.37 ± 1.11 g of food, 
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rats that received an injection of saline and then thioperamide ate on average 
2.56 ± 0.51 g of food and rats that were administered with proxyfan and then 
thioperamide ate on average 3.73 ± 1.69 g of food. Only rats that received an 
injection of saline prior to receiving an injection of thioperamide were found to eat 
significantly less (P < 0.05) food than animals receiving a double saline injection 
or even those receiving proxyfan-saline or proxyfan-thioperamide. These results 
suggest proxyfan is blocking the inhibitory effect that thioperamide has on rodent 
feeding. Significance was lost by 2 hours post the first injection. 
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Figure 5.4.; Cumulative food consumption measured at 1 and 2 hours after i.p. injections 
with; saline (S), proxyfan (P) or thioperamide (T) (n = 6). There are four different drug 
groups tested and rats received two injections 15 minutes apart. These groups include; 
saline-saline, proxyfan-saline, saline-thioperamide and proxyfan-thioperamide. Data are 
expressed as mean ± S.E.M. Two-way ANOVA with repeated measures and Bonferronni 
post hoc test was carried out. P < 0.05. 
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5.4.4 Proxyfan alone has no effect on VMN neuronal firing  
 In this experiment, at total of 20 spontaneously firing histamine-responsive 
VMN neurons were tested for their responsiveness to the application of 20 µM 
proxyfan. We firstly recorded an excitatory response to histamine from the 20 
cells tested before we then applied proxyfan to the bath surrounding the brain 
slice and determined 100 % of the cells we recorded from had no change in 
neuronal firing rate. These cells showed an average basal firing rate of 1.35 ± 
0.98 Hz and a range of 2.61-1.02 Hz. In our study, none of the 20 cells showed a 
change from basal firing rate when proxyfan was applied over a four minute 
period to the brain slice. The average firing rate during the administration of the 
drug was 1.24 ± 0.84 Hz which was not significantly different from basal firing 
levels. Figure 6.5 shows that after a basal rate of VMN neuronal firing was 
established over a ten minute period, histamine was then added and there was a 
rapid increase in neuronal firing which gradually returned to basal levels after 
around 15 minutes after the application of the drug. As can be seen in an 
example of a recording (figure 5.5), when proxyfan is added after the effects of 
histamine have been washed off, there was no change in firing rates from basal 
level.  
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Figure 5.5.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of the 20 µM proxyfan. This trace illustrates that after firstly recording a 
typical histamine neuronal response when proxyfan is added the firing rate of the cell 
being recorded from does not change from basal levels suggesting proxyfan when 
administered alone has no effect on VMN neuronal firing. Purple band indicates where 
histamine was applied and light blue band indicates where proxyfan was added. 
 
 
 
5.4.5 Proxyfan can block the inhibition in neuronal firing caused by imetit 
 After determining that proxyfan had no effect on neuronal firing when applied 
alone to a brain slice, we then wanted to establish whether proxyfan could block 
the inhibitory effects of the H3R agonist imetit on these cells. After establishing 
recording from a firing cell that was histamine responsive, we then applied imetit 
alone to establish how the cell reacts to the H3R agonist. If the cell was both 
Minutes 
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histamine and imetit responsive, we then co-applied proxyfan with imetit. We 
recorded from 22 histamine-responsive cells with an average basal firing rate of 
1.86 ± 1.33 Hz and a range of 1.19-3.09 Hz. We found 19 (86 %) of the 22 cells 
tested cells showed a reduction in firing rate when imetit was applied, suggesting 
imetit has mainly an inhibitory effect on neuronal firing within the rat VMN. The 
cells that responded with an inhibition in neuronal firing showed an average firing 
rate of 0.47 ± 0.42 Hz during and immediately after the four minute application of 
the H3R agonist. Imetit had no effect on 3 of the 22 cells (14 %) we recorded from 
with an average firing rate of 1.67 ± 1.22 Hz. No cells responded with an 
excitation of neuronal firing to the application of imetit.  
 After we established imetit causes a reduction in neuronal firing, we then 
wanted to determine whether proxyfan could block this effect. Here we co-applied 
proxyfan with imetit for 4 minutes onto 20 histamine-responsive cells and found 
that, in all cells recorded, proxyfan blocked the inhibitory actions of imetit. All 20 
cells showed no change from basal firing levels when proxyfan and imetit are co-
applied suggesting proxyfan is able to block the inhibition in neuronal firing rates 
seen when imetit alone is added. 
 Figure 5.6 illustrates that after the initial excitatory histamine response is 
recorded and imetit is then applied the cell then significantly reduces its neuronal 
firing rate almost immediately. After around 10 minutes post application of the 
H3R agonist the neuronal firing rate then returns to basal levels showing this is a 
reversible response. It is then seen that once the response to imetit is thoroughly 
washed off (after a 20 minute period), an application of proxyfan and imetit was 
added and no change from basal levels of neuronal fifing were recorded. We 
continued to record for approximately 20 minutes post the application of proxyfan 
and imetit in case of a late response but in no cases was there any deviation from 
basal firing rates.  
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Figure 5.6.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of the 20 µM imetit and then the application of 20 µM imetit with 20 µM 
proxyfan. This trace illustrates that after firstly recording a typical histamine neuronal 
response, when imetit is added the firing rate of the cell being recorded from decreases 
suggesting imetit has an inhibitory effect on VMN neuronal firing. When proxyfan is then 
co-administered with imetit there is no change in neuronal firing rates from basal levels 
suggesting proxyfan is able to block the actions of imetit and act as a neutral antagonist. 
Purple band indicates where histamine was applied, the green band illustrates where 
imetit was applied and the blue band indicates when either the imetit and proxyfan 
solution was added. 
 
 
 
Our results suggest the majority of cells (approximately 86 %) within the rat 
VMN showed very similar response to that illustrated in figure 4.9 in the previous 
chapter, with most having a inhibitory response to imetit by showing a significant 
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reduction in neuronal firing whilst and immediately after the application of the H3R 
agonist. Only a small minority of the cells recorded (14 %) were unresponsive to 
the application of imetit and no cells showed an excitatory neuronal firing 
response suggesting imetit has an inhibitory response on cells within the rat 
VMN. All cells that we co-applied proxyfan and imetit had no changes in neuronal 
firing rate suggesting proxyfan is blocking the effects of imetit in our system and 
is, thus, acting as a neutral antagonist. 
 
 
5.4.6 Proxyfan can block the excitation in neuronal firing caused by 
thioperamide 
 In this study, we recorded from 16 spontaneously firing cells within the rat 
VMN to study their response to neuronal firing rate when proxyfan is co-applied 
with the H3R agonist thioperamide. We first established that the cell we were 
recording from was histamine responsive and we then determined that proxyfan 
had no effect when applied alone to the cell (results as above). Once these 
recordings were established we then co-applied proxyfan with thioperamide and 
found this had no effect on the neuronal firing rate of the cells. All 16 cells showed 
an increase in neuronal firing when histamine was added, no change in neuronal 
response when proxyfan was applied alone, and again no change from basal 
firing rate when proxyfan and thioperamide were co-applied. To ensure these 
cells could still respond to thioperamide alone, we then applied thioperamide 
without proxyfan to the brain slice. We found the cells then showed an excitatory 
response with an almost immediate increase in neuronal firing rate. This suggests 
proxyfan is able to block the excitatory effects of thioperamide without any long-
term effects. On average, cells showed a basal firing rate of 1.35 ± 0.57 HZ with a 
range of 2.61-1.02 Hz. The average firing rate of the cells during and immediately 
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post the application of the proxyfan and thioperamide solution was 1.33 ± 0.93 
Hz. Confirming what we saw in the previous chapter, when thioperamide was 
applied alone the average firing rate was 3.15 ± 2.01 Hz during and immediately 
post the drugs application. 
 Figure 5.7 illustrates a typical extracellular electrophysiology trace response 
to the co-application of proxyfan and thioperamide. The typical increase in 
neuronal firing after histamine application is seen first, then a return to basal firing 
levels, before proxyfan is then applied. After these first two responses have been 
established we then added the proxyfan and thioperamide solution and as is 
shown in figure 6.7, and no change from neuronal firing was recorded. To ensure 
the cell was still thioperamide responsive, we then added thioperamide alone. An 
increase in neuronal firing was produced showing that proxyfan was blocking the 
effect of thioperamide, and that it was not that the cell was unresponsive to 
thioperamide. 
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Figure 5.7.; An electrophysiology trace showing a typical rat VMN neuronal response to 
the application of the 20 µM proxyfan and then the application of 20 µM thioperamide with 
20 µM proxyfan. Finally, 20 µM thioperamide was applied alone. This trace illustrates that, 
after firstly recording a typical histamine neuronal response, when proxyfan is added, the 
cell shows no response and the firing rate remains at basal levels. When proxyfan is co-
administered with thioperamide, again the cell shows no deviation in its firing rate. When 
thioperamide alone is added, an excitatory response is noted with the firing rate rapidly 
increasing. These results suggest proxyfan is able to block the actions of thioperamide 
and act as a neutral antagonist. Purple band indicates where histamine was applied, the 
light blue band illustrates where proxyfan was applied, the pink band indicates where the 
solution of proxyfan and thioperamide was added and the red band indicates where 
thioperamide alone was added. 
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As all the cells showed a excitatory response to both histamine and 
thioperamide yet showed no change in response when proxyfan plus 
thioperamide was applied, our results suggest proxyfan is blocking the excitation 
in neuronal firing produced by the H3R inverse agonist and thus is acting as a 
neutral antagonist in our system.  
 
Although all our drug applications resulted in similar responses from the VMN 
neurones it must be noted that the overall firing pattern we observed from the 
neurones we recorded from within the VMN was quite irregular with bursts of 
spikes occurring every minute or so. 
 
 
 
5.5 Discussion 
5.5.1 Proxyfan acts as a neutral antagonist at the H3R at a behavioural and 
neuronal level 
Although proxyfan has been shown to have little effect alone in some 
systems (Clark et al., 1996, Meier et al., 2004) and to alter others significantly 
(Baldi et al., 2004, Gbahou et al., 2003), the effect of this drug has never been 
tested for its effects on feeding in the rat and, to our knowledge, the effects of 
proxyfan on the electrical activity of non-histaminergic cells have not been 
published.  
As we have illustrated above, the H3R compound has no effect on food 
intake when administered systemically in both satiated and non-satiated rats. This 
shows that when endogenous brain histamine levels are both high (non-satiated 
animals) and low (in satiated animals) proxyfan alone has no significant effect on 
the food intake, suggesting in this behavioural system, proxyfan is having neither 
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an inhibitory or stimulatory effect at the H3R. We have also demonstrated that 
when proxyfan was introduced to a brain slice via a perifusion bath, the neuronal 
firing rate of VMN neurones within the brain slice were unperturbed and remained 
at basal levels. Our data suggest that proxyfan is acting neither as an agonist or 
inverse agonist at the H3R when administered alone in our extracellular 
electrophysiology system. 
Gbahou et al. (2003) demonstrate that proxyfan can be a protean agonist 
at the H3R, having a spectrum of activities ranging from potent agonist to potent 
inverse agonist. As a protean agonist it can produce different responses 
depending on the constitutive activity of the system being tested. Thus, it could be 
suggested that the lack of effect proxyfan had on food intake in both satiated and 
non-satiated animals is due to the equilibrium between the active and inactive 
conformations of the receptor. 
As shown in this and in chapter 2 of this thesis, both H3R drugs imetit and 
thioperamide have significant effects on food intake when given both at night or 
during the day and in satiated or fasting animals, with imetit causing a significant 
increase in food intake and thioperamide causing a significant decrease in food 
intake. Thus, it was interesting to find that proxyfan, which has no effects on food 
intake when administered alone, blocked any changes in food intake from basal 
levels when co-administered with either the H3R agonist or inverse agonist. As 
proxyfan has no effect alone but can have effects on food intake when co-applied 
with imetit or thioperamide, proxyfan appears to be acting as a neutral antagonist 
in our feeding system. It also shows clearly that proxyfan can cross the blood-
brain barrier to affect neuronal function, as has been shown in other studies. For 
example, proxyfan has been shown to affect memory (Cangioli et al., 2002, 
Giovannini et al., 2003), wakefulness (Gbahou et al., 2003), or drinking (Fox et 
al., 2002) in rats. 
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Our results from extracellular electrophysiology on histamine-responsive 
neurones within the rat VMN, suggests these neurones are unresponsive to 
proxyfan when it is administered alone, and is probably not acting as a H3R 
agonist or inverse agonist in this system. We also have shown in previous 
chapters that thioperamide and imetit have an excitatory or inhibitory effect on 
neuronal firing within the rat VMN, respectively. Here we found that, when these 
drugs were co-applied with proxyfan, the excitatory effects of thioperamide or the 
inhibitory effects of imetit were blocked, suggesting proxyfan is antagonising the 
effects on histamine release mediated by presynaptic H3R. Again, this suggests 
proxyfan is acting as a neutral antagonist.  
By suppressing the constitutive activity at the H3R, inverse agonists such 
as thioperamide enhance histamine release, whereas agonists such as imetit 
inhibit the release. Proxyfan alone has no effect on histamine release, but blocks 
the opposing effects of the H3R drugs, thioperamide and imetit on both feeding 
and neuronal firing of histamine-responsive cells within the VMN, suggesting it is 
acting as a neutral antagonist in both systems. The lack of effect of proxyfan 
shows that antagonism of endogenous histamine does not contribute to the 
histamine-releasing effect of thioperamide and imetit.  
The level of constitutive activity depends on both the number of 
spontaneously active conformations and the coupling efficiency of these 
conformations to G proteins (Arrang et al., 2007). It therefore depends not only on 
the receptor, but also on the response. Inverse agonists impede constitutive 
activity by promoting inactive conformations. Their maximal effect is correlated to 
the level of constitutive activity. Thus, thioperamide is blocking the natural 
constitutive activity at the H3R and promoting an inactive conformation which is in 
turn allowing the release of endogenous histamine. As Arrang et al. (2007) 
suggest proxyfan can act as an agonist when the agonist state promoted by 
proxyfan has an efficacy higher than the receptors constitutive state and it can act 
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as a inverse agonists when the state promoted by proxyfan has an efficacy lower 
than the receptor constitutive. But proxyfan alone will have no apparent activity 
when both the receptor constitutive state and the agonist state show the same 
efficacy, and thus here proxyfan is acting as a neutral antagonist (Arrang et al., 
2007). In our system, proxyfan is having no effect alone, but is able to block the 
effects of both imetit and thioperamide. This suggests both the agonist state 
promoted by proxyfan and the constitutively active state of the receptor are 
showing the same efficacy in our system and, thus, proxyfan is acting as a neutral 
antagonist.   
Our results would agree with Morriset et al. (2000) who suggested the 
pharmacological profile of proxyfan depended on the system being analysed. 
Thus, the actions of proxyfan depend on the equilibrium between the active and 
inactive conformations of the receptor and the ratio of the receptor to the various 
G proteins.  
As proxyfan is a protean agonist and we found it to act as a neutral 
antagonist in our system it suggest the H3R agonist, imetit, and the H3R inverse 
agonist, thioperamide act specifically at the H3R. It important to note, that these 
results cannot be generalised to all neurons that are involved in appetite 
regulation. However, the consistency between my in vivo and in vitro data 
suggests that the effects myself and other research groups have noted in rodents 
are in fact real and the H3R agonist, imetit and the H3R inverse agonist, 
thioperamide, are truly specific for the H3R. This adds further support to the vast 
majority of the literature (Jethwa et al., 2009, Sindelar et al., 2005, Lecklin et al., 
1998), and further brings into the question the validity of the Yoshimoto et al. 
(2006) study results described in Chapter 2 of this thesis, which found imetit and 
thioperamide to have the opposite effects on feeding to all other published 
research. Although it must be noted that it is difficult to disagree entirely with the 
findings of Yoshimoto and colleagues, as we did find imetit to have a similar effect 
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on feeding in mice as they illustrated. Also their experiments were carried out on 
H3R knockout mice, which will have no endogenous H3R tone and thus histamine 
may be unusually high in this system which could alter the data collected from 
adding H3R agonists or H3R inverse agonists.  
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Chapter 6: 
Glucose tolerance and the 
histaminergic system 
 
 187 
6.1 Introduction 
As I have illustrated in this Thesis, a large population of VMN neurones 
are responsive to histamine, but these VMN neurones are presumably responsive 
to a number of other stimuli and, therefore, are able to integrate signaling related 
to energy homeostasis. Thus, these VMN neurones are possibly the same 
population that respond to leptin, ghrelin, and other metabolic signals. A major 
integratory role within the VMN is played by glucose-sensing neurones, but these 
only make up a relatively small proportion of the total number VMN neurones, and 
can respond differently to increases or decreases in glucose. Therefore, we wish 
to determine whether the same populations of VMN neurones responding to 
histamine are also glucose responsive.  
 
 
6.1.1 Glucose sensing in the brain 
Throughout this thesis I have presented evidence that the VMN is 
essential and plays a pivotal role in the regulation and maintenance of energy 
homeostasis. One important role is dependent on the high density of glucose-
sensing cells within the VMN which will influence energy-regulating mechanisms 
(Gonzalez et al., 2008). It is important to note that small changes in levels of 
glucose probably do not have a direct role in the timing or quantity of food intake, 
but the VMN is important in integrating both long- and short-term regulators of 
energy balance, and also in counter-regulatory mechanism to protect against 
hypoglycaemia. If the VMN detects hypoglycaemia, it initiates a number of 
immediate counter-regulatory mechanisms, the most important being the 
immediate release of glucose from the liver, which is mediated by the sympathetic 
nervous system. There is also a slower release of glucagon and inhibition of 
insulin secretion to counteract against hypoglycaemia. There is also an increase 
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in feeding in response to hypoglycaemia, but this is neither immediate nor 
important unless in extreme situations. Perhaps the more important function of 
the VMN in the acute regulation of food intake may be the ability of the VMN to 
reduce feeding in response to other stimuli. 
Most brain glucose is used primarily as substrate for the energy needs of 
neurones and glia and does not alter the firing rate of the majority of neurones 
(Levin et al., 1999). However, a small group of neurones within brain areas tied to 
the neuroendocrine and autonomic control systems appear to use glucose as a 
signal to alter their firing rate suggesting some neurones might be involved in 
energy homeostasis. 
‘Glucose-sensing’ neurones are specialized cells that respond to small, 
physiological changes in extracellular glucose concentration by altering their firing 
rate (Burdakov et al., 2005). Glucose-sensing neurones are present in a number 
of forebrain regions and the brainstem, but, like histamine responsive neurones, 
are most prevalent within the hypothalamus (Adachi et al., 1995). Hypothalamic 
glucose-sensing neurones comprise groups of cells within the LH, ARC and VMN 
regions and exhibit both excitatory or inhibitory firing responses to changes in 
extracellular glucose concentration (Anand et al., 1964; Oomura et al., 1969; 
Routh VH., 2002; Wang et al., 2004). The activity of these cells in response to the 
energy status of the body, can result in changes in hormone release, metabolic 
rate, food intake and locomotor activity to ensure the brain always has adequate 
glucose (Routh VH., 2002; Levin et al., 2004; Routh et al., 2004). This continual 
monitoring of brain glucose concentrations is critical as the brain becomes 
irreversibly damaged if deprived of glucose after only a few minutes.  
Two populations of hypothalamic glucose-sensing neurones have been 
shown to exist, those excited and those inhibited by glucose (Burdakov et al., 
2005). Glucose-excited (GE) neurones and glucose-inhibited (GI) neurones are 
both located in the hypothalamic VMN, LH, ARC and PVN, and in the caudal 
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brainstem around the tract of the solitary nucleus (Song et al., 2001, Levin et al., 
1999). The first evidence for the presence of hypothalamic GI neurones was 
provided by the in vivo experiments of Anand et al. who tried to correlate blood 
glucose levels with firing activity in the ‘hunger’ and ‘satiety’ regions of the 
hypothalamus (Anand et al. 1964). Using steel microelectrodes, they found that 
spike firing of LH neurones significantly decreased after intravenous infusion of 
glucose in anaesthetised dogs (Anand et al., 1964). Oomura et al. also 
demonstrated that injection of glucose suppressed spike firing in 20% of LH 
neurones (Oomura et al., 1969). Although GI and GE neurones both respond to 
glucose albeit in opposing manners, they are not similar in their physiology 
(Routh et al., 2003).  
Relatively little is known about glucosensing in GI neurons, but what is 
certain is that they respond to increasing glucose levels by decreasing their firing 
rate. Oomura et al. propose that glucose-inhibited neuronal activity is regulated 
by the Na+-K+-ATP pump (Oomura et al., 1974). Whereas, Routh and colleagues 
obtained data indicating that they may use a Cl- channel to sense glucose (Song 
et al., 2001; Routh et al., 2003). Because decreasing extracellular glucose levels 
should lower intraneuronal ATP levels, such a Cl--channel should be responsive 
to changes in the ATP to ADP ratio. GE neurones show more similarity to 
pancreatic β-cells than GI neurons, and these similarities are proposed to account 
for how GE neurones sense glucose (Yang et al., 1999). GE neurones increase 
their firing rate when ambient glucose levels rise and cease firing when glucose is 
removed (Oomura et al., 1969). This response is thought to be modulated by a K+ 
channel that is sensitive to the intracellular ratio of ATP to ADP. Thus, it is called 
the ATP-sensitive K+ channel (KATP) (Trapp et al., 1997). The KATP channel is 
inactivated by direct binding of ATP, whereas phosphorylation of the channel 
increases its activity (Routh et al., 1997). Normal orexigenic responses to NPY 
and anorectic responses to leptin are maintained when KATP channel function is 
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interrupted, suggesting neuronal glucosensing is critical for glucoprivic, but not 
homeostatic ingestive behavior, and the ablation of KATP channel function 
attenuates the counter-regulatory response to hypoglycemia but does not alter 
basal plasma glucose levels (Miki et al., 2001). It is suspected that glucose is only 
one of several metabolic signals sensed and integrated within energy-sensing 
neurones (Levin et al., 2002). 
 
 
6.1.2 The VMN and glucose sensing 
Many glucose-sensing neurones are found in the classical ‘satiety center’ 
or VMN. Glucosensing neurones in the VMN are among the best characterized, 
with 14–19% of all VMN neurones being GE and 3–14% being GI in type (Levin 
et al., 2004). Single-cell RT-PCR studies have suggested that some, if not all, 
VMN neurones including GE neurones, are GABAergic (Miki et al., 2001; Kang et 
al., 2004). Glucosensing neurones also express receptors for and respond to 
peripheral hormones that convey signals relating to fat stores such as leptin 
(Spanswick et al., 2000) and insulin (Wang et al., 2004). The sensitivity of the 
VMN GI neurones can be modulated by systemic hyperglycaemia (Canabal et al., 
2007) and hypoglycaemia (Song et al., 2006), illustrating the importance of the 
VMN in relation to glucose sensing within the brain. The importance of glucose 
sensing within the VMN came about when data showed that mature rats with 
lesions in the VMN failed to display the preference reversal from concentrated to 
dilute glucose solutions that is seen in normal rats (Booth et al., 1972; Jacobs et 
al., 1958), indicating that the VMN could be involved in the sensing of metabolic 
signals arising from glucose. Panksepp and co-workers (1972) also established 
that rats with VMN lesions do not exhibit the prolonged depression of food intake 
after intraperitoneal glucose injections observed in control rats and in rats with 
lateral hypothalamic lesions (Panksepp et al., 1972). 
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VMN GE neurones have been noted to be inhibited when extracellular 
glucose decreased to very low levels suggesting these neurones only respond to 
large decreases in extracellular glucose that accompany profound systemic 
hypoglycemia, rather than the relatively small changes in plasma glucose levels 
(Levin et al., 1998). Thus, as with other GE neurones, VMN GE neurones are 
more likely to play a role in the counter-regulatory response to hypoglycemia 
(Yoshimatsu et al., 1984) and glucoprivic feeding (Atef et al., 1992), than in the 
control of meal initiation. A less common type of VMN neurone with inherent 
glucosensing properties are the GI neurones and which are found only in low 
abundance within the VMN. GI neurones are excited when extracellular glucose 
is decreased.  
It is important to point out that, Song et al., 2001 have shown that there 
are many neurones in the VMN that have no inherent glucosensing capacity of 
their own. Instead, their firing rate is regulated by presynaptic inputs from other 
glucosensing neurones either inside or outside of the VMN.  
 
 
6.1.3 Histamine and glucose sensing 
Histamine neurones in mammals project their efferent varicose fibres to 
almost all areas of the brain. The hypothalamus is one of the richest areas in 
density of histamine fibres, with histamine receptors being heavily localised in the 
hypothalamus (Sakata et al., 1997). Although it must be pointed out that although 
histamine receptor expression is dense within the hypothalamus, it is far greater 
in other brain regions that are not related to energy homeostasis. Glucose-
sensing neurones are found within the VMN and also tend to have receptors for 
other metabolic signals, such as leptin and insulin, demonstrating that glucose-
sensing neurones are capable of integrating different types of signals. If these 
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same neurones are also responsive to histamine, then histamine may well be 
able to modulate glucose sensing, and therefore glucose handling.  
Glucoprivation activates histamine neurones in the hypothalamus (Oohara 
et al., 1994) and enhances glycogenolysis in the brain (Sakata et al., 1994). 
Histamine neurones also accelerate lipolysis in adipose tissues to supply energy 
to the brain through activation of the sympathetic nervous system (Bugajski et al., 
1981). These findings regarding functional roles of histamine neurones suggest 
such systems are related to nutritional status and energy storage across a broad 
range, from starvation to hyperglycemia (Sakata et al., 1997). Treatment of diet 
induced obese (DIO) and db/db obese mice with histamine lowers serum 
concentrations of glucose and insulin, improving glucose tolerance and insulin 
sensitivity (Masaki et al., 2001).  
 
 
6.2 Does thioperamide affect glucose metabolism?  
Hyperglycemic responses to exogenous histamine have been shown 
(Nishibori et al., 1987). Sakata et al measured the turnover of hypothalamic 
histamine after IP infusion of insulin and demonstrated that the turnover rate of 
hypothalamic histamine was accelerated (Sakata et al., 1994). Sakata et al. 
suggest the accelerating effect of insulin on histamine release is mediated by 
hypoglycemia as ICV infusion of the glucose analogue 2-deoxy- glucose (2-DG) 
induces hyperglycemia and also increases the turnover rate of hypothalamic 
histamine (Sakata et al., 1994, Sakata et al., 1991). These results suggest a lack 
of neural glucose in the hypothalamus increases histamine turnover (Oohara et 
al., 1994, Sakata et al., 1994). Sakata and colleagues have shown hypothalamic 
histamine is activated and released in response to an energy deficit thus 
suggesting hypothalamic histamine may play a vital role in glucose utilization and 
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ensuring homeostatic maintenance of energy supplies in the brain (Sakata et al., 
1997). As shown in Chapter 2 of this thesis, thioperamide is a potent H3R inverse 
agonist that causes significant reductions in food intake when given both centrally 
and peripherally. But thioperamide has also been shown to significantly increase 
plasma glucose in rats (Yoshimatsu et al., 1993).  Yoshimatsu et al. showed that 
thioperamide produced a hyperglycemic response through activation of 
endogenous histamine in rats (Yoshimatsu et al., 1993). Thioperamide removes 
the normal feedback autoinhibitory control system of both histamine synthesis 
and release at the level of histamine nerve terminals thus increasing histamine 
neuronal activity and endogenous histamine release in vivo (Arrang et al., 1987).  
As it has been shown by a number of research groups that histamine 
turnover is accelerated and endogenous histamine release increases when 
glucose levels are low (Oohara et al., 1994, Sakata et al., 1994, Yoshimatsu et 
al., 1993), we can assume that histamine plays a role in glucose utilization. 
Thioperamide, by blocking the autoinhibitory controls on histamine that the H3R 
has it causes a increase in histamine release which could then go on to play a 
key role in glucose tolerance and consumption. We wanted to determine whether 
injecting the H3R inverse agonist, thioperamide and, thus, increasing histamine 
release within the animal before injecting a bolus of glucose would affect the 
animals natural ability to partition glucose.  
We carried out this experiment on 18 CD-1 male mice (7 weeks of age) 
and injected either 20 mg/kg of thioperamide of saline (100 µl injection volume) 
into the intraperitoneal cavity of the animal (n = 9 per group). Twenty minutes 
after the initial injection of either thioperamide or saline was given, we took the 
circulating blood glucose levels of the animal being tested by collecting blood 
from a small incision in the tail and using a One Touch Ultra 2 glucometer 
(LifeScan, Johnson-Johnson, UK). We then administered 2 g/kg of glucose into 
the intraperitoneal cavity. We took further circulating blood glucose readings, at 
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15, 30, 60 and 120 minutes post the injection of glucose. Blood glucose levels 
were presented as mmol/l and results were analysed and presented as mean ± 
SEM. Data from feeding groups were analysed using a two-way ANOVA with 
repeated measures and Bonferroni post hoc tests (see graph 7.1). 
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Figure 6.1.; Circulating blood glucose levels (mmol/l) measured at 15, 30, 60, 120 
minutes after i.p. injection with glucose. (n = 9). Data are expressed as mean ± S.E.M. 
Two-way ANOVA with repeated measures and Bonferroni post hoc tests, no significance.  
 
 
We found that thioperamide had no effect on glucose handling in the CD1 
mouse (figure 6.1). Although thioperamide-treated animals did show some trend 
towards an increase in glucose, their blood levels returned back to basal levels 
faster than control group, and so there was no statistical significance. These 
results suggest that the increase in histamine resulting from the administration of 
thioperamide has little effect on the handling of glucose and is not associated with 
the anorexic effects of the H3R inverse agonist. These preliminary results suggest 
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the actions of thioperamide are not directly affecting glucose sensing and 
metabolism, but further more in depth hormone studies are needed to determine 
the levels of compounds such as insulin and glycogen to determine whether 
histamine is affecting their levels when glucose levels vary. It also would be 
interesting to see what effect thioperamide has on glucose tolerance in obese 
models. 
 
 
6.3 SF-1 neurones and possible role of PACAP  
One of the major problems in studying the VMN is that is that we do not 
know the phenotype of the cells. Steroidogenic factor 1 (SF-1) is a member of the 
nuclear receptor family of intracellular transcription factors and is important in the 
development of the VMN. It regulates steroid hydroxylases and is a cell-specific 
nuclear regulator. Since SF-1 is only expressed in the VMN in the brain it can be 
used to target VMN neurones. Zhao and colleagues have demonstrated that 
targeted deletion of SF-1 results in the failed development of the VMN resulting in 
an obese animal (Zhao et al., 2004). The SF-1 promoter has also been used to 
drive expression of Cre-recombinase, to selectively knock out “floxed” genes in 
the VMN. For example, SF-1-driven deletion of leptin receptors also results in an 
obese phenotype (Dhillon et al., 2006). Many VMN neurones are glutamatergic, 
but less is understood about the neuropeptide populations in this area. Two 
possible neuropeptide candidates are pituitary adenylate cyclase-activating 
polypeptide (PACAP) and brain-derived neurotrophic factor (BDNF). These two 
neuropeptides appear to be in separate populations because most PACAP 
neurones in the adult mouse express SF-1, notably in the dorsomedial region of 
the VMN, but very few BDNF neurones in this region do (Hawke and Luckman, 
unpublished). Ideally, we would like to look at individual populations of cells within 
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the VMN, but that is not currently possible. Although SF-1 cells are probably a 
mixed population, Dhillon et al. (2006) suggest they mostly respond in the same 
direction and are excited by leptin, much as we would expect for histamine. 
Therefore, we wanted to determine whether SF-1 cells also contain a sub-
population of glucose-sensing neurones. If they do, then our aim would be to see 
how these glucose-sensing neurones respond to histamine. 
 
VMN cells are predominantly glutamatergic, like many hypothalamic 
neurones, and at least some of the effects of SF-1 cells in the VMN are mediated 
by glutamate (Tong et al., 2007). One VMN-enriched gene is PACAP (Segal et 
al., 2005; Kurrasch et al., 2007), which plays a role in controlling both appetite 
and energy expenditure in mice (Morley et al., 1992, Tachibana et al., 2003, 
Matsuda et al., 2005; Matsuda et al., 2007). At least some of leptin’s effects are 
mediated by this VMN PACAP population (Hawke et al., 2009). Leptin signaling in 
the VMN plays an important role in regulation of energy homeostasis. 
Extracellular recordings have revealed that at least half of VMN neurones 
respond to the application of leptin (Irani et al., 2008). Moreover, 
electrophysiological recordings from SF-1 neurones show the large majority are 
depolarized by leptin (Dhillon et al., 2006). Electrophysiology and 
immunohistochemistry confirm that SF-1 cells in the VMN are a target for leptin, 
and that targeted genetic ablation of leptin receptors in the VMN results in obesity 
(Dhillon et al., 2006). SF-1-Cre lepr flox/flox mice exhibit significantly less PACAP 
expression in the VMN than wildtype littermates (Hawke et al., 2009). 
As PACAP is clearly vital in VMN controlled feeding and the majority of 
leptin-sensitive neurones contain PACAP we hypothesis that the same population 
of cells could also be histamine-responsive and these cells could be mediating 
their affects on food intake via similar neuronal pathways. 
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6.4 How does glucose act SF1-positive neurones?  
Extracellular electrophysiology determines the effects on a subset of 
neurones when a substrate is applied. The electrode will detect electrical activity 
generated by the neurones adjacent to the electrode tip, but the major downside 
to extracellular electrophysiology is that it is impossible to easily determine the 
identity of the neurones being recorded. Also, extracellular recordings may be 
generated by the collective activity of many cells and are affected by the 
simultaneous activation of many neurones by synaptic transmission. With single-
cell, patch-clamp electrophysiology, you can either fill the recorded cell with a 
marker and identify it post-recording using immunocytochemistry or, as done 
here, record from pre-identified neurones. This is possible because the SF1-Cre 
mouse we have used was originally crossed with a green-florescent protein 
(GFP) reporter mouse, so that GFP in the offspring is now expressed only in SF-1 
neurones (Dhillon et al., 2006). Thus, with help from Dr Mino Belle, we have 
preliminary data to begin the task of phenotyping the VMN neurones that are 
sensitive to glucose and histamine.  
To determine how glucose affects neuronal firing within the VMN we 
measured changes in the excitability of VMN neurones in vitro using whole-cell 
patch recordings from SF-1 VMN neurones pre-identified by their expression of 
GFP. Mice (7-9 months old) expressing GFP driven by the SF-1 gene in the VMN 
were bred and group housed on a 12:12 hour light:dark cycle with lights on at 
8:00 h. Animals were fed ad libitum. Animals were terminally anaesthetized with 
isofluorane and killed by decapitation. The brain was immediately removed and 
coronal brain slices containing the VMN were collected using a Vibroslicer 
(Campden Instrument, Loughborough, Leicestershire, UK) into an ice-cold low 
Na+/Ca2+, high Mg2+ sucrose-based incubation artificial cerebro-spinal fluid 
(aCSF) (in mM: NaCl 95; KCl 1.8; KH2PO4 1.2; CaCl2 0.5; MgSO4 7; NaHCO3 
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26; glucose 15; sucrose 50; Phenol Red 0.5mg/l; oxygenated with 95% O2; 5% 
CO2; pH 7.4, measured osmolality 300-310 mosmol kg-1). For patch-clamp 
recordings, slices were transferred to a recording bath and were continuously 
perifused (1.5-2.5 ml min-1) with oxygenated recording aCSF at room 
temperature. The recording aCSF was identical to the incubation solution except 
for the following (mM): NaCl 127; CaCl2 2.4; MgSO4 1.3; sucrose 0. Slices were 
allowed to recover for at least 1 hour prior to whole-cell recording. Cell membrane 
was ruptured with or without minimum holding currents using a patch pipette 
electrode (7-10 MΩ), made from thick-walled borosilicate glass capillaries 
(Harvard Apparatus Ltd, Kent, UK) using a two-stage vertical micropipette puller 
(Narashige, Tokyo, Japan). Signals were sampled at 30 kHz, stored and analyzed 
using Spike2 software (Cambridge Electronic Design, Cambridge, UK). All data 
acquisition and step protocols were generated through a micro 1401 mkII 
interface (CED). GFP neurones were visually identified using a Leica 
epifluorescent microscope (DMLFS; Leica Microsystems Ltd, Milton-Keynes, UK) 
equipped with filters optimized for visualizing GFP through a 40x water-immersion 
lens (HCX APO). Neurones were allowed to recover for 10-20 seconds, and all 
data were collected within 4 minutes of cell membrane rupture to minimize any 
potential cell dialysis effects (see Belle et al., 2009 for more details on the setting 
up and recording of whole-cell patch-clamp electrophysiology).  
To determine the cell’s response to increased glucose we firstly bath 
applied 1 mM glucose solution mixed with fresh aCSF for 1 minute to determine 
the cells response to low glucose and then bath applied 5 mM of glucose solution 
mixed with fresh aCSF for 5 minutes and recorded the changes in membrane 
potential and neuronal firing.  
Unfortunately due to the lack of SF-1-Cre lepr wt/wt mice, genotyping 
drawbacks and time restrictions we were only able to collect recording from a few 
cells, only one of which was intrinsically glucose sensitive.  
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Figure 6.2.; This diagram (see next page) illustrates the area within the mouse 
hypothalamus we recorded from and allows us to demonstrate the GFP identified SF-1 
cells within this area. A. illustrates the dorsomedial ventromedial hypothalamus (VMHDM) 
where our electrode was placed, B. illustrates a low magnification of the VMHDM area 
and demonstrates the GFP within the SF-1 cells in this area, C. demonstrates the SF-1 
cells expressing GFP under a high magnification which allowed us to specifically record 
from this subset of cells using whole cell-patch clamp electrophysiology, D. illustrates our 
glass pipette electrode recording from a SF-1 GFP expressing cell, E. illustrates more 
clearly the glass pipette electrode recording specifically from a SF-1 cell. The yellow 
dotted lines indicate the edges of the glass electrode.  
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As discussed in the introduction of this chapter, both GE and GI neuronal 
populations are found within the VMN, with a slightly higher population being 
glucose excited. We hypothesized that as more VMN glucose responsive cells 
are found to be GE than GI we would expect to find cells that increased their 
neuronal firing when glucose was added. The one recording we obtained, was 
found to be a glucose-inhibited neurone. As can be seen in figure 6.3 when the 
higher concentration of glucose was added (5 mM) we recorded a gradual 
hyperpolarisation of 10 mV in the membrane potential, which eventually resulted 
in an inhibition of cell firing. The cell did begin to return to basal membrane 
potential levels around 30 minutes after the high-glucose medium was thoroughly 
washed off, showing this was a reversible decrease in firing. The membrane 
properties of this neurone (results not shown), suggested that it had similar 
properties to glucose-inhibited neurones recorded in the lateral hypothalamus 
(Burdakov et al., 2005).  
 
 
 
Figure 6.3.; This patch clamp electrophysiology trace shows the change in membrane 
potential the SF-1 GFP VMN cell we recorded from demonstrated when the glucose 
concentration within the aCSF solution was increased from 1 mM to 5 mM. There is a 
gradual lowing of the membrane potential seen after the higher concentration of glucose 
is added suggesting this particular VMN cell is glucose-inhibited. This recording was 
carried out by Dr Mino Belle. 
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6.5 Future work 
The regulation of feeding by histamine and glucose sensing both involve the 
VMN. We began to investigate whether glucose sensing interacted with 
histaminergic signaling within the VMN. Unfortunately due to a number of 
setbacks and a lack of time, we were only able to carry out very preliminary 
studies.  
With the help and expertise of Dr Mino Belle we demonstrated glucose 
sensing by at least some SF-1 cells within the dorsomedial VMN. Obviously as 
only one recording was obtained, we would plan to carry out more recordings on 
this population of SF1-positvie cells and determine whether the majority are 
glucose inhibited or glucose excited. 
Once the population of glucose responsive cells has been characterized, we 
would then aim to determine whether these cells also are influenced by the 
histaminergic system. To determine this we would apply the H3R inverse agonist 
thioperamide which would increase histamine release within the slice and see if 
thioperamdie modified the firing patterns of glucose-sensing neurones. 
We found thioperamide had no significant effect on the glucose tolerance of 
CD1 mice when given before a bolus injection of glucose, though there may have 
been a slight increase in circulating glucose as suggested in other reports. It is 
too early to determine if histamine is interacting directly in the VMN to modify 
glucose handling. Thus, one further study would be to determine the effects of 
thioperamide on glucose tolerance in obese mice. We could also measure insulin 
and glucagon responses in the blood of mice that received thioperamide.   
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Chapter 7: 
General Discussion 
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General Discussion 
 The key aims of this PhD thesis were to determine the involvement of the 
histaminergic system in relation to food intake and appetite control and whether 
the H3R could, like the H1R, be a possible target for the development of 
pharmacological products to advance the fight against obesity. We also wanted to 
determine where in the rat brain H3R ligands were acting and if they were acting 
directly on known ‘feeding’ and ‘satiety’ centres within the hypothalamus. We 
aimed to establish what effects histamine has on neuronal firing within the rat 
VMN, including whether H1 or H3 receptors are present within the rat VMN and 
whether the drugs we tested in in vivo feeding studies also altered neuronal firing 
in this area, which is known to be pivotal in the regulation of feeding. Our final aim 
was to ensure our H3R drugs, imetit and thioperamide, were acting specifically at 
the H3R. 
 
 
7.1 The histaminergic system can be pharmacologically manipulated 
to affect food intake 
 Histamine is an important central neurotransmitter and is involved in a large 
number of functions including arousal, cognition, locomotor activity, autonomic 
and vestibular functions, feeding and drinking, sexual behaviour and analgesia 
(Hough LB., 1988; Schwartz et al., 1991; Wada et al., 1991, Chotard et al., 2002, 
Gomez-Ramirez et al., 2002, Hancock et al., 2004). A number of research groups 
have demonstrated the importance of histamine in controlling food intake and all 
have suggested it is a potent anorexigenic agent (Yoshimatsu et al., 1993, 
Yoshimatsu et al., 2002, Yoshimatsu H., 2006, Yoshimoto et al., 2006, Gotoh et 
al., 2007). For example, behavioural studies have illustrated that histamine 
suppresses food intake when administered both centrally or systemically (Doi et 
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al., 1994, Lecklin et al., 1998, Lecklin et al., 1995, Endou et al., 2001). We have 
demonstrated that when histamine is administered centrally into the rat it results 
in a rapid, yet short-lasting, highly significant reduction in food intake. These 
results concur with other reports suggesting histamine is a potent hypophagic 
agent. 
Of the four documented histamine receptors only the H1R and H3R have been 
found to be involved in the regulation of feeding and obesity in rodents (Masaki et 
al., 2006). H1R activation causes a reduction in food intake and, thus, 
pharmaceutical agencies first looked to establish drug therapies that targeted this 
H1R as a treatment for weight gain. The main issue with targeting the H1R is that 
it is involved in a large number of bodily functions and it is distributed widely 
throughout peripheral tissues, as well as the CNS (Kinnunen et al. 1998). Thus, 
altering the activity of this receptor will not specifically target just one of its many 
functions, but will result in a number of adverse effects, including drowsiness. 
Therefore, we focused our attention on the H3R which has been illustrated by a 
number of reports to have potential anti-obesity effects, though the exact 
therapeutic benefits remain controversial. For example, thioperamide, a potent 
H3R inverse agonist should theoretically reduce food intake by increasing 
endogenous histamine levels which then activate the H1R resulting in a reduction 
in food intake. This has been found by some research groups (Lecklin et al., 
1998, Sindelar et al., 2004), but others found it to have no effect (Itoh et al., 
1998), and some even found giving thioperamide increased food intake and 
weight gain in mice (Yoshimoto et al., 2006). Therefore, we wanted to determine 
what effect on food intake a H3R agonist and two H3R inverse agonists would 
have on food intake in our chosen rat model. We found that the H3R agonist 
imetit, caused a significant increase in food intake, whereas the H3R inverse 
agonists thioperamide and NNC1202, caused dramatic hypophagia in the rat. 
Using analysis of the behavioural satiety sequence, we found that imetit and 
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thioperamide appeared to change feeding without causing any unexpected, 
adverse effects. By contrast, NNC1202 caused the animals to withdraw and 
become inactive, displaying “sickness-like” behaviour, which explains the 
dramatic and prolonged reduction in food intake caused by non-selective actions.  
We also wanted to determine whether feeding in mice and rats were equally 
affected by imetit and thioperamide, or whether these drugs, as suggested by 
some research groups (Tokita et al., 2006, Yoshimoto et al., 2006), exerted 
species-related differences in their actions and abilities to alter feeding. We found 
that both imetit and thioperamide caused a significant reduction in food intake in 
mice. This suggests that thioperamide can cause hypophagia in both rats and 
mice and, thus, inverse agonists at the H3R remain a potential target for anti-
obesity therapies. The effects of imetit on the other hand appear to alter 
depending on the species of animal being investigated. The reasons for these 
differences are currently unknown, but may reflect differences in H3R splice 
variants expressed in different areas of the CNS or in different species. Splice 
variant may interact differently with pharmacological reagents such as imetit and 
thus result in distinct outcomes in different species. 
 
 
7.2 The hypothalamus is a key target for the histaminergic system 
 The hypothalamus is a key brain area identified as having an important role 
in controlling food intake and energy expenditure (King BM., 2006). From brain 
lesion studies, the VMN and PVN are regarded predominantly as satiety centres, 
and the LH as a feeding centre. But the ARC, DMN and SCN all play important 
roles in controlling appetite as well (Beck et al., 2000). Histamine is known to 
reduce food intake, but where and on what neuronal types it is acting has not 
been fully elucidated. Histaminergic nerve fibres are found in virtually all parts of 
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the brain but with especially high densities being apparent within the posterior 
hypothalamus, including in particular the VMN, SCN and PVN, although all 
hypothalamic areas receive a fairly strong histaminergic innervation with 
histaminergic fibres (Gomez-Ramirez et al., 2002). The H1R is found throughout 
the mammalian PNS and CNS but has specifically been shown to be present 
within the VMN and PVN (Masaki et al., 2003). It is widely accepted that 
histamine acts via the H1R to reduce food intake. We found using c-Fos, the 
neuronal marker for activation, that cells were activated within the hypothalamus 
of the rat brain. In particular, there was increase neuronal activation within the 
VMN, PVN, ARC, LH and DMN, all known to play a part in the regulation of 
appetite. As H1R are present within the rat hypothalamus, histamine acts through 
the H1R to reduce food intake there is increased neuronal activation within this 
area, we could assume that histamine is acting either directly or indirectly through 
the VMN, PVN, ARC, LH and DMN to have its hypophagic effects.  
There is a high density of H3R within the mammalian hypothalamus, striatum 
and nucleus accumbens (Hussain et al., 2002). In particular, H3R mRNA have 
been detected in a number of areas within the hypothalamus including the VMN 
and the ARC (Lovenberg et al., 1999). Although the highest densities of H3R can 
be found in the CNS, they have also been found to be present, albeit in much 
lower levels, within the PNS, for example, in the GI tract, the airways and the 
cardiovascular system (Celanire et al., 2005). In much the same manner as 
histamine, the application of the H3R agonist, imetit, and the H3R inverse 
agonists, thioperamide and NNC1202, caused increased neuronal activation 
within the same key feeding centres of the rat brain. H3R have been shown to be 
present within the hypothalamus of the rat brain, in particular the VMN and ARC 
(Lovenberg et al., 1999), It is widely assumed that H3R inverse agonists and 
antagonists should affect food intake by blocking the negative feedback 
mechanisms of the H3R that control the synthesis and release of histamine and 
 208 
by doing so a increase in histamine is seen which then could go on to activate 
hypothalamic H1R resulting in anorexia. It is important to point out here that due 
to the high level of constitutive activity at the H3 receptor, the receptor has 
intrinsic activity even without the action of a ligand, and hence why the H3R 
inverse agonist thioperamide is effective here. H3R agonists on the other hand 
could be causing a reduction in endogenous histamine resulting in hyperpagia. It 
is important to point out here that as H3R can reside on the terminals of neurones 
containing other neurotransmitters that themselves affect feeding behaviours, this 
is another possible mechanism which may result in the changes observed on 
food intake. 
 
 
7.3 H1 and H3 receptors are present within the rat VMN 
The VMN plays a crucial role in regulating food intake. It has been 
demonstrated in lesion studies and clinical observations that damage to the VMN 
is associated with increased food intake and morbid obesity (Anand et al., 1951). 
The VMN is referred to as the “satiety centre” of the brain and therefore, if 
damaged, it can no longer enforce feeding restraints resulting in a overeating and 
weight gain (Sclafani, 1971, Bray et al., 1981). The VMN has direct links with the 
PVN and DMN and via these it connects indirectly with the LH (Harrold et al., 
2004), illustrating the complex circuitry surrounding the VMN and the importance 
it carries in regulating food intake within the hypothalamus. VMN lesion-induced 
obesity has been found in both rodents (Mayer et al., 1955) and humans (Bray et 
al., 1975) demonstrating the importance of researching this area when looking for 
pharmacological targets against obesity. The VMN is reported to be the 
preferential site of histamine-mediated suppression of food intake in the 
mammalian brain (Haas et al., 2008) and, thus, we aimed our electrophysiology 
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research the rat VMN. We found that approximately two-thirds of VMN cells 
responded to histamine with an increase in firing.  
Histamine causes a reduction in food intake via the H1R most probably 
within the VMN thus we could assume this increase in neuronal firing is due to the 
H1R. Therefore, we co-administered a H1R antagonist, pyrilamine and blocked 
histamine’s excitatory affects on neuronal firing. This provides further evidence to 
support the presence of the H1R within the rat VMN. Ookuma et al. (1993) had 
suggested H1R have a suppressive role on feeding because these receptors are 
distributed more densely in the nuclei involved in the suppressive function of food 
intake, such as the VMN.  
There is much less research identifying the distribution of the H3R within 
the rat brain compared to the H1R, but it is suggested that the H3R can regulate 
histamine release within the VMN, potentially through its autoinhibitory pathways. 
Using the H3R inverse agonist thioperamide, we were able to demonstrate the 
presence of H3R in or near the VMN. By co-applying the H1R antagonist, 
pyrilamine with thioperamide, we were also proved that the H3R population in the 
VMN are autoreceptors as opposed to heteroreceptors. Our results  collective 
results strongly suggest that H1R andH3R present in the VMN have a key role in 
the regulation of appetite. 
 
 
7.4 Thioperamide and imetit are acting specifically at the H3R 
The H3R is a 7TM GPCR with a high level of constitutive activity (Gbahou 
et al., 2003). Using the fact H3R can act constitutively to our advantage, we aimed 
to determine whether the H3R agonist, imetit, and the H3R inverse agonist, 
thioperamide, were acting specifically at the H3R to have their effects on feeding 
and neuronal firing. GPCRs are allosteric proteins that adopt inactive and active 
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conformations in equilibrium. The active conformation is promoted by agonists, 
such as imetit, or can occur spontaneously, leading to constitutive activity of the 
receptor. Alternatively, inverse agonists, such as thioperamide, promote an 
inactive conformation and decrease constitutive activity (Gbahou et al., 2003). 
Constitutive activity refers to the synthesis of a protein or an enzyme at a 
constant rate regardless of physiological demand or the concentration of a 
substrate. Compounds that bind to GPCRs without altering the equilibrium 
between active and inactive states of the receptor are referred to as neutral 
antagonists (Milligan et al., 2003). Some ligand can act as protean agonists. One 
such compound is proxyfan, which depending on the system it is introduced to 
can act as an agonist, antagonist or neutral antagonist depending on the level of 
constitutive activity. We have shown that in both of in vivo studies looking at 
proxyfan’s effects on feeding and in our in vitro system investigating proxyfan’s 
effect on VMN neuronal firing, proxyfan alone has no effect. But we demonstrated 
that proxyfan can block the actions of both the H3R agonist imetit and the H3R 
inverse agonist thioperamide both in vivo and in vitro. Therefore, in the feeding 
circuitry it appears that proxyfan is acting as a neutral antagonist. As proxyfan is a 
protean agonist, we could use it as a tool to determine the ligand-specific nature 
of our imetit andthioperamide. We found that imetit and thioperamide were acting 
specifically at the H3R as proxyfan, when co-administered with the H3R agonist 
and H3R inverse agonist, blocked the actions of both these compounds.  
 
 
7.5 Conclusion 
 This PhD thesis has investigated the histaminergic system and if such a 
complex signaling system could be manipulated pharmacologically to have a 
beneficial effect on feeding behaviours. We have shown that histamine itself is a 
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potent anorexigenic agent and by focusing our initial investigations on H3R 
compounds, we have proven that the H3R inverse agonist thioperamide causes 
significant hypophagia in both rats and mice. However, imetit, an H3R agonist, 
produces significant hyperphagia in rats whilst it reduced feeding in mice. Others 
have postulated that certain H3R drugs can have opposing effects on food intake 
depending on the animal model being tested, suggesting species-related 
differences could pose a problem for anti-obesity drug development.  
We have also illustrated the key areas activated by histamine and the 
H3R-selective compounds tested, highlighting the feeding and satiety centres 
known to play a vital role in controlling food intake. This suggests possible areas 
or action that histamine, imetit, thioperamide and NNC1202 include the VMN, 
DMN, ARC, PVN and LH all integral in the control of appetite. Unfortunately, the 
coded compound, NNC1202, also appeared to have very strong adverse effects, 
which precludes it from future development. 
We have shown that both H1R and H3R are present within the VMN of the 
rat brain and that histamine produces an excitatory neuronal firing response via 
both these receptors. We have also concluded that H3R are autoreceptors within 
the rat VMN. As the VMN plays one of the most fundamental roles in the 
regulation of feeding and we have shown a population of both H1 and H3 
receptors within this area, this is an important site for the histaminergic regulation 
of feeding.  
Finally we have proven, using a neutral antagonist that the main H3R 
compounds tested during this PhD were acting specifically via the H3R in rats 
and, thus, allows us to conclude confidently that the effects of both imetit and 
thioperamide on feeding and neuronal VMN firing were a direct result of their 
efficacy at H3R.  
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